EMERGING MEDICAL TECHNOLOGIES® SPOTLIGHT

• Online Database
• PDF
• eBook

• Search by Keyword/Market (e.g., heart valve, orthopedics, etc.)
• Search by Company Name

The Online Database Format Includes Advanced Searching:

Keyword & Exact Phrase Searching:		Search By Medical Market:
Search By Conference:		Search By Company Name:
Search By Region:

Technology descriptions for companies currently covered as of 06/04/12 include:

• Company 1 - Small molecule drug candidates directed at ion channel targets to repurpose existing therapies for atrial fibrillation
• Company 2 - Novel spherical nucleic acid (SNA) constructs exhibiting biocompatibility and versatility as intended therapeutics to treat heart disease, cancer, skin conditions and bacterial infection
• Company 3 - Novel therapeutic intended to treat dry age-related macular degeneration and prevent blindness
• Company 4 - Innovative oral therapy to treat rheumatoid arthritis and inhibit disease progression
• Company 5 - First-in-class oncology therapeutics to treat female and male cancers utilizing membrane-disrupting peptides to target cancer cells without harming healthy tissue
• Company 6 - Blended active glycolic acid used in cosmetic and beauty products
• Company 7 - Novel DNA-based immunotherapies to treat HIV
• Company 8 - Research and development of innovative biotechnologies
• Company 9 - Catheter-based medical technologies for the treatment of cerebral aneurysm and other cardiovascular disease
• Company 10 - Formulations for lymphatic delivery of highly lipophilic pharmaceuticals
• Company 11 - Reformulation of existing pharmaceuticals to provide more targeted results, lessen the risk of side effects and reduce patient costs; lead product is an oral form of an existing IV-only cancer drug
• Company 12 - Therapeutics intended to treat diabetes, diabetic complications, and kidney disease through the inhibition of blood vessel growth, preventing hyperglycemia-induced damage to proteins and tissues
• Company 13 - Novel formulations of existing pharmaceuticals to expand applicable patient populations and therapeutic uses
• Company 14 - Affordable analytical instruments, biomanufacturing systems, and consumable labware products for biological research and drug discovery
• Company 15 - Novel therapeutic to treat age-related macular degeneration and prevent blindness
• Company 16 - Cell-based nuclear receptor reporter assay technology used in drug development that allows for the storage and preservation of cells for later use
• Company 17 - Innovative combination drug therapies to treat overactive bladder and urinary incontinence
• Company 18 - Targeted UV phototherapy device to treat dermatological diseases including eczema, psoriasis and vitiligo
• Company 19 - SMaRT RNA technology intended to treat a broad spectrum of diseases including HIV, hemophilia and dyslipidemia
• Company 20 - Sustainable chemicals using unconstrained metabolism technology for reaction flexibility
• Company 21 - Novel, first-in-class therapeutic utilizing beloranib to treat severe obesity
• Company 22 - Technology that enables Innovative reformulation of previously approved therapeutics to expand indications or improve safety
• Company 23 - Budesonide-based therapy for the treatment of eosinophilic esophagitis
• Company 24 - Optical measurement instruments using back-scattering interfermetry to detect molecular interaction assays and assist in developing drug applications
• Company 25 - Innovative platform that optimizes DNA to produce in vivo therapeutics with multiple indications
• Company 26 - SideView Mono trocar for single access laparoscopic surgery
• Company 27 - A patented electro-chemical technology for coating teeth with a high concentration of target materials that last for long periods of time, and include the following applications: (1) Fluoritray, a non-invasive, painless tooth fluoridation, producing a thick protective Fluoroapatite layer lasting for more than one year, reducing sensitivity and significantly improving resistance to bacteria and the acidic mouth environment; and (2) UltraWyte, for superior tooth whitening
• Company 28 - Patent-pending T-Loc(TM) Technology, used for the treatment of fractures and injuries to the shoulder joint and allowing precise, reproducible surgeon-controlled tensioning and low-profile, knotless fixation
• Company 29 - Molecular diagnostics technologies that perform directed analyses of cell-free DNA in blood and are used to provide safe, highly accurate, and affordable prenatal tests for maternal and fetal health
• Company 30 - A novel, disposable device used for intra-abdominal pressure monitoring in patients that are receiving gastric feeding, require safe monitoring of gastric residual volume, or are being screened for intra-abdominal hypertension
• Company 31 - Cost effective, non-invasive point of care diagnostics that use bio-sensor chips to provide direct, digital, state of the art sensitivity (fM - pM) and selectivity through proprietary semiconductor processing of CNT FETs and may be used to diagnose a variety of diseases and related health risks
• Company 32 - Highly compact intensity-modulated proton therapy medical system powered by a dielectric-wall accelerator and intended for use in oncology patients; features a revolutionary design with a substantially smaller structure and greater flexibility than other accelerators
• Company 33 - Spiral Laminar Flow (SLF) prosthetic grafts are used to reproduce the body's natural blood flow patterns and treat cardiovascular disease
• Company 34 - Novel MRI scanner to diagnose disease and provide real time guidance of thermal energy procedures such as lesion biopsies and tumor treatments
• Company 35 - Minimally invasive ultrasound device that allows for rapid evaluation of fallopian tubes to assess fertility at point of care
• Company 36 - Cellular Regeneration Technology (CRT) utilizing cell interaction and a functional polymer scaffolding to provide a single-surgery treatment for damaged articular cartilage in the knee
• Company 37 - A second-generation biomimetic coating comprised of 2 protein components (FN and SDF-1α) which may be applied to cardiovascular prostheses in order to help avoid tissue rejection and subsequent device failure
• Company 38 - Non-invasive system to detect and alert users of sleep-time hypoglycemia for the monitoring of type 1 diabetes
• Company 39 - Innovative products designed to alleviate pain and enhance physical comfort in those affected by illness, disability, injury, pressure and poor ergonomics
• Company 40 - Oral active molecule therapeutic to improve memory and learning in patients with Alzheimer's Disease
• Company 41 - Novel cervical collar used in emergency situations to immobilize the neck while chemically cooling to lower brain temperature to slow metabolism, improve cell membrane stability and reduce inflammation
• Company 42 - Diagnostic test for lung cancer using biological olfactory sensor arrays
• Company 43 - Innovative medical isotopes and cancer treatment elements used in thyroid and respiratory cancer therapies
• Company 44 - Novel small molecules and monoclonal antibodies for the treatment of vascular disease and to enhance wound healing, specifically diabetic macular edema and inflammatory bowel disease
• Company 45 - In vivo positron emission tomography imaging agents to detect cancer and autoimmune disease
• Company 46 - Novel therapeutics to remove acetaldehyde and other toxic aldehydes that impair protein function and cause mutation in DNA
• Company 47 - First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer's
• Company 48 - Novel anti-angiogenic cancer therapy that inhibits blood supply to prevent tumor growth
• Company 49 - G protein-coupled receptor therapeutics to combat multiple sclerosis
• Company 50 - Novel therapy to treat iron overload caused by chronic transfusion therapy
• Company 51 - Blood-based molecular diagnostics that track multiple biomarkers for early diagnosis of a variety of diseases including cancer and Alzheimer's
• Company 52 - Magnetically targeted drug delivery system enabling patient specific delivery options to treat peripheral artery disease
• Company 53 - First-in-class oral therapeutic to disrupt the natural course of lactose intolerance by stimulating lactose-metabolizing bacteria in the colon and offering long-term symptom relief
• Company 54 - Molecular test to detect pathogens and bacteria that can lead to nosocomial infections
• Company 55 - Novel non-invasive test to asses infertility and egg quality in women through the use of genetic biomarkers
• Company 56 - Aneurysm embolization system that promote rapid, peri-procedural stasis in wide neck ruptured and unruptured aneurysms, taking the place of traditional coils
• Company 57 - Novel monoclonal antibody therapies targeting receptor tyrosine kinases to treat cancers
• Company 58 - Small molecule therapeutics to treat cardiometabolic diseases including dyslipidemia/hypercholesterolemia and diabetes
• Company 59 - Novel front-line therapies for the treatment of inflammatory bowel disease, specifically ulcerative colitis
• Company 60 - Novel therapeutics to treat diseases affecting mucosal tissue
• Company 61 - Oral therapeutics that inhibit the breakdown of calcitonin for the treatment and prevention of osteoporosis and related bone disease
• Company 62 - Comprehensive portable device to provide point-of-care diagnostics for a variety of diseases
• Company 63 - Point-of-care molecular diagnostic device utilizing electrochemicals to provide rapid, enzyme-free detection of nucleic acids for infectious disease
• Company 64 - Peptide-based immunotherapy intended to treat and prevent pancreatic cancer by targeting mutated ras genes
• Company 65 - Orthobiologic implant to fill bone voids utilizing parathyroid hormone peptides to prevent further bone loss in osteoporosis and spinal injuries
• Company 66 - Invasive fractional flow reserve device analyzer that uses computed tomography images to determine arterial blood flow and pressure, allowing better diagnosis of ischemic stenosis
• Company 67 - Selective small molecule histone deacetylase inhibitors to treat multiple myeloma with possible indications for inflammatory, neurodegenerative, infectious and genetic disease
• Company 68 - Small molecule therapeutics for acute central nervous system disorders; the company's lead product is intended to reduce brain swelling and hemorrhage resulting from ischemic and traumatic injury
• Company 69 - Innovative aortic valvuloplasty balloon for the treatment of calcific aortic stenosis
• Company 70 - Novel allogeneic cell graft with copper chelator technology for use in bone marrow transplants to treat leukemia and lymphoma in patients without an available familial donor
• Company 71 - Sophisticated implants and surgical tools featuring a biomechanically-compliant nail for the fixation of hip fracture in third age patients suffering from osteoporosis
• Company 72 - Novel screening technology based on oncoproteins to differentiate benign infection from true disease and detect cervical cancer and other cancers associated with human papillomavirus (HPV)
• Company 73 - Novel therapeutics that inhibits translation of neurotoxic proteins for the treatment of neurodegenerative disorders, including Alzheimer's and Parkinson's
• Company 74 - Innovative refractive ophthalmologic surgery technologies and instruments for flapless epithelial surface removal and the treatment of keratoconus
• Company 75 - Colorimetric blast dosimeter provides immediate information as to the level of blast exposure relative to brain injury via a color change imaging technology
• Company 76 - Innovative dental implants, prosthetics, bone graft materials and surgical tools to treat oral ailments with minimally invasive technologies
• Company 77 - Non-invasive medical devices and mobile health applications utilizing acoustic respiratory monitoring technology to improve the management of chronic respiratory diseases including asthma and COPD
• Company 78 - Small molecule oral therapeutic that combats osteoporosis and builds bone by inhibiting the activity of the Sclerostin protein
• Company 79 - Breakthrough implantable stimulation system that uses neuromodulation to treat refractory epilepsy
• Company 80 - Ultrasound instrument that combines light and doppler technology to monitor the efficacy of advanced breast cancer therapies; also offers a light-only version for home health
• Company 81 - Oncology and companion diagnostics with special capabilities in the area of mRNA and miRNA
• Company 82 - Biodegradable drug delivery implants to treat and prevent wound infection and manage pain
• Company 83 - Novel implantable and external brain stimulation devices for the treatment of neurological disorders
• Company 84 - Warm blood perfusion system to preserve hearts and lungs for transplantation
• Company 85 - Innovative drug candidates to reduce intraocular pressure and treat retinal diseases
• Company 86 - Osteoporosis treatment through novel nasal spray
• Company 87 - Technologies for genetic analysis preparation to predict disease risk and drug response
• Company 88 - Novel first-in-class pharmaceuticals to improve vascular access in renal and vascular diseases
• Company 89 - Small molecule therapies for neurodegenerative diseases
• Company 90 - Topical mechlorethamine gel therapy for the treatment of early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma
• Company 91 - Novel oral therapeutics to treat cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), and neurodegenerative disorders
• Company 92 - Antithrombotic therapies for use in acute and subacute care
• Company 93 - Inhaled therapies to treat and prevent respiratory conditions including infections, progressive diseases, and allergic rhinitis
• Company 94 - Therapeutics to treat disease-associated pain and inflammation
• Company 95 - Novel electronic whole-genome sequencing employing solid-state technology
• Company 96 - Novel prescription products targeting reduced submental fat
• Company 97 - Antibiotics focused on Riboswitches (RNA drug targets) to treat drug resistant fungal and bacterial pathogens
• Company 98 - Novel therapeutics for the treatment of drug addiction and smoking cessation through reduction of craving function in brain
• Company 99 - Gene-, protein-, and serum-based biomarker analysis technology to identify potential cancer
• Company 100 - Novel therapeutic antibodies for the treatment of infectious disease, cancer and inflammation
• Company 101 - Automated microfluidic systems and instrumentation for single-cell analysis
• Company 102 - Natural color dental implants to restore function and aesthetics
• Company 103 - Antiviral pharmaceuticals that bind to caspids to treat HIV and HBV
• Company 104 - Live tumor cell processing platform for predictive testing which uses functioning signaling profiles to guide cancer therapy
• Company 105 - Novel molecular therapies for the treatment and prevention of metabolic disease associated with altered mitochondrial function
• Company 106 - High concentrate Omega-3 fatty acids for use in pharmaceuticals, developed from algae
• Company 107 - Novel molecules to target chronic T-cell mediated inflammatory diseases
• Company 108 - Point-of-care blood and urine analyzer to detect infectious disease and test blood levels; lab-quality results available within minutes of testing
• Company 109 - Atraumatic, self-retaining surgical tissue retractors for thyroidectomy and related procedures that feature low profile, disposable designs
• Company 110 - Vertical lumbar traction system to realign spine, reduce disc herniation and lower back pain
• Company 111 - An FDA-cleared dual-balloon catheter for urinary drainage that is designed to reduce adverse events resulting from Foley urinary catheterization, including the occurrence of Catheter Associated Urinary Tract Infections (CAUTI), sepsis, and bladder cancer in long-term users
• Company 112 - Biopolymer implants, biomaterials and therapeutics to repair damaged heart structure and treat congestive heart failure
• Company 113 - DNA-based diagnostic tests used to detect diseases and conditions affecting women, such as endometriosis, infertility, and pre-term labor
• Company 114 - Brain Anaesthesia Response (BAR) monitoring system to improve existing EEG technology and reduce intra-operative awareness
• Company 115 - High-quality reconstructive total joint implants for the hip and knee
• Company 116 - Whole-Body Thermometry (WBT) advanced medical diagnostic device for non-invasive analysis, including tissue signature disorder recognition
• Company 117 - Innovative technologies for patient monitoring to include neurological, cardiovascular and pain management indications
• Company 118 - Novel allogeneic cell-derived biomaterials that do not require synthetic scaffolds and are used to regenerate cardiovascular and other soft tissues
• Company 119 - Innovative instrument to simplify insertion of artificial spinal disc implants
• Company 120 - ICDR, a simple yet sophisticated Internal Cavity Drug Retention system for controlled and highly effective delivery of therapeutic agents into the bladder. Based on advanced materials technologies, the ICDR system improves drug bioavailability and reduces toxicity, significantly enhancing treatment potential, safety, and compliance.
• Company 121 - An innovative enabling platform technology that harvests tens of millions of a patient's own adipose-derived regenerative cells in one hour, for immediate application
• Company 122 - Disposable medical device to improve stroke risk during heart bypass procedures
• Company 123 - A pioneering ozone-oxygen-vacuum system for healing chronic, hard-to-heal wounds. The technology is non-invasive and medically proven for diabetic foot, PVD, venous ulcers, and more.
• Company 124 - EpiLert is a wireless, watch-like device providing real-time ALERT to CAREGIVERS of an ongoing epileptic seizure
• Company 125 - Resin-based vehicles that quickly deliver medications transmucosally to the bloodstream and formulations that treat such conditions as smoking cessation, anxiety, chronic breakthrough pain, and migraines
• Company 126 - The Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI/MBI - a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake
• Company 127 - Self-adjustable vaginal ring pessary to treat urinary incontinence and genital prolapse without drugs
• Company 128 - Novel thyroid FNA analysis technology combines cytopathology and Afirma Gene Expression Classifier for nodule assessment
• Company 129 - Next generation G-protein coupled receptor-biased ligand pharmaceuticals which are intended to limit adverse drug effects
• Company 130 - Novel biotherapeutic technologies featuring self-contained subcutaneous delivery mechanisms
• Company 131 - Innovative ultra-sensitive immunodiagnostic systems for use in research and in-vitro diagnostics
• Company 132 - Therapeutics based on natural killer cells (NKT), a subset of immune cells, intended for the treatment of autoimmune and inflammatory diseases in addition to asthma, cancer, and dermatitis
• Company 133 - Innovative antibiofilm catheter lock technology to reduce infection associated with indwelling catheters
• Company 134 - Patient-specific epigenetic therapeutics utilizing small molecule histone methyltransferase (HMT) inhibitors for the treatment of cancer
• Company 135 - Expanding hydraulic implant for use in lumbar spinal fusion procedures
• Company 136 - Novel small molecule therapies for respiratory disorders
• Company 137 - Novel diagnostics utilizing protein based biomarker technology focused on nosocomial disease
• Company 138 - Targeted oral therapeutics to correct mineral metabolism and metabolic disorders
• Company 139 - Proprietary implant technology featuring a hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea
• Company 140 - Cosmetic and drug delivery systems based on nanotechnology
• Company 141 - Innovative therapies utilizing pepducins to modulate G-protein receptors, thereby expanding treatments for cancer, diabetes, inflammation, and regenerative medicine
• Company 142 - Therapeutics for the treatment of post-operative and chronic pain
• Company 143 - Novel ophthalmic therapies to treat ocular diseases
• Company 144 - Third-generation transcatheter aortic valve prosthesis with increased safety, greater ease-of-use, and longer durability
• Company 145 - Ultrasonic devices for non-invasive fat removal from the chin, arm, and eye-bags and for skin tightening
• Company 146 - The Rx Timer Cap is a patented "smart cap" with a built-in LCD timer that fits common prescription vials and lets patients know exactly how long it has been since they last took their medication
• Company 147 - Sutureless, adjustable mitral annuloplasty toolset for surgical and robotic procedures
• Company 148 - A novel annuloplasty ring for heart valve repair. The Intra-annular Ring represents a unique solution for children allowing the valve to grow following implantation.
• Company 149 - The first home-based telemonitoring system for patients with age-related macular degeneration, the leading cause of blindness in people over age 50 in the western world
• Company 150 - A nanotechnology-enabled portfolio of therapeutic products for use in medical applications
• Company 151 - Proprietary technology for decellularizing biological organs/tissues to create an extra-cellular matrix retaining its original architecture, mechanical properties, and vascular network - suitable for scaffold transplantation or growing new functional organs/tissues by recellularization
• Company 152 - A battery-powered device which lifts and acquires a healthcare patient weighing up to 500 lbs. - without any caregiver's touching, logrolling, or lifting - and transports them to the next destination, then gently discharges them onto the desired horizontal surface
• Company 153 - The patented EXMI technology uses pulsed magnetic fields that penetrate up to 7,5 cm into the body, stimulating nerves (neuromodulation), contracting muscles (rehabilitation), treating pain/depression, and increasing blood flow
• Company 154 - Requiring only one drop of blood, the proprietary LBIdx(TM) Plasma Thermogram(TM) tests will significantly improve the clinical diagnosis and monitoring of autoimmune disease and cancer, vastly improving patient outcomes
• Company 155 - New gene-based medicines to treat "dominant" genetic diseases, particularly for the eye
• Company 156 - Technology that provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes. The method is convenient, easy-to-use, and validated. It measures tissue accumulation of Advanced Glycation End products (AGEs) by means of fluorescence techniques. AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes and cardiovascular disease.
• Company 157 - An oral delivery platform for medications, food supplements, and other soluble substances that is easy-to-use, friendly, inexpensive, and requires no third-party assistance
• Company 158 - Ventritek 105 is a novel medical device that provides full treatment for Stroke/SAH/ICH patients by replacing the current long and risky procedure
• Company 159 - An inhaler with variable dosage of Asthma medicine, based on a built-in exhaling measurement of the airway obstruction level
• Company 160 - The RGS Vertex360(TM), which competes with the Gamma knife in the non-invasive treatment of brain tumors, is a highly precise cobalt 60 radiation system that utilizes the OsiriX(TM) based Explorer 4D(TM) treatment planning system, also developed by the company
• Company 161 - Innovative central nervous system therapies; Allon is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP)
• Company 162 - Vaccine platform technology for cancer and infectious diseases based on Listeria monocytogenes that has been engineered to be safe for use in humans and express specific disease antigens
• Company 163 - Real-time, non-contact, high resolution tissue temperature monitoring & mapping products that improve the safety and efficacy of ablation therapy by avoiding injury to surrounding tissue
• Company 164 - Oncology drugs that utilize novel mechanisms of action
• Company 165 - Electronic stimulation technologies that maintain muscle strength during recovery in the intensive care unit or other periods of inactivity
• Company 166 - The fentanyl iontophoretic transdermal system (IONSYS), an investigational, pre-programmed drug delivery system comprising a compact, needle-free, self-contained system that provides patient-controlled analgesia for adult inpatients requiring post-operative opioid therapy
• Company 167 - Two novel technologies that boost immune responses, including a synthetic toll-like receptor agonist for use as an adjuvant to vaccines , and a viral vector that targets immature dendritic cells
• Company 168 - A molecular diagnostics test that examines somatic alterations in cancer-related genes by applying massively parallel sequencing to routine clinical specimens, enabling targeted therapy
• Company 169 - Nanofibers designed for use in tissue engineering, drug delivery, and wound care
• Company 170 - Vascular closure device that seals the femoral artery following cardiac catherization
• Company 171 - An aerosolized long-acting muscarinic antagonist that treats chronic obstructive pulmonary disease (COPD)
• Company 172 - Novel metal abstraction peptide (MAP) platform technology that delivers platinum to cancer cells by incorporating it into cancer-targeting proteins, thereby improving treatment while limiting side effects and damage to healthy cells
• Company 173 - Long-acting, intravenous lipoglycopeptide used to treat acute bacterial skin and skin structure infections
• Company 174 - Innovative new topical therapies for dermatology applications, including photodynamic therapy for sebaceous gland disorders and small molecule therapeutics that treat acne, inflammatory skin diseases, and sebaceous gland hyperactivity
• Company 175 - Novel, minimally invasive surgical devices for the treatment of sinusitis
• Company 176 - Novel drugs that treat cancer by targeting cellular protein homeostasis pathways
• Company 177 - A next-generation eye drop medication that uses Rho-kinase inhibitors to treat glaucoma
• Company 178 - Minimally invasive spinal disc regeneration technologies (SRTs) with a goal of biologically regenerating the tissues of the disc to restore the natural visco-elastic, biomechanical, and fluid characteristics of the inner core and outer tensil ring
• Company 179 - MedApps' solutions utilize cloud computing to connect patients and professional care providers, enabling proactive healthcare delivery
• Company 180 - Novel 3D cell culture devices for stem cell, tissue engineering, cancer, and drug discovery applications
• Company 181 - Developing a whole-plant therapeutic, AMZ0026, that exhibits immunomodulator properties for the treatment of HIV/AIDS. Preliminary clinical studies in patients that are seropositive for HIV-1 have demonstrated a positive effect on CD4 and CD4/CD8 blood serum levels.
• Company 182 - A Leptin product as a novel hormone replacement therapy for Alzheimer's disease (AD) and/or as a preventative for those who are at risk
• Company 183 - EMMA (Electronic Medication Management Assistant) - a remote medication administration unit that is placed in a patient's residence to enable a healthcare professional (i.e., pharmacist or nurse) to remotely administer their oral medications
• Company 184 - A disruptive next-generation low profile (14 French), pre-mounted and pre-packaged "package-to-patient" percutaneous Transcatheter Heart Valve (THV)
• Company 185 - EPIFLO utilizes cutting-edge oxygen concentration technology to create tissue regenerative processes driving closure of delayed-healing acute or chronic wounds
• Company 186 - Drugs to treat dry Age Related Macular Degeneration (dAMD) and other vascular diseases of the eye, including Glaucoma, DME, and Diabetic Retinopathy
• Company 187 - Endoluminal device for incisionless treatment of obesity
• Company 188 - Software that can read and analyze the image stack of a CT scan and draft a report that includes major pathological findings, identification of key images, and quantitative measurements - provided to the radiologist at the customers site
• Company 189 - Developer of easy-to-use genetic tests (clinically validated DNA SNP patterns) that empower individuals to prevent certain chronic conditions and manage their existing health and wellness through actionable guidance
• Company 190 - A therapeutic for HIV that is divergent from current approaches, in that rather than fight against HIV's greatest strengths - mutation frequency & rate of replication - the drug exploits these "strengths" to cause viral population collapse
• Company 191 - A device that uses non-invasive ultrasound to disrupt the blood-brain barrier, for delivery of large molecule therapeutics to treat primary and metastatic brain tumors
• Company 192 - The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology, and molecular genetic testing
• Company 193 - Developing healthier drugs from whole-plants. MAHDL, developed to elevate HDL-C, has undergone tests in man with positive results and has an IND from the FDA. Other whole-plant therapeutics are under development for dementia.
• Company 194 - ZeroFold, the lowest profile balloon available for improving deliverability and effectiveness of balloon angioplasty catheters
• Company 195 - A revolutionary technology to sterilize proteins in dehydrated formulations by irradiation (beta, gamma) or Ethylene Oxide
• Company 196 - Next-generation vaccines based on patented LAMP Technology that induce a strong and complete immune response, with applications in allergy, cancer, and infectious disease
• Company 197 - The world's first homozygous parthenogenetic stem cell lines that can provide therapeutic cells with the potential to be transplanted into hundreds of millions of individuals of differing ages and racial backgrounds with minimal risk of immune rejection
• Company 198 - A web-enabled, low level electromagnetic therapy system, that provides HealthCare providers in the Complementary and Alternative Medicine (CAM) marketplace with a device that improves both their Patients' Health and their Business
• Company 199 - Bioluminescent (light producing) proteins and related substrates that can: 1-be used as an adjunct to surgery, including laparoscopy, 2-track the progression of disease and evaluate the effectiveness of therapy, and 3-diagnosis a disease process before there are symptoms or anatomical features such as tumors
• Company 200 - A patented ultrasound miniaturization technology which has enabled the creation of iPod sized ultrasound pain therapy systems with unprecedented operation times of up to 6 hours on a single cell phone battery
• Company 201 - Miniaturized, hand-held, instrument-mounted optical measurement and navigation systems for surgical applications
• Company 202 - Turnkey SaaS software solution that dramatically reduces errors, turnaround times, and costs of MRI, CT, and PET-CT diagnostic reports
• Company 203 - Fast-track development of novel drugs for an unmet medical need - Alzheimer's disease - with rapid payback on investment
• Company 204 - Technology platforms that improve surgical efficiency in complex orthopedic procedures such as total joint replacement, spinal fusion, and trauma fixation: 1-For medical device manufacturers, RepAssist(TM) reduces training costs, dramatically compresses the time it takes for new reps to provide value in the OR, and enhances rep efficiency with existing accounts. 2-For hospitals/surgery centers, Virtual Backtable(TM) significantly enhances OR team proficiency in organizing and utilizing instrumentation, independent of the team's experience level with the implant system or surgeon, resulting in improved surgical efficiency and higher surgeon satisfaction.
• Company 205 - Implantable devices that allow surgeons to reduce the morbidity of spinal deformity surgery with a procedure that is quicker, safer, and more cost-effective than existing techniques
• Company 206 - Minimally invasive, joint preserving treatment option for chronic knee osteoarthritis (OA) pain; an alternative to total knee replacement (TKR)
• Company 207 - A broad platform of minimally invasive intramedullary devices to improve fracture fixation, reduce soft tissue trauma, and speed the patient's return to normal daily activities
• Company 208 - Intra-articular ion channel modulators for the treatment of osteoarthritis (OA) in all synovial joints
• Company 209 - A breakthrough platform technology that provides highly porous (>65%), load-bearing orthopedic implants in both surface active (metal, ceramic) and resorbable materials
• Company 210 - An easy-to-use, low-cost, point-of-care (POC) ELISA-based adjunctive screening kit, specifically for oral cancer
• Company 211 - A neurostimulation technology to improve function and independence after stroke
• Company 212 - Novel portable diagnostic tool to detect a wide variety of protein analytes and un-amplified DNA at point of care
• Company 213 - Hand-held smart drill with robotic technology that provides: safe depth control, accurate depth measurement, bone density measurement, and performance feedback for orthopedic and spine applications
• Company 214 - An affordable drug delivery pump/patch that is cost-competitive with pre-filled pen injectors and offers a superior end-user experience
• Company 215 - A disruptive, non-invasive, and long-term neuro-monitoring technology with the potential to reduce stroke and damage from aneurysms, tumors, and other neurologic trauma
• Company 216 - A minimally invasive stent platform that offers safe, simple, and accelerated healing for the treatment of endoluminal diseases
• Company 217 - MGI Medical's "Pulse Flowmeter" provides sensitive, early detection of hemodynamic instability through continuous, non-invasive assessment of peripheral blood flow. This permits early detection and management of blood loss and/or heart failure when there have been no changes in vital signs.
• Company 218 - An ultrasensitive hand-held probe that is capable of detecting specialized, subcutaneously injected magnetic materials and is used to locate lymph nodes to support the diagnosis and treatment of cancer
• Company 219 - A non-invasive, accurate, and easy-to-use female fertility monitor
• Company 220 - A low-cost incision guide that is applied with an adhesive sticker before a medical scan and leaves behind an ink imprint of locational markings (such as a grid or ruler) on the patient's skin so that the surgeon can accurately correlate target locations with the medical image
• Company 221 - Technology that enables and facilitates seamless stenting of all coronary bifurcation disease scenarios
• Company 222 - A biopharmaceutical company with an extensive library of structurally diverse bioactive peptides with broad applications in the health, beauty, and pharmaceutical industries
• Company 223 - 1-A spray drying technology to enable the storage of plasma in diverse environments by methods that are far simpler/less costly than those used currently and 2-A product to enable platelets to be stored in refrigerators rather than at room temperature to: (i) improve safety, (ii) extend shelf life, and (iii) significantly reduce costs
• Company 224 - A mechanical thrombectomy kit that will help restore blood flow and reduce hemorrhagic complications associated with acute ischemic stroke therapy
• Company 225 - Miniature infrared thermal imaging cameras combined with a spectroscopic infrared real-time in vivo analysis device for the early detection/accurate identification of internal lesions and tumors, as an add-on to existing endoscopes
• Company 226 - A unique lipid-soluble anti-oxidant heavy metal chelator that is safe and effective, for which the company is pursuing orphan drug approval
• Company 227 - ImplantLock, a device that enables a safe alternative to vertical bone augmentation or sinus lifting as well as immediate functional loading even after tooth extraction
• Company 228 - Advanced medical technology that combines CO2 laser capabilities with autologous stem cells to significantly improve cardiac output in patients with heart disease or heart failure
• Company 229 - A take-home conception aid system that is designed to address the growing unmet need of delayed/unsuccessful natural fertility that historically has had similar results to intrauterine insemination (IUI), yet can now be done in the privacy of the home
• Company 230 - Integrated molecular diagnostic system that is easy to use and requires little or no training
• Company 231 - Technologies that: 1-Temporarily plug body passageways with a thermo-transitioning gel that is delivered as a cold liquid, solidifies at body temperature, and is later flushed away and 2-Keep body passageways open with gentle passively dilating devices, as well with more rigid construction of an open design, to prevent eventual long-term blockage
• Company 232 - Non-invasive disposable device to automatically deliver a new therapy called *Remote Ischemic Preconditioning*, an adjunct to traditional treatments for heart attack and stroke that mitigates ischemia-reperfusion injury and has been clinically shown to reduce infarct size by 50%, without side effects
• Company 233 - Biologically compatible polymers that provide non-surgical regenerative therapies for treating chronic and acute episodes of pain
• Company 234 - The only device-based therapy, offering low-cost and non-invasive treatment for a wide range of antenatal conditions; thereby promising to prevent preterm birth
• Company 235 - The first miniature and highly accurate guide for brain surgery that is fully MRI-compatible and gives the possibility to perform simultaneous bilateral procedures, in addition to being easy-to-use and cost-effective
• Company 236 - A hand-held device with a touch-screen interface that identifies a patient's preferred language and then collects his/her information, medical history, symptoms, and complaints, which are then summarized into the caregiver's language and can be accessed on the device/through a facility's electronic health records (EHR) system
• Company 237 - Innovative single-use surgical retractors designed to manage all MIS exposure needs in gynecological, digestive, visceral, and vascular surgery
• Company 238 - Small, discrete, and disposable device to reduce food intake
• Company 239 - Cartilage repair using cell therapy - true, 100% hyaline cartilage tissue, in a single procedure, using an off-the-shelf product
• Company 240 - X-ray light valve device for use in conjunction with mammography screening and future imaging modalities
• Company 241 - Genetic test for expectant mothers that detects spina bifida
• Company 242 - Hand-held, disposable device that transdermally removes spider and reticular veins without a sclerotherapy agent
• Company 243 - Needle-free silicone patch for vaccine delivery
• Company 244 - Next-generation PCR system that can provide absolute quantification of nucleic acid molecules, at higher resolution and lower target levels than the current standard, thereby identifying diseases earlier in progression
• Company 245 - ClearRing is a minimally invasive prostatic reshaping implant for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia
• Company 246 - Immediate detection and identification of bacteria in bodily fluids through optical spectroscopy with low quantities of material without bacteria culturing
• Company 247 - Temporary implantable ventricular assist device (VAD) that wraps around the heart and squeezes it to help pump blood
• Company 248 - Non-invasive nitric oxide gas (gNO) technology and iontophoresis drug delivery for treating diseases of the skin and nails
• Company 249 - Immunomagnetic cell capture system which isolates and removes pathogens directly from the blood in under 30 minutes
• Company 250 - Synthetic 3D extracellular matrices to support tissue growth for use in a wide range of regenerative medicine
• Company 251 - Small molecule plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME)
• Company 252 - Prefilled, easy-to-carry epinephrine auto-injection device for people with severe allergies
• Company 253 - Micro-needle skin patch for delivery of the influenza vaccine
• Company 254 - Hand-held device that sublingually monitors changes in carbon dioxide (CO2) levels for the prevention of septic shock
• Company 255 - Minimally invasive memory polymer devices for use in peripheral vascular, non-vascular, and neurovascular applications
• Company 256 - Energy-based thermal surgery device that provides better soft tissue cutting and coagulation
• Company 257 - Aerosol-based inhaled insulin delivery device
• Company 258 - A light-based medical device in the form of an LED patch with a proprietary, optimized formulation of light which triggers local, controllable, and safe Nitric Oxide (NO) production to treat diseases triggered by underlying vascular dysfunction
• Company 259 - Implantable, wireless, intracranial pressure monitor for use in patients with tumors, prior strokes, and traumatic brain injuries (TBI)
• Company 260 - Self-expanding, fully removable, temporary inferior vena cava (IVC) filter used in conjunction with the placement of a central line for the prevention of pulmonary embolism
• Company 261 - The BNX(TM) (Beacon-Needle-eXchange) needle delivery system for use in gastrointestinal endoscopic procedures including: Endoscopic Ultrasound (EUS), Endoscopic Bronchial Ultrasound (EBUS), and Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
• Company 262 - Low-cost mobile device and software that adapts smartphones into ECG machines
• Company 263 - Next-generation prefilled drug delivery devices, including prefilled syringes, auto-injectors, and IV systems, offering improved product performance at lower costs
• Company 264 - Electrophysiological mapping device for the treatment of complex cardiac arrhythmias
• Company 265 - Hand-held, non-contact vein illumination device for imaging veins just below the surface of the skin
• Company 266 - Miniaturized, continuously adaptable, left ventricular assist device (LVAD) for the treatment of heart failure
• Company 267 - Drugs to treat breast and other cancers by targeting cancer stem cells
• Company 268 - Real-time vital signs monitoring with data collected from earbuds and streamed wirelessly to mobile devices or the web for viewing
• Company 269 - Drug therapy for the treatment of rare diseases such as hereditary inclusion body myopathy (HIBM)
• Company 270 - Compounds for oncology indications, including: 1-the prevention of A) chemotherapy-induced nausea and vomiting (CINV), B) post-operative nausea and vomiting (PONV), and C) chronic cough and 2-treatment for patients with non-small cell lung cancer (NSCLC) whose tumors express an Anaplastic Lymphoma Kinase (ALK) fusion protein
• Company 271 - Portable, self-contained system for the precise minimally invasive removal of diseased tissue, to restore natural tendon and soft tissue function in the elbow, knee, ankle, foot, and shoulder
• Company 272 - Thermal pulsation system for effective, in-office treatment of evaporative dry eye
• Company 273 - Non-invasive neuromodulation device that exposes the brain to an oscillating magnetic field, for the treatment of psychiatric and neurological disorders such as major depressive disorder and bipolar depression
• Company 274 - Real-time orthopedic surgery imaging system that will save valuable time for surgeons and hospitals, while improving surgery accuracy and patient safety
• Company 275 - An interactive, computer-assisted system utilizing image-guided robotics to enhance the quality of hair follicle harvesting during hair restoration surgery
• Company 276 - Wireless, non-invasive, and portable brainwave recording device for convenient at-home sleep monitoring and analysis to: 1-offer insight into the diagnosis and treatment of conditions such as Alzheimer's, autism, cancer, epilepsy, depression, and schizophrenia and 2-reveal how drugs affect the brain
• Company 277 - Implantable drug delivery device using nanochannel-based chip to control/modulate release
• Company 278 - Non-invasive device to alleviate the symptoms of subjective tinnitus that synchronously presents sound using headphones and tactile representations to an intra-oral array on the tongue
• Company 279 - A family of single-use devices that provide quantitative pressure measurements, while alleviating doubt and uncertainty during common medical procedures such as central line insertions, spinal taps, and epidurals
• Company 280 - Ozone injection system for multiple spinal applications, including herniated disc, to eliminate the need for multiple steroid injections and/or a surgical discectomy
• Company 281 - Bone anchorage technology for use in spine, trauma, and general orthopedics
• Company 282 - Non-systemically absorbed compounds for the treatment of diabetes and obesity, as an alternative to gastric bypass surgery
• Company 283 - Diagnostic tests that leverage the ability to extract clinically relevant information from maternal blood, including a non-invasive prenatal test to diagnose specific genetic and other inherited disorders
• Company 284 - Regenerative stem cell therapy to treat heart failure (HF), acute myocardial infarction (MI), angina, peripheral artery disease (PAD), and hard-to-heal wounds including burns, diabetic foot ulcers, venous stasis ulcers, and pressure ulcers
• Company 285 - A non-invasive hand-held system for accurately measuring circulating blood volume in real-time, to quickly identify and treat shock
• Company 286 - Device used to safely deliver epidural anesthesia during childbirth and other procedures
• Company 287 - Implantable neurostimulation device for the treatment of obstructive sleep apnea (OSA)
• Company 288 - Pressurized olfactory drug delivery device to bypass the blood brain barrier and deliver greater pharmaceutical concentrations
• Company 289 - Pancreatic islet cell transplantation as a potential cure for Type I diabetes
• Company 290 - Liver dialysis system that removes protein-bound toxins plus water-soluble toxins from blood and is more effective and cost-efficient than currently available therapies
• Company 291 - System that is capable of simultaneous quantitative and independent determination of up to 100 biomarkers in individual cells, not possible with existing technologies, for early disease diagnosis and monitoring of treatment efficacy
• Company 292 - Molecular testing that analyzes gene expression in airway epithelial cells to detect early signs of lung cancer
• Company 293 - Biocompatible surgical mesh with high tensile stiffness and strength, similar to native tendon, that is sutured over torn or degenerative tissue as a reinforcement to surgical repair to allow for rapid tissue in-growth
• Company 294 - Next-generation quantitative angiography
• Company 295 - A "smart shirt" that can count a patient's heartbeats through its sensors, record a medical quality electrocardiogram (ECG), and detect the respiration rate, body temperature, and position of the patient (standing, walking, lying, asleep, or fallen)
• Company 296 - Soft, flexible devices with tissue-like characteristics that can be used for health and wellness, cardiology, and neurology to make surgical diagnosis and treatment easier - based on a new generation of thin, conformal electronics technology that endures bending, twisting, and stretching without sacrificing performance
• Company 297 - Technology that manages the exit sites of central venous catheters by promoting the formation of a biological seal around the catheter that blocks the route for bacteria
• Company 298 - A non-invasive, optical brain monitor for monitoring hypnosis (depth of anesthesia) and level of sedation via direct non-invasive measurement of changes in deoxyhemoglobin (deoxy Hb)
• Company 299 - A disposable skin patch that provides diabetics with a painless, BLOODLESS, easy-to-use, and rapid method for monitoring glucose levels
• Company 300 - Interwoven biopolymer 3D-oriented matrices that more accurately mimic natural extra cellular matrix (ECM) for use in cell and tissue engineering applications
• Company 301 - Revolutionary HyperQ technology based on advanced signal processing of the high frequency ECG signal, enabling more accurate results in the initial diagnosis of coronary artery disease (CAD)
• Company 302 - Optical Ultrasound Tomography(R) (OUT) identifies brain injuries, brain hematomas, malignant breast cancers, and Inflammatory Breast Cancer safely and quickly and displays 3D images in "real time" and can transmit the images to waiting hospitals and surgeons. The cameras are lightweight and portable, and can be mounted on a bedside providing continuous monitoring of hemorrhages and the flow of blood. They can be used in an ambulance, on the battlefield, on the Little League field, and in the ER.
• Company 303 - A scalable molecular diagnostic chip platform that will allow for the diagnosis of diseases in five minutes as well as in-home monitoring of conditions such as: profound venous thrombosis, embolisms, and myocardial infarctions (MI)
• Company 304 - Transcutaneous vagus nerve stimulation to treat patients suffering from drug-resistant epilepsy or other difficult-to-treat neurological and psychiatric disorders
• Company 305 - Implantable device consisting of a series of miniature magnetic beads, linked together to form a "bracelet" around the Lower Esophageal Sphincter (LES) for the treatment of gastroesophageal reflux disease (GERD)
• Company 306 - Wireless 3G cellular-enabled blood glucose meter that instantly transmits glucose values to a care-management server and provides instant feedback and coaching to patients with diabetes
• Company 307 - Accurate, ultra-low-cost whole genome sequencing by way of a simple, single-molecule detection process
• Company 308 - Drug therapy focusing on the carotid body for the treatment of sleep-related breathing disorders
• Company 309 - Deep brain stimulation probe technology for advanced and personalized treatment of degenerative or functional brain disorders, such as Parkinson's disease and dystonia
• Company 310 - Versatile, easy-to-use, accurate, and cost effective aorto-ostial stent positioning system to facilitate precise stent implantation in coronary and renal arteries
• Company 311 - Device that increases the size of skin grafts without the use of chemicals, biologics, or enzymes
• Company 312 - Immediate and permanent contraception implant for women to use as an alternative to surgical tubal ligation
• Company 313 - Tissue expander technology that allows both diagnostic and therapeutic capabilities never before available during tissue expansion
• Company 314 - Tendon repair device that utilizes a simple and familiar technique to ingeniously join tissue together, with broad applications across a range of surgical sub-specialties
• Company 315 - Novel solutions for wound closure
• Company 316 - Sternal closure system that maintains rigid fixation of the sternum in multiple directions of force and eliminates the common causes of sternal dehiscence
• Company 317 - Bioseparation technology, for use outside of the research lab, with broad applications from molecular diagnostics to transplant therapies
• Company 318 - Non-invasive system for the treatment of acute ischemic stroke and other vascular disorders using externally applied ultrasound that can be rapidly and easily deployed by virtually any emergency room staff
• Company 319 - Genomics-based diagnostic tests for obstructive coronary artery disease (CAD), cardiac arrhythmias, and heart failure (HF)
• Company 320 - Nicotinic receptor agonist compounds for the treatment of asthma and other inflammatory respiratory and non-respiratory diseases
• Company 321 - Femoral vascular access catheter that uses a longer and shallower angle arteriotomy, providing better site closure WITHOUT vascular closure implants
• Company 322 - Surgical instruments, medical lasers, and other medical devices
• Company 323 - KeyHole Cup(R) is designed to provide a safer and efficient entry into the abdominal cavity during laparoscopic surgery. It allows for a more rapid insufflation than standard techniques, mitigating associated risks.
• Company 324 - Cost-effective lab-on-a-chip system that anyone can use to get laboratory quality results in any location, within minutes, and with minimal training
• Company 325 - ImagistxProstate(R), a breakthrough prostate imaging technology providing a diagnostic tool to identify prostate cancer via its 21 MhZ center frequency, 512 element array, and 3D ultrasound capabilities
• Company 326 - Proven patented technology platform that rapidly and accurately measures oxidative stress and oxidizability in blood and other biologic fluids, with multiple diagnostic applications
• Company 327 - Real-time pathology solution for cancer surgical guide, with microchip-based in vivo imaging systems
• Company 328 - A disposable, flexible conduit that provides a protective channel through which an endoscope is inserted for sinus surgery, to keep the introduction site open throughout the course of the procedure, thereby minimizing trauma along the nasal passageway
• Company 329 - Novel bilateral brain monitor with independent hemisphere indexing for the direct measurement of the effects of anesthetics and sedatives, which allows for patient-specific dosing
• Company 330 - Intelligent continuous glucose monitoring device utilizing recent innovations in microneedle and bluetooth technology, to provide a more accurate and pain-free method than what current devices offer
• Company 331 - Professional and home use devices for automated bladder assessment incorporating a novel, extremely compact, 3D ultrasound scan head and embedded image processing technology
• Company 332 - Ultrasound-based molecular imaging agents that can be used to: 1-diagnose and stage disease, 2-monitor response to therapy in the pharmaceutical research setting, and 3-elucidate the biology of disease processes in the basic science setting
• Company 333 - Portable brain sensing system to rapidly diagnose ischemic stroke at point-of-care; other indications include identification of brain trauma and cerebrovascular abnormalities and continuous monitoring of stroke patients
• Company 334 - Minimally invasive system for decompressing pinched nerves in the spine, based on highly maneuverable tools and a precise tissue-removal mechanism
• Company 335 - The Vortex ZDS(TM) catheter reduces Catheter Associated Urinary Tract Infections (CAUTIs) by at least 50% to replace Foley catheter as the indwelling urinary catheter of choice
• Company 336 - Non-invasive real-time diagnostic tools for early detection, prevention, and management of Acute Kidney Injury (AKI) in critical care environments
• Company 337 - A unique permanent injectable bulking agent for the endoscopic treatment of GERD (chronic heartburn)
• Company 338 - Therapies for the treatment of acute wounds, chronic wounds, scarring, abnormal scarring, inflammation and pain, fibrosis, surgical adhesions, and orthopedic procedures
• Company 339 - A Percutaneous Tracheostomy (PT) system that simplifies the traditional PT technique to be used by more physicians OUTSIDE of the Operating Room (OR) and in faster times than current devices
• Company 340 - Mammary Aspirate Specimen Cytology Test (MASCT System(TM)) that collects a small amount of nipple aspirate fluid (NAF) in 10 minutes, using no radiation and is painless
• Company 341 - Cardiac mapping catheters to analyze electrical heart activity for the diagnosis of cardiac arrhythmias
• Company 342 - Thermal infusion fluid warmer device that enables surgeons to manage and warm up to five fluids at once
• Company 343 - Next-generation insulin analogs for both the rapid-acting and long-acting insulin markets
• Company 344 - New embolotherapy catheter that minimizes reflux when administering medication
• Company 345 - Non-surgical, removable hearing device that transmits sound through the teeth for the treatment of single-sided deafness
• Company 346 - Medical devices for the treatment of neurovascular conditions
• Company 347 - Next generation X-ray scintillator device that provides high resolution imaging
• Company 348 - Permeable, micro-porous, flexible, and user-friendly implants in tubular or patch shape for bone reconstruction and fracture repair in surgical procedures
• Company 349 - Flexible endoscopy and endoluminal surgery device
• Company 350 - Drug therapy for the treatment of inner and middle ear disorders
• Company 351 - In vivo optical imaging devices for real-time diagnosis in a broad range of applications
• Company 352 - Headset that detects and records brainwaves for the diagnosis of Alzheimer's disease and other neurological disorders
• Company 353 - Drug therapy by way of modulating the N-methyl-D-aspartic acid receptor for the treatment of depression and other central nervous system disorders
• Company 354 - Smart-phone based ultrasound imaging system
• Company 355 - Minimally invasive devices using radiofrequency (RF) energy for the treatment of gastroesophageal reflux disease (GERD) and fecal incontinence (FI)
• Company 356 - Portable, non-invasive device designed to offer transcutaneous pulsed electro-magnetic field stimulation therapy for treating post-operative pain and inflammation in superficial soft tissue
• Company 357 - Implantable electronic gastric stimulation device for the treatment of obesity
• Company 358 - High-intensity ultrasound energy for non-invasive reduction of arterial plaque
• Company 359 - Catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels
• Company 360 - The VortxRX delivers non-invasive Histotripsy with image guidance to treat benign prostatic hyperplasia (BPH). Histotripsy homogenizes prostatic tissue non-thermally as it is monitored in real time with ultrasound imaging.
• Company 361 - Robotic and manual endoscopy devices for increased ergonomics during laparoscopic surgery
• Company 362 - Eye-tracking device for earlier diagnosis of Parkinson's disease and other neurological diseases
• Company 363 - Device that uses localized vibrations to reduce pain during injections
• Company 364 - The first non-invasive, prep-free imaging test for colon cancer
• Company 365 - Biologically-active plastic surgical patch for rotator cuff and tendon injuries, designed to promote healing and formation of new bone
• Company 366 - Catheter-based drug delivery system for the treatment of vascular disease and restenosis
• Company 367 - Anti-infectives for the treatment of severe infectious diseases
• Company 368 - Device for the intraocular delivery of photoactive nanoparticles for the treatment of retinitis pigmentosa, macular degeneration, and diabetic retinopathy
• Company 369 - Venous stenting device and ablation technology for the treatment of chronic venous disease
• Company 370 - Devices that facilitate minimally invasive access to a beating human heart and the delivery of therapeutic options intended to treat complex cardiovascular diseases
• Company 371 - Customized Sound Therapy (CST) system for tinnitus therapy
• Company 372 - Artificial sphincter device for use in ostomy and stoma care
• Company 373 - Microcatheters for treating and preventing acute ischemic stroke
• Company 374 - Spinal probe that uses radiofrequency (RF) ablation on nerves thought to be the cause of chronic back pain
• Company 375 - Disposable device for the prevention of catheter-related infections from hemodialysis
• Company 376 - Single-use needle-free injection system for liquid medications
• Company 377 - Non-invasive Auto-Targeting Neurostimulation (ATN) device for high-stimulation pinpoint treatment of lower back pain
• Company 378 - Portable, patch-based device that delivers "slow release" ultrasound to treat localized pain and induce soft tissue healing
• Company 379 - Shape memory implants that restore motion and eliminate pain for patients requiring soft tissue repair, fracture fixation, or joint fusion
• Company 380 - Removable adhesion barriers for spinal, tendon, and nerve-related surgery to reduce post-operative scarring, pain, numbness, muscles weakness or limited motion
• Company 381 - Orthopedic implants for limb lengthening/correction/reconstruction
• Company 382 - Neurocatheter for the removal of blood clots in the brain
• Company 383 - Portable/mobile nuclear cardiology imaging system
• Company 384 - The first and only wire-independent embolic protection that uses any single guide wire of choice for the entire procedure and seamlessly integrates with standard workflow
• Company 385 - Single-use devices that will address epicardial access, protection, and treatment facilitating the electrophysiologist's ability to perform cardiac ablations more efficiently and with a higher degree of safety and effectiveness
• Company 386 - Irrigation devices for improved visualization during upper and lower gastrointestinal (GI) procedures
• Company 387 - DNA-testing platform that enables results from a wide variety of gene signatures to be delivered quickly, simply, and cost-effectively at the point-of-care (POC) within an hour
• Company 388 - A market leading non-invasive hypoglycemic symptom detection device that protects diabetics from emergency low-blood sugar events. Hypoglycemia healthcare costs average $7,000 per episode and can result in death to the patient.
• Company 389 - High-stability, short-length expandable implants that eliminate the need for complex bone augmentation - shortening overall time to implantation and significantly lowering treatment costs
• Company 390 - System that cools cerebral spinal fluid to reduce injuries associated with spinal and cerebral ischemia
• Company 391 - Infection control technology that does something no other product can - protect and disinfect BOTH the needleless injection site and the end of the IV tubing male luer
• Company 392 - Biodegradable, inflatable balloon device which separates healthy organs from adjacent tumors receiving radiation therapy
• Company 393 - The first passive fetal movement monitor (detector, analyzer, and data logger) for expectant mothers to use at home
• Company 394 - A minimally invasive implantable pulse generator (IPG) to treat obese and type II diabetics by applying electrical stimulation to the duodenum
• Company 395 - Implantable artificial pancreas for the treatment of patients with Type I & Type II diabetes
• Company 396 - Non-invasive hand-held device that detects abnormal heart sounds and uses a smart-phone interface for the diagnosis of coronary artery disease (CAD)
• Company 397 - Aerosol technology which efficiently delivers therapeutics into the abdominal cavity of patients during surgery to combat post-surgical complications such as pain and adhesions
• Company 398 - Self-powered miniature pacemaker and leadless electrodes implantable through minimally invasive procedures; used to treat arrhythmia
• Company 399 - Innovative sutureless technology for blood vessel anastomosis
• Company 400 - Incubator with 12 fully owned portfolio companies and 20+ fully owned pipeline technologies, driven by unmet market need
• Company 401 - The only device enabling simultaneous, non-invasive, and continuous measurement of blood flow and oxygen saturation
• Company 402 - Functional optical imaging technology for the early diagnosis and guided treatment of blinding retinal diseases and diseases of other organs of the body; it is the only optical imaging approach that allows visualization of the capillaries, non-invasively (without any contrast agent)
• Company 403 - A point-of-care diagnostic system for rapid, sensitive, quantitative biomarker panels that delivers laboratory-quality results in a clinic or doctor's office, within minutes
• Company 404 - Next-generation, cost-effective ophthalmic implants made from STAR(R) biomaterial that will help patients suffering from glaucoma and corneal blindness
• Company 405 - Continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of tight glycemic control (TGC) in the intensive care unit (ICU)
• Company 406 - Non-invasive devices for continuous real-time evaluation of hemodynamic changes
• Company 407 - Grafts for small diameter (less than 5mm) artificial blood vessels in both peripheral and coronary applications
• Company 408 - 1-Deep brain stimulator (DBS) to treat movement disorders, 2-A hybrid auditory implant (HAI) to treat severe hearing loss
• Company 409 - Innovative hydrogel technology for tissue repair including cartilage, bone, and dermal of the knee, wrist, elbow, shoulder, and ankle
• Company 410 - An ophthalmic device company delivering Navigated Retinal Laser Therapy to address the unmet need for durable and cost-effective outcomes in the treatment of major vision-threatening retina diseases, primarily caused by a complication of diabetes
• Company 411 - Best-in-class platform to optimize genes and proteins in human therapeutics
• Company 412 - Cloud/web-based medical imaging data management software and infrastructure as services - to replace picture archiving communication system (PACS) at a significantly reduced cost
• Company 413 - Incubator with over 100 highly novel medical technology inventions spanning most medical markets
• Company 414 - The only minimally invasive cure for spinal stenosis that maintains the natural dynamics of the spine
• Company 415 - Technology to embed Nitric Oxide (NO), part of the innate immune system, into polymer medical devices to make them antimicrobial without the issues of antibiotic resistance
• Company 416 - Minimally invasive catheter-based system that safely, rapidly, and effectively removes thrombus and restores blood flow in the peripheral vasculature utilizing ultrasound energy to destroy clots, without harming adjacent healthy tissue or generating dangerous emboli
• Company 417 - 1-Effective cryosurgical tool that is simple and safe to use without cryogenic gasses or liquids for all medical office skin lesion removal needs, 2-Cervical freeze attachment for gynecology use, 3-Third-generation technology to accommodate cryosurgical treatments for prostate, liver & renal cancers and cardiac aberrant foci ablation
• Company 418 - Remote (wireless) continuous EEG (cEEG) brain monitoring of critical care patients that significantly reduces mortality rates, improves patient outcomes, and saves millions of dollars in patient care expense
• Company 419 - Atherosclerotic plaque dissolution through chemical means for treating occlusive and non-occlusive atherosclerotic disease that may reduce the need for permanent implants like drug-eluting stents (DES), while also potentially addressing plaque instability
• Company 420 - Revolutionary raman-spectroscopy based platform technology licensed from the BC Cancer Agency to aid in the early detection of cancer
• Company 421 - 1-Non-invasive in vitro diagnostic (IVD) blood test for the detection and/or monitoring of 14 different types of cancer, 2-Combination Immunogene Therapy (CIT) technology that could lead to a vaccine or possibly treat those already diagnosed with cancer
• Company 422 - A low-cost, clip-on eye-piece for mobile phones that mimics and replaces the expensive laser-based Shack-Hartmann wavefront aberrometers to diagnose the most common refractive eye disorders: myopia (nearsightedness), hypermetropia (farsightedness), astigmatism, and presbyopia (age-related visual impairment)
• Company 423 - Non-invasive, rapid assessment of dP/dt in Cardiac Resynchronization Therapy (CRT) for lead placement, lead optimization, and monitoring
• Company 424 - Unique, patented, activated collagen, CellerateRX(R) for the expanding diabetes and greater wound care markets
• Company 425 - A medical implant surface technology company focused on the design and manufacturing of proprietary and cellular-friendly interbody fusion devices for the spine
• Company 426 - Anatomically appropriate orthopedic implants, unique instrumentation, and biologics for pediatric and small stature patients
• Company 427 - Proprietary medical devices and patient interfaces for the enhancement of patient safety through capnography monitoring
• Company 428 - 1-Adult stem cell collection and storage, 2-VSEL(TM) (very small embryonic-like) stem cells for tissue regeneration, 3-Contract cell manufacturing for clients around the world, Progenitor Cell Therapy, 4-Therapeutics such as a T-cell regulatory technology to treat disorders of the immune system, 5-A wound healing technology that uses autologous bone marrow-derived stem cells, 6-An autologous bone marrow-derived cell line selected to treat damaged heart muscle following AMI
• Company 429 - A business and technology research & development platform, dedicated to delivering innovative solutions for the musculoskeletal disorders industry
• Company 430 - Ellanse, the first dermal filler family offering a complete customized solution in medical aesthetics
• Company 431 - A Peripheral Nerve Stimulation (PNS) system for patients suffering from severe, intractable pain
• Company 432 - Portable, disposable, non-powered suction device for negative pressure wound therapy (NPWT)
• Company 433 - Device that prepares 10 million micro-droplets per hour for use in drug discovery, genomics, molecular epidemiology, and proteomics
• Company 434 - Non-invasive imaging system for the early detection of pre-cancerous tissue and to guide early treatment intervention
• Company 435 - A handheld breath analyzer for the measurement of fat metabolism
• Company 436 - Portable pediatric vision-screening device for early diagnosis of serious vision abnormalities
• Company 437 - Minimially invasive percutaneous implantable cardioverter defibrillator (PICD) for the treatment of cardiac arrhythmias
• Company 438 - A non-invasive, automatic analyzer that uses measurements of sweat gland activity to determine whether a patient is at risk for diabetes
• Company 439 - Compact, home-based device for male fertility assessment
• Company 440 - Device for the early detection, assessment, and monitoring of mild perceptual impairment (MPI), an early indicator of mild cognitive impairment
• Company 441 - Device providing sustained intravesical drug delivery for the treatment of Overactive Bladder (OAB), Interstitial Cystitis (IC), and other bladder conditions
• Company 442 - Percutaneously-inserted interspinous process fusion cages that provide for stabilization of the spine
• Company 443 - Implantable neurostimulation system for the treatment of obstructive sleep apnea (OSA)
• Company 444 - Physical and chemical resurfacing of orthopedic implants and stents which allows for drug elution without the use of a binding polymer
• Company 445 - Wireless, implantable heart device that allows Congestive Heart Failure (CHF) patients to monitor data using a handheld instrument
• Company 446 - Percutaneous vertebral augmentation (PVA) system for controlling bone cement delivery and leakage during spinal surgery
• Company 447 - Remotely controlled percutaneous catheter system for use in a wide range of interventional applications
• Company 448 - Novel and clinically-validated percutaneous approach for the treatment of functional mitral regurgitation in the heart failure population
• Company 449 - Sutureless, anastomotic connectors to provide a controlled method of joining vessels
• Company 450 - Minimally invasive orthopedic device for the treatment of hip pain
• Company 451 - Handheld device for monitoring chronic disease home-care patients using a single drop of blood
• Company 452 - 1-Novel 510(k)-cleared XCOIL(TM) mechanical thrombectomy device initially targeting DVT and stroke patients and 2-Novel 510(k)-cleared EViTAR(TM) double-lumen, coaxial neurocatheters for intracranial delivery of small molecules, biologics, stem cells/gene-based therapies, and smart sensor enhancements
• Company 453 - Microwave-based soft tissue ablation
• Company 454 - Implantable device to treat epilepsy by anticipating seizures and delivering intracranial drugs
• Company 455 - Injectable, synthetic bone subsitutes
• Company 456 - Device that delivers iron transdermally for patients with iron-deficiency anemia
• Company 457 - Implantable pacing and defibrillation device that detects the early onset of atrial fibrillation and chronic heart failure and delivers targeted medications
• Company 458 - Device for dry powder pulmonary delivery to treat patients with Parkinson's disease
• Company 459 - A thrombectomy catheter for peripheral artery disease (PAD) that features a rotating, extending tip
• Company 460 - A unique, non-invasive tool for the analysis of muscle function to assist in the evaluation and treatment of neck and back injuries and illnesses
• Company 461 - Vital signs monitoring device for use as an early congestive heart failure (CHF) crisis indicator at home, to avoid acute/expensive hospitalizations
• Company 462 - Novel bioresorbable regenerative scaffolds that provide 3D architecture for enhanced tissue repair
• Company 463 - Novel implantable ultrasound flow-measuring devices with flow data wirelessly transmitted from within the body
• Company 464 - Technology for nurses/pharmacy technicians/emergency responders to more safely and effectively vaccinate the public in the event of a biological or viral pandemic
• Company 465 - Modular, powered, proprietary articulating technology for endoscopes and laparoscopes, enabling surgical safety, flexibility, and procedural innovations
• Company 466 - Medical image viewing solution that enables physicians to access/view critical patient images/information from anywhere, without compromising the security/privacy of the data
• Company 467 - An elegant, user-friendly alternative to traditional eye dropper bottles that will allow multi-dose of preservative-free ophthalmic formulations
• Company 468 - Device-based technology with an anti-inflammatory therapeutic platform to appreciably widen the present window of treatment for ischemic stroke to 12-18 hours
• Company 469 - Novel micro-texture pattern applied to surfaces and medical devices to inhibit bacterial colonization and reduce infection by producing an unsuitable environment for growth; this no-kill approach without the use of biocides does not contribute to antimicrobial resistance
• Company 470 - StimBrace addresses osteoarthritic knee pain by intelligently strengthening leg muscles to stabilize and brace the knee during real-world use
• Company 471 - Image-guided interventional endoscopy products
• Company 472 - An expandable, funnel-shaped cannula for the removal of intravascular material during extracorporeal circulation
• Company 473 - Teraherz-based, real-time, video-rate imaging system
• Company 474 - A wearable product that uses Touch Activated Phlebotomy (TAP) technology to reduce the inconvenience of blood sampling and facilitate simpler diagnoses
• Company 475 - Radiofrequency (RF)-based detection systems to reduce the risk of retained surgical sponges
• Company 476 - A removable surgical implant to improve vision loss resulting from presbyopia
• Company 477 - A minimally invasive, green, laser-based technology for the treatment of benign prostatic hyperplasia (BPH), as an alternative to traditional TURP surgery
• Company 478 - An artificial silicone microchip, which stimulates retinal cones and rods to restore retinal function
• Company 479 - An automated, continuous glucose monitor for bedside use in intensive and critical care
• Company 480 - A small, injectable ophthalmic implant containing multiple, laser-activated reservoirs designed for the on-demand, physician-controlled release of ocular drug therapies to the back of the eye
• Company 481 - A non-invasive, portable device that treats glioblastomas with electrical fields
• Company 482 - A bionic retina designed to restore sight to millions blinded by retinal degenerative diseases
• Company 483 - 1-Biochemical sensing technologies for continuous glucose monitoring and 2-Drug-delivery devices for osteoporosis management
• Company 484 - Less invasive technologies and a more effective option for Primary Open Angle Glaucoma patients
• Company 485 - 1-A long-term cardiac rhythm monitor and 2-A disposable electrocardiography (ECG) monitor for use for up to 30 days
• Company 486 - Devices for arthroscopy, hip, knee, and spine surgery, in addition to radiofrequency identification (RFID) tracking technology
• Company 487 - A percutaneous implant for mitral valve repair
• Company 488 - Capsule-based hydrogels to reduce food intake in obese patients
• Company 489 - Novel, implantable cardiovascular device for the treatment of a prevalent cardiovascular condition
• Company 490 - Whole-body imaging technology for orthopedic applications
• Company 491 - Advanced surgical devices for ear, nose, and throat (ENT) surgery
• Company 492 - 3D full-breast ultrasound imaging device for the detection of benign or malignant masses
• Company 493 - Radiofrequency (RF)-based device for the treatment of congestive heart failure (CHF)
• Company 494 - A wireless, touch-screen insulin pump featuring a blood glucose meter, food library, and an activity monitor
• Company 495 - Synthetic cartilage technology for joint repair
• Company 496 - A vertebral restoration system that uses spine-specific osteogenic biomaterials to restore vertebral stability
• Company 497 - Advanced long-term hemodialysis and peritoneal dialysis catheters
• Company 498 - Portable and advanced point-of-care diagnostics equipment
• Company 499 - Endovascular device targeting the treatment of abdominal aortic aneurysms (AAAs)
• Company 500 - A wireless, remote-controlled unit targeting tissue expansion for breast reconstruction
• Company 501 - User-friendly, simple, and needle-free transdermal delivery system that can deliver a broad range of compounds, including: peptides, proteins, small molecules, and vaccines
• Company 502 - Brachytherapy device for gynecological cancers
• Company 503 - Ophthalmic implant for improved vision in patients with end-stage age-related macular degeneration (AMD)
• Company 504 - Small, disposable, discreet, and very convenient alternative to CPAP for obstructive sleep apnea (OSA) patients
• Company 505 - A wearable, battery-operated, bionic leg - used as a robotic aid during therapy sessions, until the patient recovers their gait so they can walk/continue to improve without it
• Company 506 - Surgical films, meshes, sutures, and other products constructed from a new class of absorbable biomaterials
• Company 507 - Advanced sealants and anti-adhesion agents for use in vascular and general surgery
• Company 508 - Devices to treat diseases and injuries of the foot and ankle, resulting in faster ambulation, superior cosmesis, and less pain
• Company 509 - Benchtop-based positron emission tomography (PET) imaging system
• Company 510 - System that features an intramedullary implant for fusion or fixation of the sacroiliac (SI) joint using a small incision
• Company 511 - Magnetic technology used to destroy blood clots
• Company 512 - P.L.E.A.S.E.(R) (Precise Laser Epidermal System) - a novel transdermal delivery device for high molecular weight drugs, that can be used by medical personnel or the patient
• Company 513 - Technology platform that uses physical vapor deposition, thin film technology, and thin film metals to produce stents and other implants that feature greater biocompatibility
• Company 514 - Laparoscopic devices for single-port surgery and natural orifice transluminal endoscopic surgery (NOTES)
• Company 515 - Device that stimulates the urinary bladder electrically in order to modulate key renal functions, thus, breaking the vicious cycle of cardio-renal interaction in congestive heart failure (CHF) patients
• Company 516 - Endometrial ablation system that uses a low-profile insertion diameter, automatic power settings, an atraumatic tip, and an ergonomic handle, to provide therapy quickly and comprehensively
• Company 517 - A two-step treatment for ischemic stroke patients that provides rapid reperfusion as well clot capture and retrieval
• Company 518 - Transcatheter cardiac valve replacement technology
• Company 519 - Laser system that uses an integrated ocular measurement technology and short-pulse laser to perform surgical incisions for refractive cataract surgery
• Company 520 - Advanced surgical field illumination technologies to improve surgeon visualization and reduce surgeon fatigue in less invasive surgery
• Company 521 - Home dialysis system that integrates multiple, advanced micro-technologies
• Company 522 - Deep brain stimulation (DBS) technology for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI)
• Company 523 - External fixation system that uses specialty clamps to: reduce the construct weight, enable greater flexibility for the surgeon, and reduce operating times
• Company 524 - Ablation system that uses a specialty catheter to deliver low-pressure liquid nitrogen for tissue ablation during endoscopy
• Company 525 - Disposable device to provide fast, objective measurement of vaginal cervical length, which assists in the determination of whether the patient is undergoing preterm labor
• Company 526 - Optical sensing technology for non-invasive pH monitoring of stored platelets
• Company 527 - Software allowing physicians to remotely monitor vital signs using smartphones and hybrid tablet devices such as the iPhone, BlackBerry, Android, Windows Mobile devices, and iPad/Android-based tablets
• Company 528 - Patch-based technology that delivers a weekly, low-dose contraceptive to women
• Company 529 - Integrated system that monitors the activity of patients and caregivers in long-term care environments and features a proprietary fiberoptic sensor to detect patient movement, thereby detecting falls and helping to prevent pressure ulcers
• Company 530 - Remotely-operated, in vivo, miniature robotic products for laparoscopic surgery
• Company 531 - Angioplasty stenting system intended to reduce procedure times
• Company 532 - Integrated system comprising reusable and disposable devices, components, and software to enable magnetic resonance imaging (MRI)-guided neurological procedures
• Company 533 - Devices used to assist in the introduction and advancement of endoscopes in the upper and lower gastrointestinal (GI) tract
• Company 534 - Wireless platform for continuous monitoring of vital signs
• Company 535 - 510(k) cleared device using acoustic reflectometry to continuously monitor breathing tubes for placement, movement, and obstruction, enabling adverse event prevention
• Company 536 - Platform of technologies used to lower intraocular pressure (IOP) for glaucoma patients, including the Gold Shunt implant, the 790 laser for trabeculoplasty, and a sensor to continuously monitor IOP
• Company 537 - Paddle that measures the mechanical properties of breast tissue during mammography, reducing pain and discomfort
• Company 538 - Implantable neurostimulation device to treat inflammation
• Company 539 - Repositionable transcatheter aortic valve replacement system
• Company 540 - Technology to treat cardiac arrhythmias
• Company 541 - Diagnostic system for hematology and HIV-immune monitoring in developing countries
• Company 542 - Bronchoscopically-placed nitinol coil for lung volume reduction
• Company 543 - Controlled electrical pulses delivered to nerve clusters to improve swallowing function and control in patients with acute dysphagia
• Company 544 - Hand-held device intended for use in facial rejuvenation
• Company 545 - Hand-held device that deactivates the axillary glands using electromagnetic energy, thereby eliminating the problem of massive underarm sweating
• Company 546 - Hand-held point-of-care and home-based testing devices that measure blood viscosity for patients taking Warfarin
• Company 547 - 3D scanning technology that measures ear canal shape and tissue compliance
• Company 548 - Bioabsorbable drug-eluting stent for chronic sinusitis patients
• Company 549 - Catheter securement system that features a small anchor placed subcutaneously
• Company 550 - Wireless systems to enable remote safety and wellness monitoring for geriatric patients
• Company 551 - An intravascular continuous glucose monitor comprising a single-use catheter and sensor system that enables direct measurement of plasma glucose in flowing blood
• Company 552 - Non-invasive meters for continuous glucose monitoring
• Company 553 - The DISTALOCK Intramedullary Nail and Drill System uses an innovative approach to facilitate the accurate placement of locking screws used to stabilize the rod-like implants, or nails, used for long bone fractures
• Company 554 - Drug-eluting balloon product for cardiac and peripheral arteries
• Company 555 - Advanced vascular closure device designed to reduce the time to hemostasis
• Company 556 - Low-energy, pain-free atrial cardioverters for atrial fibrillation (AF)
• Company 557 - Combines imaging technology and advanced algorithms to assess early embryo viability at the 4-cell stage
• Company 558 - Radiofrequency-based ablation catheter for atrial fibrillation (AF) that features integrated microwave radiometry technology
• Company 559 - Non-surgical procedure to reverse some of the physical effects of vaginal childbirth
• Company 560 - Intravenous (IV) catheter system which substantially increases successful IV insertions and provides top-of-class passive needle safety; also applicable to many other vascular access applications where higher success rates and less vessel trauma are important
• Company 561 - Spine implant system that stabilizes and restores the spinal anatomy of persons that have suffered a vertebral compression facture (VCF)
• Company 562 - 1-Trans-nasal catheter for real-time imaging of atrial fibrillation (AF) ablation procedures; 2-Intra-cardiac catheter for real-time image guidance of percutaneous valve and other structural heart repair procedures; 3-High-definition intravascular ultrasound (IVUS) system, with near-OCT image resolution; and 4-Image-guided, endoventricular injection catheter for stem cell and/or biological agent therapy for congestive heart failure (CHF)
• Company 563 - Next-generation solution for patent foramen ovale (PFO) closure that directly treats the pocket of the PFO (in-tunnel closure), while minimizing the impact to the atrial spaces
• Company 564 - Hydrogel-based ocular bandage to protect clear corneal incisions following cataract and intraocular lens placement surgery, covering vulnerable tissue as the incision heals, and reducing pain and discomfort in the days following surgery
• Company 565 - Hand-held intra-operative surgical probe used in diagnosing, staging, and treating breast cancer, to reduce residual cancer/repeat surgery after breast cancer lumpectomies
• Company 566 - Effective antimicrobial coatings and compounds that are broad-spectrum and fast-acting against clinically relevant pathogens, including multi-drug resistant strains such as MRSA
• Company 567 - Next-generation drugs with better efficacy and safety, plus longer duration of action, for rheumatoid arthritis, anemia, organ transplants, and blood diseases
• Company 568 - Next-generation extracellular matrix (ECM) products for advanced wound healing and tissue regeneration, with improved handling, strength, resorbability, and infection control over existing products
• Company 569 - Low-cost disposable devices that enable efficient and patient-friendly delivery of colonoscopy and colon prep services at convenient care settings on a walk-in basis
• Company 570 - System that provides a new direction in dialysis, through a new mode of access through two implantable ports that allow safe repeated access into arteries and veins, so that the dialysis process works with the natural direction of blood flow
• Company 571 - Polymer-based liquid bandage with antimicrobial properties to: cover intact skin or minor cuts, scrapes, burns, and minor irritations of the skin; help keep them clean and dry; and help protect them from infection
• Company 572 - Disruptive diagnostic platform, using an innovative multi-modality approach, to advance cardiovascular health assessment for the prevention of heart attack and stroke
• Company 573 - Fixation with compression technology that offers significant improvement over existing products with applications in small & long bone, spine, and the sternum
• Company 574 - First spinal instrumentation system developed specifically to restore healthy kinematics in lumbar flexion for the treatment of lumbar spinal stenosis with or without degenerative spondylolisthesis
• Company 575 - A portable pneumatic compression system for the treatment of venous and arterial insufficiency, to be used in the hospital, secondary care facility, and home
• Company 576 - Revolutionary portable device to provide easy and efficient screening methods for early detection of age-related macular degeneration, diabetic maculopathy, and other types of retinal disease in the human eye
• Company 577 - Highly effective non-toxic cancer therapy based on the use of recombinant human alpha-fetoprotein conjugated with cytotoxic drug
• Company 578 - Orthopedic implants for the reconstruction of distal extremities
• Company 579 - Implant fault detection and monitoring technology
• Company 580 - Leak-proof, rupture-proof breast implant technology, with the potential to replace all existing saline and gel implants
• Company 581 - Next-generation non-invasive portable ultrasound system for the treatment of fat, skin, and other plastic surgery and dermatology applications at all anatomical sites - without anesthesia and surgery
• Company 582 - Highly multiplexed real-time PCR-based assays for the accurate detection of hospital-acquired antibiotic resistant bacteria such as MRSA, MSSA, and pathogens causing Sepsis and gastrointestinal infections
• Company 583 - 24-hour intraocular pressure monitoring of glaucoma patients by a telemetric, implantable micro sensor
• Company 584 - Electrochemical biosensors for the in-hospital diagnostics, home health care, and consumer diabetes markets
• Company 585 - New medical grade preservative that is non-toxic and capable of preserving urine, blood, plasma, and serum at room temperature; designed and used by the space program
• Company 586 - Molecular diagnostics and therapeutics for back-related and joint-related pain
• Company 587 - Technology that can detect in real time an acute myocardial infarction and derive a 12-22 lead ECG with only 3 leads or 5 electrodes
• Company 588 - Minimally invasive surgical suturing devices, using standard type curved needles and all standard sutures, for conventional and single-port laparoscopy, urogynecology, cardiac surgery, and endoscopic interventional therapies, including NOTES
• Company 589 - IVC filter utilizing unique anchoring technology that allows for optimal placement during implantation, superior migration resistance in vivo, and easy retrieval after the threat of PE has been eliminated
• Company 590 - Effective, reliable use of autologous adult stem cells (ASCs) to enhance fusion in spine and orthopedic surgery
• Company 591 - Fail-safe and inexpensive system that employs a technology to prevent errors in the intravenous administration of drugs and blood transfusion
• Company 592 - Device that applies gentle pulsing forces, in combination with standard orthodontics, to move teeth faster through accelerated bone remodeling
• Company 593 - Forward-looking intravascular ultrasound (FLIVUS) catheters that can determine correct stent size and placement through a field of view which extends beyond the catheter tip
• Company 594 - Lightweight and portable system with unsurpassed fluid balance accuracy for blood purification and fluid management
• Company 595 - Single-use, disposable "sensing embedded" surgical glove 1-to accurately map cervical length/dilatation during pre-term/full-term labor, 2-as a tool in general surgery, and 3-as a tool in telemedicine
• Company 596 - Reagents for use in non-invasive MRI, PET, and optical imaging
• Company 597 - Non-invasive device that acts as a robotic physical therapist for treating chronic head and neck pain
• Company 598 - A genomics diagnostic tool company, with a transformative technology that integrates sample preparation and sequencing on a chip, delivering actionable data in the doctor's office; supported by a $30 million large grant project with access to 15 million samples associated with cradle to grave electronic medical records established a decade ago
• Company 599 - Patient monitoring system providing real-time continuous information via four physiological parameters - sensed at the tissue level, reflecting the patient's systemic metabolic state
• Company 600 - Prevention and treatment of osteoporosis-related fractures
• Company 601 - A unique, simple-to-use, single-use inhaler device to address major unmet needs in the respiratory and drug-delivery fields; specifically, the acute treatment of asthma and COPD
• Company 602 - Growth factor, stem cell, scaffold, and bioadhesive technologies that improve the body's ability to regenerate healthy cartilage, improve joint function, and prevent degenerative disease
• Company 603 - Bioceramics for the treatment of post-myocardial infarction (MI), mitral valve regurgitation, applications to coronary and peripheral stents, and other technologies
• Company 604 - Cost-effective, laser-based antimicrobial treatments for Chronic Rhinosinusitis (CRS)
• Company 605 - Modular, 3D, real-time, stereoscopic vision and recording systems to change the surgical paradigm from 2D to 3D-HD stereoscopic vision for minimally invasive surgery (MIS)
• Company 606 - Next-generation infusion pump platform to bring new standards of accuracy and ease-of-use to the hospital and homecare markets
• Company 607 - Non-hormonal, one-size-fits-all intravaginal contraceptive ring
• Company 608 - Single-use high-definition (HD) surgical camera that will provide high-quality HD imaging at a fraction of the price of current market leading HD cameras
• Company 609 - Endoscopic accessory devices that fill unmet needs in the field of gastrointestinal (GI) endoscopy
• Company 610 - Needle technology that reveals visible blood flow at the instant of vein penetration without activation or additional instruction
• Company 611 - Non-invasive method for detecting the presence of a right-to-left cardiac shunt (i.e., PFO) to enable medical treatment and/or closure before the occurrence of a debilitating or life-threatening stroke or heart attack
• Company 612 - Patent-protected, FDA-approved, gentler power-assisted liposuction devices offering more controlled and faster fat removal, with less trauma to the doctor and patient
• Company 613 - Technology for: 1-prophylactic treatment of allergic asthma and 2-infection control in surgical theatres
• Company 614 - Non-invasive, controlled, and sustained release back-of-the-eye therapeutics for sight-threatening diseases such as: severe uveitis, diabetic macular edema, and age-related macular degeneration (AMD)
• Company 615 - Technology that can regenerate nerves
• Company 616 - Compound that can regenerate new blood vessels and has a biodegradable stent
• Company 617 - Tissue-engineered, autologous heart valves for the replacement of malformed or malfunctioning heart valves
• Company 618 - The first robotic system capable of offering full force-reflection to laparoscopic surgeons in any surgical practice
• Company 619 - An intraocular lens, customized to the patient's vision needs and adjustable throughout the patient's life, for greater quality of vision
• Company 620 - Minimally invasive stents to treat patients suffering from dysfunctional uterine bleeding (DUB), urinary tract obstruction, prostate enlargement (BPH), or prostate cancer
• Company 621 - 1-Real-time device navigation and positioning system for cardiovascular interventions and 2-Real-time angiography-based system, designed to assist in delivery of a transcatheter heart valve (THV)
• Company 622 - Biomimetic prosthetic vascular grafts that are transformed in the body into bioartificial arteries which resemble "healthy" arteries in form and function
• Company 623 - Novel neurovascular clot retrieval device for acute ischemic stroke intervention
• Company 624 - Flexible endoscopic tools for interventional gastroenterologists to perform therapeutic procedures
• Company 625 - Modern, sophisticated system to ensure a proper blood match is obtained and the patient gets the correct cord blood unit in a timely manner
• Company 626 - Implantable device to treat patients with left ventricular dilation following a Myocardial Infarction (MI) heart attack
• Company 627 - Blood glucose monitoring system designed to integrate test strips, the lancing device, and lancets into one compact glucose meter
• Company 628 - A wound dressing constructed from a biocompatible matrix and coagulating agents
• Company 629 - PediGuard is the world's first and only hand-held device capable of alerting surgeons to potential pedicular or vertebral breaches. Real-time feedback is provided via audio and visual signals.
• Company 630 - Hand-held, battery-powered product using intense therapeutic ultrasound (ITU) technology for skin care
• Company 631 - Bone cement for cranial defect repair
• Company 632 - A vascular robotic system designed to place coronary guidewires, stents, and balloon catheters during percutaneous coronary interventions
• Company 633 - An integrated system featuring sensors and software to enable the monitoring of seniors in multiple care settings
• Company 634 - Minimally invasive therapy for enlarged prostate
• Company 635 - Controlled Deployment Technology (CDT), which uses a low-profile access sheath that may be increased to provide a wider working diameter
• Company 636 - A portable device that provides therapeutic hypothermia in emergency care settings
• Company 637 - Hand-held, disposable nerve stimulator for use during surgeries
• Company 638 - An absorbable skin stapler for skin closure that eliminates the need for removing staples after surgery
• Company 639 - Esophageal cardiac monitoring device for use in surgery and critical care
• Company 640 - Proprietary devices for obtaining, shaping, and implanting ankle and knee cartilage grafts from foot joints
• Company 641 - Quantitative and qualitative cardiac assays to assist in the diagnosis of cardiovascular diseases at the point of care
• Company 642 - Advanced, portable and easy-to-use noninvasive devices for the assessment of traumatic brain injury (TBI) at the point of care
• Company 643 - Next-generation wellness program with sophisticated physical and mental health diagnostic software
• Company 644 - Combination of a proprietary ELISA substrate with Raman spectroscopy to dramatically increase the performance of immunoassays for diagnostics, research, and drug discovery
• Company 645 - Surgical instruments to reduce the trauma of full access surgery
• Company 646 - Non-ablative skin rejuvenation technology which produces immediate and visible aesthetic improvement together with long-term skin remodeling effects
• Company 647 - Implantable medical device that helps diabetic patients control their eating habits, lowering their blood glucose and body weight, by applying electrical stimulation to the stomach during meals
• Company 648 - Ophthalmic devices for minimally invasive treatment of corneal blindness and vision correction using proprietary corneal implants and microsurgical instrumentation
• Company 649 - Device that measures the presence, progression, and severity of any disease condition and the effectiveness of treatment and timing of non-acute death
• Company 650 - Non-obtrusive CPAP mask that uses the natural oral cavity anatomy to create the seal required for effective CPAP treatment
• Company 651 - rEEG(R) technology for the assessment of neurophysiological abnormalities and determination of psychiatric treatment
• Company 652 - Miniaturized wireless telemetry, physiological monitoring, and rehabilitation devices including applications in electrophysiology, sleep disorders, and movement disorders
• Company 653 - Dedicated Diabetic Machine (DDM) insulin regulation therapy for type 2 diabetes
• Company 654 - Non-invasive glucose monitoring device targeting the eye
• Company 655 - Universal oncology, cardiology, stroke and diabetes molecular imaging agents
• Company 656 - Implantable hearing device that provides extraordinary acoustic performance in a completely invisible device
• Company 657 - Surgical sponge detection using radiofrequency identification
• Company 658 - Home monitoring technologies with automatic fall detection capabilities
• Company 659 - Implantable neuromodulation devices for epilepsy and other neurological disorders
• Company 660 - Unique non-invasive blood pressure and cardiac output monitor, offering a precise hemodynamic profile with real-time data posted within a minute
• Company 661 - Single-port, multi-channel laparoscopic surgical platform
• Company 662 - Advanced over-the-wire vascular access device
• Company 663 - Technologies that improve visualization during laparoscopic surgery, permit laparoscopic suturing, and enable simpler removal of ureteral stones
• Company 664 - Portable hyperthermic perfusion system for raising the core temperature of the thoracic or peritoneal cavity
• Company 665 - Optical guidance systems for computed tomography (CT), fluoroscopy, and magnetic resonance imaging (MRI) procedures
• Company 666 - Liposome-encased nanoparticles for computed tomography (CT) contrast imaging
• Company 667 - Cartridge-based portable hemodialysis machine
• Company 668 - Capillary force vaporizer technology
• Company 669 - Home-based diagnosis of sleep disorders
• Company 670 - Office-based, minimally-invasive ablation device for enlarged prostate
• Company 671 - Medical imaging technologies for clinical and pre-clinical applications
• Company 672 - Ultrasound systems powered by the Scan Engine, a device that may be interchanged with any of the company's 3 carts, promoting efficiency and cost-effectiveness
• Company 673 - A drug-eluting stent coated with bioabsorbable polymers
• Company 674 - Parts and services for new and refurbished imaging and patient monitoring technologies
• Company 675 - Inhalation delivery technologies
• Company 676 - Synthetic bone substitutes
• Company 677 - Organ-specific molecular imaging
• Company 678 - Image analysis for the diagnosis of Alzheimer's and other diseases
• Company 679 - High-speed, disposable dental drill
• Company 680 - Software systems for cardiology
• Company 681 - Spinal implant for remote-controlled spine deformity and trauma correction
• Company 682 - Endoluminal treatment for morbid obesity
• Company 683 - A non-invasive diagnostic medical device that replaces the current traumatic procedure used to detect pediatric VUR (urinary reflux) and prevent kidney damage in 4M children annually
• Company 684 - Highly differentiated aorto-ostial stent and delivery platform for both peripheral and coronary applications
• Company 685 - Medical records application on a simple USB flash drive for patients, providers, and insurers
• Company 686 - Intelligent orthopedic devices that will address the growing clinical and economic cost of orthopedic implant failure and osteoporosis
• Company 687 - Pro-Vas is a novel less-invasive alternative to vasectomy for men seeking permanent contraception
• Company 688 - Minimally invasive lumbar annular repair technologies to prevent disc re-herniation and interrupt disc degeneration
• Company 689 - Innovative imaging that provides real time and wide field visualization of cancer margins during surgery to increase tissue conservation and comprehensive removal of cancerous areas, specifically for the treatment of breast cancer
• Company 690 - Device to non-invasively detect and monitor blood borne diseases in vivo, without taking blood
• Company 691 - Products ranging from needleless injection site connectors, to safety syringes, and biodiagnostic sampling devices
• Company 692 - Products for the urinary incontinence market
• Company 693 - New medical diagnostic system for the early detection of lung cancer
• Company 694 - Non-invasive ultrasound device for the treatment of glaucoma
• Company 695 - Technology that will impact the way surgeons perform laparoscopic surgery, making it possible for one surgeon to do what now requires two, and to reduce the number of surgical incisions for most all procedures
• Company 696 - Varicose vein stripping under direct vision for ablation of the diseased saphenous vein in a kit that reduces trauma, minimizes bleeding, and expects improved clinical outcomes
• Company 697 - Advanced biofeedback stimulator with diagnose and treatment modes
• Company 698 - Device for treating diseases in patients with acute renal failure (ARF) and acute inflammation induced by cardio pulmonary bypass (CPB) surgery, to produce improvement in survival rates and reduce costs
• Company 699 - Technology that bridges the gap between low-tech aspiration and complex electromechanical aspiration systems for use in thrombus removal, rotational vacuum assisted biopsy, tissue resection, and spinal disc decompression
• Company 700 - A handheld device for the as-needed treatment of allergic rhinitis
• Company 701 - Non-compressible hemostatic fibrin sealant for high-volume bleeding in intraoperative surgery and trauma
• Company 702 - Minimally invasive device for midface lift and other lift procedures
• Company 703 - Robotic ankle and foot prosthesis
• Company 704 - Handheld CD4 cell counter
• Company 705 - Auto-adjusting portable oxygen system
• Company 706 - Magnetically-guided enteral feeding tube
• Company 707 - Wireless electrocardiography
• Company 708 - Human fibrinogen-based tissue sealant
• Company 709 - Gastrointestinal endoscopy products
• Company 710 - Interventional cardiology devices for chronic total occlusions
• Company 711 - Dental imaging
• Company 712 - Type 1 Diabetes medication delivery
• Company 713 - Innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders such as migraine, Parkinson's disease, schizophrenia, and bipolar disorder
• Company 714 - In-situ formed hydrogels for radiation oncology and oncologic surgery
• Company 715 - Protein signature-based diagnostic tests for prostate, lung, and breast cancers
• Company 716 - Synthetic polymer for osteoarthritis therapy
• Company 717 - Controlled warm air delivery device for human head lice removal
• Company 718 - Polymolecular system for the treatment of inflammatory disease
• Company 719 - Critical care monitoring technologies
• Company 720 - Advanced feeding tube technology which can be placed using ultrathin endoscopes
• Company 721 - An accurate, low-cost home healthcare device for use by patients to self-measure Intraocular Pressure (IOP)
• Company 722 - Ultrasonic technologies and related techniques for aesthetic surgery
• Company 723 - Therapeutic ultrasound to treat hypertension
• Company 724 - Breast imaging system for early breast cancer detection
• Company 725 - RFID technology and software systems for medical device manufacturers, distributors, and hospitals
• Company 726 - Smart card platform that identifies and authenticates a patient to the healthcare provider and matches the patient to his or her medical record
• Company 727 - "Lap-Pak" is a flexible, one-piece, device contoured to enable the rapid and secure re-positioning of the bowels to expose the surgical site while eliminating the need for re-positioning during surgery
• Company 728 - Enhanced meter dose inhalers and spacer devices for the treatment of Asthma and COPD
• Company 729 - Sensor-based, video-monitored, automatic/semi-automatic laryngoscope that makes intubation easy, safe, and fast
• Company 730 - The first point-of-care device able to give a rapid determination of platelet quality through a multi-dimensional test, thus, avoiding the use of poor quality platelets and improving transfusion outcome
• Company 731 - Portable diagnostic device used to determine the presence and level of Myocardial Ischemia (MI)
• Company 732 - Suite of diagnostic imaging products using near-field and forced-resonance principles targeting several specialties including cardiology, oncology, orthopedics, and neurology
• Company 733 - Rapid endovascular vessel occlusion and blood flow interruption
• Company 734 - Flat panel x-ray sources for use in sterilization systems, compact CT systems, and a non-radioactive blood irradiator
• Company 735 - Non-invasive, easy-to-use device that uses pulsed radio frequency energy (PRFE) for tissue growth, wound healing, and pain relief
• Company 736 - Robotic assistance device for CT-guided soft tissue interventions
• Company 737 - Fatigue-resistant/fiber-reinforced bone cement for orthopedic joint replacement
• Company 738 - Full line of products specifically dedicated to avoiding a total joint replacement and preserving the shoulder, hip, knee, or ankle joints
• Company 739 - Single-use, disposable silver ion delivery device to treat Osteomyelitis (OM)
• Company 740 - Micro-format, CMOS-based, imaging technology for minimally-invasive, disposable endoscopic medical procedures
• Company 741 - Fish-skin-derived tissue regeneration technology for chronic wounds and hernia repair that improves upon current human and porcine technologies through improved economics & clinical performance, reduced disease transfer risk, and absence of cultural constraints on usage
• Company 742 - Hand-held ultrasound tool that displays a see-through image in the medical practitioner's line of sight, at the patient's skin surface
• Company 743 - Minimally invasive ultrasound-guided RF ablation system to treat symptomatic uterine fibroids through a transcervical approach
• Company 744 - Products for minimally invasive bypass surgery
• Company 745 - Rapid/sensitive/cost-effective diagnostic products for detecting microbes causing hospital associated infections
• Company 746 - Diagnostic products for rapid infection determination at the point-of-care (POC) for professional and consumer markets
• Company 747 - Cancer immunotherapy device, which selectively removes specific blood-borne inhibitors of the immune system
• Company 748 - POC/PST device to directly detect clot formation and do it in real time
• Company 749 - 1-Low-cost, disposable point-of-care (POC) Pap smear replacement requiring no lab or technician; 2-Disposable, woman-controlled, cervical cap embedded with an anti-HIV drug to provide contraception and help prevent infection from HIV
• Company 750 - Small/wearable/all-mechanical insulin delivery device containing a 3-day supply of insulin
• Company 751 - The next major step in the treatment of early breast cancer: replacing lumpectomy with a percutaneous, minimally invasive outpatient procedure under local anesthesia that not only eradicates the cancer, but is not disfiguring and leaves no scar
• Company 752 - Stand-alone/rapid/autologous cell harvesting processing and delivery technology
• Company 753 - System that measures airway inflammation to determine asthma severity for improved treatment
• Company 754 - Minimally invasive, image-guided therapies to treat back pain
• Company 755 - Products enhancing focally-delivered radiation and drug therapies for patients with spinal metastatic disease or bone tumors
• Company 756 - Needle-free drug delivery for migraine attacks and cluster headache episodes
• Company 757 - Image-guided ultrasound for prostate cancer tissue ablation
• Company 758 - Obstetric position tracker and ultrasound technology
• Company 759 - Compact ultrasound devices
• Company 760 - Continuous blood glucose measurement devices
• Company 761 - Radiosurgical therapy for neurovascular and inflammatory ocular conditions
• Company 762 - Wound closure technology
• Company 763 - Neurosurgical tumor removal
• Company 764 - Surgical device for treating benign prostatic hyperplasia (BPH) and other conditions
• Company 765 - Radiofrequency balloon catheter technology
• Company 766 - The TOPS(TM) System is an implantable device that allows axial rotation, lateral bending, extension, and flexion. The implant facilitates bending, straightening and twisting movements at the affected segment of the spine while blocking excessive posterior and anterior sagittal translation.
• Company 767 - Implants for sensorineural hearing loss
• Company 768 - Medical textiles for hemostasis
• Company 769 - 1-System for use in spinal surgical procedures such as vertebroplasty, 2-System to provide immediate vascular access through the intraosseous space for the delivery of essential drugs and fluids, 3-System for aspirations, biopsies, and stem cell collections
• Company 770 - Pressure cycling technology (PCT) to safely, conveniently, and reproducibly control the actions of molecules in biological samples
• Company 771 - Low-cost technology to survey the genome in its native state, in context, and at ultra-high resolution, without the need for DNA amplification
• Company 772 - Temperature management technology to treat hyperthermia and hypothermia, prevent damage from stroke, and enhance cancer therapies
• Company 773 - Unique solutions for ophthalmic conditions such as: presbyopia, myopic progression using contact lenses, intraocular lenses and lasik, or other corneal surgeries
• Company 774 - Non-invasive radiofrequency (RF) energy-based system to treat vaginal stretching caused by childbirth
• Company 775 - High-quality, cost-efficient, single-room proton beam radiotherapy (PBRT) system as an alternative to conventional high-energy x-rays
• Company 776 - Controlled, targeted deep-tissue therapeutic warming system to promote pain relief, reduce joint stiffness, and enhance recovery/rehabilitation programs
• Company 777 - 1-Artificial larynx, 2-Ear, nose, and throat (ENT) prostheses/implants
• Company 778 - microRNA-based tests to diagnose various cancers and gastrointestinal diseases
• Company 779 - Brain training software aimed at enabling individuals to strengthen cognitive function using the concept of neuroplasticity
• Company 780 - Non-invasive near-infrared (NIR) laser energy for the treatment of: acute ischemic stroke, spinal cord injury, traumatic brain injury, global cerebral ischemia, spinal cord injury, Alzheimer's disease, Parkinson's disease, and sepsis
• Company 781 - Hydrogel materials that can be fabricated into devices, nanogels, and polymer solutions with applications in ophthalmology as well as cardiology, urology, and tissue engineering
• Company 782 - Advanced polymer-based biomaterials for applications in cardiology, dentistry, orthopedics, surgery, and urology
• Company 783 - Neurostimulation device to block residual limb pain caused by complications of amputations, as well as chronic pain after surgery, and migraine pain
• Company 784 - Joint, spine, and trauma implants
• Company 785 - "Minimally invasive" gene repair
• Company 786 - Implantable device for the surgical treatment of obesity without reliance on sutures, staples, or other mechanisms that puncture the stomach wall
• Company 787 - Microdermabrasion system with polyester/nylon bristle tips and variable vacuum levels for particle-free/crystal-free performance
• Company 788 - Elastic, self-expanding devices to specifically improve left ventricle relaxation and diastolic function
• Company 789 - Point-of-care handheld immunoassay system providing high-performance quantitative laboratory blood test results in an inexpensive, portable, and easy-to-use configuration
• Company 790 - Routine serum DNA blood tests for early cancer diagnosis and management
• Company 791 - Minimally invasive alternative to the surgical treatment of obesity
• Company 792 - Drug-eluting balloons that allow for controlled release of different and even multiple substances, for the treatment of coronary (CAD) and peripheral artery disease (PAD)
• Company 793 - Cancer prognostic tests for predicting specific individual patient clinical outcomes
• Company 794 - Genomics-based in vitro diagnostic (IVD) tests developed from FFPE tissue for personalized medicine
• Company 795 - Needleless/transdermal delivery system for insulin, analgesics, or vaccines with on/off control of dosing
• Company 796 - MRI-compatible ultrasound applicator to deliver controlled thermal therapy to the cancerous regions of the prostate gland
• Company 797 - Non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system
• Company 798 - Antimicrobial solutions to reduce the incidence of Surgical Site Infections (SSIs) in spinal surgeries
• Company 799 - Tissue repair platform that obviates the need for sutures, stapes, glues, or other foreign bodies and instead allows the body to repair and heal itself
• Company 800 - Catheter-based system to treat large vessel acute ischemic strokes
• Company 801 - Next-generation remote patient monitoring (RPM) to continuously monitor vital life-sign functions such as: heart rate, respiratory rate, body position, activity level, and skin temperature
• Company 802 - Total Artificial Heart (TAH) to replace both ventricles of a failed heart, thus, restoring the circulatory system to normalcy
• Company 803 - Antalgic-Trak(R) (A-T) is the only non-surgical spinal decompression system in the world engineered with a series of multi-axis articulating sections that provide and create spinal "Range-Of-Motion" (ROM) therapy
• Company 804 - Portable DNA analyzers for on-demand, non-batched testing, with real-time polymerase chain reaction (PCR) results in 30-60 minutes
• Company 805 - Novel biomimetic shape memory hydrogel implants for minimally invasive vessel protection following surgical treatment of degenerative conditions of the anterior spine
• Company 806 - System designed to prevent contrast-induced nephropathy (CIN)
• Company 807 - A novel suite of workflow tools that automate the viewing, analysis, and interpretation of x-rays for musculoskeletal disease
• Company 808 - Technology to preserve the normal, healthy tissue of patients that today is damaged as a by-product of current treatments
• Company 809 - Ventricular Assist Device (VAD) that can be inserted above the diaphragm
• Company 810 - Handheld, non-invasive, real-time Central Venous Pressure (CVP) monitor for cardiology and nephrology diagnostic applications
• Company 811 - Next-generation stent platform with: significantly thin walls for reduced restenosis, ease-of-use, superior deliverability, and improved radiopacity for accurate placement
• Company 812 - In-line, battery-powered, disposable, lightweight, and completely portable blood and IV fluid warming device, capable of intravenous application and irrigation warming
• Company 813 - Next-generation endovascular devices that incorporate advanced fiber optics technology into currently used products/procedures to improve patient outcomes without adding to procedure time/cost
• Company 814 - Digital fluorescence scanners for molecular pathology research, biomarker development, and clinical molecular diagnostics (MDx) for personalized medicine
• Company 815 - Software for efficiently coordinating the delivery of patient care outside of hospitals; it optimizes home care operations and can turn a medical practice into an ACO
• Company 816 - Polymer technologies for drug delivery and regenerative medicine with applications in orthopedics and spine
• Company 817 - A-FX(TM) is a minimally invasive platform technology for creating an orthopedic implant in-situ which provides superior fixation in osteoporotic bone
• Company 818 - Non-invasive device designed to offer transcutaneous pulsed electro-magnetic field stimulation therapy for treating postoperative pain and edema in superficial soft tissue
• Company 819 - Non-invasive reverse thermal gradient technology to treat conditions of tendons, ligaments, muscles, fasciae, and joints
• Company 820 - Automatic screw delivery system for cranial maxillo-facial bone fasteners
• Company 821 - Non-invasive brain physiological measurement technologies
• Company 822 - Smallest/passive/implantable tag using RFID (radio-frequency identification) technology
• Company 823 - Diabetic pain relief via topical dermal administration and controlled release of pure Nitric Oxide (NO)
• Company 824 - A percutaneous, catheter based system for the temporary isolation of the liver from the systemic blood circulation and local administration of chemotherapy drugs at high concentrations, directly into the liver without systemic side effects - under optimal drug conditions
• Company 825 - Vacuum-based clean surface nanotechnology for faster and larger osseointegration
• Company 826 - Technology for: 1-Glaucoma diagnosis and 2-Real-time homecare monitoring of intraocular pressure (IOP)
• Company 827 - Precision stapling devices enabling minimally invasive vascular connections, especially for Coronary Artery Bypass Graft (CABG) surgery
• Company 828 - The technology, based on growth factor extract from reindeer bones, improves bone formation in bone healing problems
• Company 829 - A range of injectable gels made from hyaluronic acid for applications in Aesthetic Dermatology, Ophthalmology, and Orthopaedics
• Company 830 - Mobile air purification unit that captures and destroys airborne pathogens
• Company 831 - Therapy delivery platform for the upper airway with applications to initially target chronic sinusitis, nasal allergies, cystic fibrosis, and CPAP users
• Company 832 - 1-Multi-generational devices using hybrid technologies for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures, 2-Low profile single-patient-use tissue retractor, 3-Range of 7Fr intra aortic balloon catheters with fluid-filled technology that plugs into current hardware
• Company 833 - Percutaneous anastomosis device to improve long-term vascular access for dialysis and cancer patients
• Company 834 - Intelligent 3DHD visualization and guidance platform for ophthalmic, cranial, and spine surgeries
• Company 835 - Wireless/battery-less antenna on a chip (tag) for continuous tracking of blood samples
• Company 836 - Permanently implanted electrical neural stimulators to treat balance/hearing/perceptual disorders
• Company 837 - Real-time advanced fluid sensing with smart solutions for safe preparation and delivery of IV medications
• Company 838 - Electrical stimulators via electrode garments for the treatment of pain related to chronic/acute soft tissue injuries
• Company 839 - Non-invasive neuromodulation technology platform to therapeutically address several major areas of disease; the Company's lead indication is Parkinson's Disease (PD)
• Company 840 - Surgical instrument designed to solve recurrent problems in managing sutures, tissue reattachment, and visualization during surgical procedures
• Company 841 - Nanolayer surface technology to improve the osteoconductive/bio-resistant/anti-infective attributes of implants
• Company 842 - 1-Biopsy needles with enhanced ultrasound visualization, 2-Microencapsulated tissue markers, 3-Devices for the local, accurately positioned, chemoablative treatment of soft tissue cancers
• Company 843 - The NuLens(TM) Dynacurve IOL is an implantable, flexible lens that changes it curvature in response with the movements of the eyes accommodative muscle system
• Company 844 - Systems to diagnose neurological and sleep disorders
• Company 845 - Technology that precisely eliminates irregularly shaped/invasive solid tumors while avoiding significant damage to surrounding healthy tissue and is non-toxic
• Company 846 - Extracellular matrix (ECM) implant that is completely integrated, remodeled, and replaced by the patient’s native tissue over time
• Company 847 - Non-surgical/injectable tissue revitalization and stabilization to address lower back pain (LBP) and the underlying problem of mechanical insufficiency
• Company 848 - 1-System for remote home patient monitoring of glucose, blood pressure, and thermal weight, 2-Glucose meter cell phone
• Company 849 - 1-A proprietary non-invasive ophthalmic diagnostic device designed to quickly detect elevated advanced glycosolated end products (AGEs) for very early detection of diabetes and 2-A rapid non-invasive, ophthalmic-based glucometer for painless and convenient measurement of glucose levels
• Company 850 - Implantable replacement valve to treat incompetent deep vein valves causing degenerative pain, swelling, and non-healing ulcers associated with chronic venous insufficiency (CVI)
• Company 851 - Advanced blood purification to reduce cytokine storm and inflammation that leads to multi-organ failure in sepsis and other critical care diseases
• Company 852 - Next-generation anatomic pathology (AP) with improved speed, automation, and ease-of-use
• Company 853 - Injectable biopolymer for the direct treatment of acute myocardial infarction (AMI)
• Company 854 - Endoear(R) is the world's first implantable hearing device of its kind, created for the treatment of mild to moderate hearing loss
• Company 855 - Wireless device for the treatment of stress/urge/mixed urinary incontinence (UI)
• Company 856 - Communication device that acquires neurological signals from the brain and translates them into speech
• Company 857 - Visually guided catheter ablation for atrial fibrillation
• Company 858 - Next-generation vessel closure
• Company 859 - Pneumatic compression devices targeted to the lymphedema, venous insufficiency, and sports medicine markets
• Company 860 - Technology that enables the "packaging" of chronic therapies/biologics in an easy-to-use, disposable patch-like device
• Company 861 - Instrumentation that provides surgeons with real-time sensing/feedback from the operative site
• Company 862 - Lab-free salt intake monitor for hypertension/congestive heart failure (CHF) patients
• Company 863 - Endoscopically placed device for the treatment of obesity
• Company 864 - Minimally invasive radiofrequency (RF) device to treat aging skin
• Company 865 - Optical biopsy needle that will accurately diagnose prostate cancer, yet eliminate random prostate biopsies
• Company 866 - New holding company for various orthopaedic device companies, such as Enztec and OMNI life science
• Company 867 - Catheters for dissolving/removing cerebral blood clots then delivering therapeutics to the diseased site
• Company 868 - Targeted molecular assays for onco-diagnostics/personalized medicine
• Company 869 - Biomarker discovery platform for detecting Type 2 Diabetes, Prostate Cancer, and Amyotrophic Lateral Sclerosis (ALS, aka Lou Gehrig's disease)
• Company 870 - Molecular diagnostic technologies for organ transplantation and various complex genetic disorders
• Company 871 - Non-invasive breast cancer diagnostic test via breast fluid analysis
• Company 872 - Non-invasive vascular disease detection that combines the advantages of MRI with the temporal resolution and ease-of-use of ultrasound
• Company 873 - Endoscopic/removable device that mimics the effects of gastric bypass surgery on a patient's metabolism
• Company 874 - "Smart" cells than can determine the type of disease/injury present in the body and repair/regenerate tissue accordingly
• Company 875 - Imaging systems for the non-invasive, in vivo detection of cancerous and pre-cancerous lesions
• Company 876 - Microarray-based technology enabling targeted next-generation sequencing of genomic regions of interest
• Company 877 - Minimally invasive therapy for Emphysema
• Company 878 - Comfortable, soft, and pliable cloth mask for the treatment of obstructive sleep apnea
• Company 879 - Wearable neuroimaging cap for mapping brain function
• Company 880 - Computer-controlled rehabilitation table for the management of lower back pain
• Company 881 - 1-Bioactive/conductive polymer materials and coatings for implantable biomedical devices and 2-Next-generation all-polymer leads that may be grown in the body
• Company 882 - Non-invasive tests to detect fetal chromosomal abnormalities
• Company 883 - Devices to treat low back pain
• Company 884 - Wearable sensor technology that safely and accurately measures individual sleep patterns
• Company 885 - Vascular navigation system designed to more accurately and rapidly position venous catheters (CVC and PICC)
• Company 886 - Minimally invasive breast tumor diagnosis and treatment
• Company 887 - Lightweight, waterproof, medical alert pendant for seniors - to avoid the dangers of missed medications
• Company 888 - Non-invasive DNA-based prenatal diagnostic test
• Company 889 - Heart pump technologies
• Company 890 - DNA sequencing technology for the detection of biomarkers for infectious and other diseases
• Company 891 - Computer-assisted surgical devices for total joint replacement
• Company 892 - Diagnostic and therapeutic ophthalmic devices
• Company 893 - Nanomaterials for angiogenesis/anti-angiogenesis/diagnostic applications
• Company 894 - Non-invasive neurostimulation device to restore vision to patients suffering from stroke, traumatic brain injury (TBI), dry age-related macular degeneration (AMD), and glaucoma
• Company 895 - Surgical/restorative dental implants
• Company 896 - Molecular diagnostic/prognostic tests for cancer
• Company 897 - Device to treat osteoarthritis
• Company 898 - Minimally invasive implant for treating spinal stenosis
• Company 899 - Non-polymeric drug-eluting stent (DES)
• Company 900 - Variety of diagnostic tests for infectious diseases, cardiology, hepatology, and various cancers
• Company 901 - Non-woven fabric with extended shelf-life to restore/repair tissue function
• Company 902 - Device for removing uterine fibroids without hysterectomy
• Company 903 - ALIVIOS Intelligent Eyewear enables people challenged with low vision to do more, including the ability to zoom in and out, improve brightness and contrast of whatever they are looking at, and even quickly store visual information for a closer look later
• Company 904 - Diagnostic retinal imaging system for use in the primary care setting
• Company 905 - The Unyvero(TM) System is a novel high-multiplex MDx/IVD platform for severe infectious disease (Pneumonia Application has 39 analytes: 17 pathogens, 22 antibiotic resistance markers)
• Company 906 - Inferior vena cava (IVC) filter that includes: 1-automatic self-centering, 2-bi-directional deployment and retrieval, 3 -atraumatic design, and 4-total transluminal filtration
• Company 907 - Compliant balloon platform technology for use in neuroradiology, cardiovascular, and peripheral vascular applications
• Company 908 - Mechanical thrombectomy device to treat ischemic stroke
• Company 909 - Artificial heart technologies
• Company 910 - Cancer diagnostic test which enables the development of personalized therapeutics
• Company 911 - Bone graft material that is: 1- synthetic, 2-non-immunogenic, 3-inclusive of all bone regenerative properties of an autograft, and 4-cost-effective
• Company 912 - Portable/rapid cooling technologies via the nasal cavity to improve patient outcomes after cardiac arrest, stroke, or traumatic brain injury (TBI)
• Company 913 - Tests for the diagnosis/prognosis of cardiovascular disease
• Company 914 - Cost-effective solutions for the improved detection and prevention of cancer in the gastrointestinal (GI) tract
• Company 915 - Neuromodulation for hypertension/heart failure
• Company 916 - System to repair abdominal aortic aneurysms (AAA)
• Company 917 - Endoscopic device to treat sinusitis
• Company 918 - Drug delivery platform that releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory and ischemic diseases
• Company 919 - Aortic embolic protection device for acute and long-term use
• Company 920 - Autologous adult stem cell technology, cultured from the nasal passageway, to repair damage resulting from spinal cord injury
• Company 921 - 1-Minimally invasive treatment of spinal compression, 2-Minimally invasive treatment of long bone factures, 3-Neuromodulation catheter that can be introduced into the spinal canal to treat pain
• Company 922 - Next-generation needleless drug delivery
• Company 923 - Minimally invasive neurosurgical and orthopedic instruments and implants
• Company 924 - Tissue fusion via infrared laser to replace sutures
• Company 925 - Ultrasound system that can measure true tissue elasticity in a reproducible/quantifiable/user-independent manner
• Company 926 - Next-generation nanostructured capacitors for: 1-implantable cardiac defibrillators (ICD) and 2-microsteerable cardiac ablation and related catheters
• Company 927 - Minimally invasive spine implant (facet versus pedicle screw)
• Company 928 - Spine implant that allows for post-operative adjustment of the implant size via radio control
• Company 929 - Spine fusion implant for motion preservation/dynamic stabilization
• Company 930 - Next-generation medical devices with anti-fouling surface modifications that reduce the risk of complications over long durations
• Company 931 - Device for the treatment of benign prostate hypertrophy (BPH), prostatitis, erectile dysfunction (ED), lower urinary tract symptoms, and infertility
• Company 932 - Andara technology for the treatment of acute spinal cord injury
• Company 933 - Polymer implant to repair meniscal tears via tissue regeneration
• Company 934 - Electrodes/neural interface products for functional neurosurgery and neurostimulation
• Company 935 - Non-systemic/non-invasive system that delivers magnetic versus electrical pulses for the treatment of depression
• Company 936 - Implantable neuromodulation device designed to electrically alter the pain signal pathways
• Company 937 - Next-generation implants, stem cell enabling technology, and other minimally invasive surgical instruments
• Company 938 - Invisible hearing device
• Company 939 - Cooling and compression therapy for the relief of pain/swelling after orthopedic/other surgery
• Company 940 - Catheter insertion systems, designed for extended IV dwell time, to eliminate the risk of related bloodstream infections
• Company 941 - A rapid, monthly test that uses glycated albumin to monitor gestational and type 2 diabetes more effectively
• Company 942 - Products for surgical RF ablation, valve replacement or repair, and coronary artery bypass (CABG) grafting
• Company 943 - Biomaterial with exceptional hardness/low friction/bio-inertness that also prevents the leaching of metallic ions into the body
• Company 944 - Disposable and needleless patch that can be placed on the body inconspicuously for insulin delivery - an alternative to daily insulin injections
• Company 945 - Small shunt-like device implanted into the bloodstream to modify, collect, or eliminate a broad range of Target Cells
• Company 946 - Artificial heart made of biosynthetic tissues, with two-pumps
• Company 947 - Permanently implantable/wireless/miniature sensors to transmit cardiac output, blood pressure, and heart rate data
• Company 948 - Fully implantable device for the treatment of central sleep apnea in heart failure patients
• Company 949 - Heart valve implant
• Company 950 - AdaptDx - A novel diagnostic instrument that can detect and track age-related macular degeneration (AMD) from its beginning stages, allowing for early intervention
• Company 951 - Nanotechnology-based liquid that absorbs energy on a near-molecular scale versus relying on the mechanical properties of solid materials
• Company 952 - Cyanoacrylate-based products for wound care and infection prevention
• Company 953 - Femtosecond pulse laser system for various ophthalmic applications
• Company 954 - Technology that uses the patient's own blood to make either: 1-A surgical sealant to prevent/stop bleedings or 2-A gel to stimulate the healing of chronic wounds
• Company 955 - Real-time/multi-user image communication/collaboration system that consolidates images and text records into a single point of access
• Company 956 - Polymer-based/biodegradable/drug-eluting peripheral vascular stent for tibial and infrapopliteal arteries
• Company 957 - Ultrasound-based diagnostic biosensor that enables blood analysis at the molecular level for the patient self-testing market
• Company 958 - Non-invasive biomechanical diagnostic system that records/analyzes range of motion (ROM) in a full 3-D environment for musculoskeletal diagnostics/therapeutics
• Company 959 - Full Sense(TM) Bariatric Device which is implanted and extracted via endoscopy and causes satiety leading to weight loss
• Company 960 - Continuous glucose monitoring specifically for use in the Intensive Care Unit (ICU)
• Company 961 - Real-time interactive training visualization system, specifically for the task of training any designated personnel in successfully accomplishing a limited "focused assessment with sonography for trauma" (FAST) examination
• Company 962 - Molecular diagnostic tests to: 1-Differentiate between squamous and non-squamous non-small-cell lung cancer, 2-Differentiate between mesothelioma and adenocarcinoma, 3-Identify more than 20 types of cancer
• Company 963 - Nasal stent to treat obstructive sleep apnea
• Company 964 - 1-Pacing/sensor-enabled device for Cardiac Resynchronization Therapy (CRT), 2-Real-time modality to quantify cardiac performance, 3-System that adds ingestible microchips to drugs
• Company 965 - Pocket-sized, affordable, and easy-to-use resuscitation devices that can be effectively deployed by both trained professionals and laymen
• Company 966 - Wearable health monitoring system for potential diabetes, heart disease, and sleep apnea applications
• Company 967 - Biomarkers for the screening and diagnosis of cervical and other cancers
• Company 968 - Implantable vagus nerve stimulation system for the treatment of tinnitus and post-stroke motor rehabilitation
• Company 969 - Smart, accurate guiding device based on image technology for orthopedic trauma procedures such internal fixation with intramedullary (IM) nails, osteotomy, and others
• Company 970 - Non-invasive molecular diagnostics for autism, chronic obstructive pulmonary disease (COPD), multiple sclerosis, and diseases with a genetic susceptibility
• Company 971 - Natural polymer technology that mimics the physiological clotting cascade without reliance on blood-derived proteins - to stop severe bleeding, reinforce staple and suture lines, and repair tissues
• Company 972 - Effective and convenient phototherapy system available for in-home treatment of scalp/small-area psoriasis and other photo-responsive skin diseases
• Company 973 - Electroporation-delivered/DNA-based vaccines against cancers and infectious diseases
• Company 974 - Next-generation computer-assisted laparoscopic tool composed of multiple rigid elements with intervening controllable joints
• Company 975 - Novel, POC diagnostic instrument that rapidly diagnoses blood coagulation defects based on sonorheometry - a patented ultrasound-based technology that is faster, easier to operate and interpret, and cheaper than competing technologies
• Company 976 - Fluorescent markers/optical sensors that provide an accurate and rapid determination of kidney function
• Company 977 - Ready-to-market medical device for assessing - via the eye - exposure to neurotoxins, cyanide, and low level radiation. Future products include assessment of mild TBI and other health conditions, including diabetic diseases of the eye.
• Company 978 - The SatiSphere System is a non-invasive obesity device that safely and effectively uses the body's natural physiology to treat obesity by regulating satiation mechanisms, slowing digestion, and discouraging excessive eating
• Company 979 - Catheter ablation for the treatment of cardiac arrhythmias
• Company 980 - Monitoring products/clinical services for advanced ambulatory cardiac monitoring
• Company 981 - Technology used in: 1-Finished products designed for micro-surgical/microscopy procedures and robotics and 2-Biosensors with applications in gene expression, neuroscience, and nanotechnology
• Company 982 - Resorbable hydrogel that 1-Seals annular tears in the intervertebral disc and 2-Provides an environment for nucleus regeneration
• Company 983 - Non-invasive/fast/easy-to-use/reliable medical devices that test for neuro-visual disorders
• Company 984 - High-dose drug delivery system for the minimally invasive and repeatable treatment of liver cancers, colorectal cancer, and hepatitis
• Company 985 - Technologies that integrate bone and cartilage forming peptide and small molecule therapies with osteostimulating matrices
• Company 986 - A non-invasive, safe cardiac diagnostic system that in a 10-minute test reliably detects existence or absence of ischemia and monitors treatment efficacy
• Company 987 - Injectable porous scaffolds/spheres/composites with fully interconnected pores, for multiple applications
• Company 988 - Compact, remote, wireless, real-time device for biomedical monitoring such as cardiac, neurological, sleep disorder, obstetrics, orthopedic, and other vital signs outside the hospital/clinic
• Company 989 - Permanent implant to address mitral regurgitation directly
• Company 990 - Portable/lab-quality diagnostics for the ER/ambulance/physician's office/home/field
• Company 991 - Percutaneous injection treatment for patients with internal disc derangement (IDD) who have failed conservative care/are not yet candidates for total disc replacement (TDR)/spinal fusion
• Company 992 - Technology that allows surgeons to rapidly treat tissue at the surgical site/reduce blood loss
• Company 993 - A1c diabetes testing at the point of care, with results in under 4 minutes
• Company 994 - Next- generation/predictive blood tests to help warn of potential future health problems
• Company 995 - Vertebral compression fracture treatment
• Company 996 - Orthopedic imaging
• Company 997 - 1-Artificial vascular graft with self-sealing, non-woven, synthetic fiber structure, 2-Ventral hernia mesh
• Company 998 - 1-Prohealing coronary stent as an alternative to drug-eluting stents (DES), 2-Balloon -expandable/crush-resistant nitinol peripheral stent, 3-Nano-based transcatheter, 4-Anatomy-specific combination embolic protection and stent delivery systems, 5-Localiz
• Company 999 - Early detection of Alzheimer's disease via an eye drop and laser eye scan
• Company 1000 - Drug-coated balloon angioplasty technology
• Company 1001 - Behavioral remote patient monitoring system that uses wireless sensors to non-intrusively track and report on the daily patterns of seniors' activities
• Company 1002 - System that assesses, then provides therapy to develop infant feeding skills
• Company 1003 - Painless, continuous glucose monitoring
• Company 1004 - Wireless/wearable/ultra-compact device that automatically tracks/wirelessly uploads data about a person's activities (exercise intensity levels, calories burned, sleep quality, steps, distance)
• Company 1005 - Joint reconstruction device that ideally/anatomically matches the size/shape of the facet joint
• Company 1006 - Platforms for: 1- Pedicle screw fixation (even with poor bone quality), 2-Vertebral compression fractures, 3-Simple- to-use trauma products
• Company 1007 - Implantable device for maintaining adequate blood flow to the brain in patients experiencing a buildup of excess cerebral spinal fluid (CSF) due to trauma
• Company 1008 - 1- Straightforward knotless suture anchor, 2-Instrumentation for percutaneous suture management, 3- Endotendonous repair system, 4-Shape memory staples
• Company 1009 - Coagulation analyzer to eliminate unnecessary blood transfusions
• Company 1010 - Simple, rapid, blood-based cancer tests to provide accurate and individualized clinical information on disease status/treatment selection/treatment response
• Company 1011 - Neurostimulator for cardiac contractility
• Company 1012 - Endoscopically delivered devices focused on slowing gastric emptying, to treat all stages of obesity
• Company 1013 - Autonomic nervous system stimulation for pulmonary and headache disorders
• Company 1014 - Optimization of T cell receptors (TCRs) for use in adoptive T cell therapy - to target and destroy cancerous/infected cells
• Company 1015 - Technology for wound care and slow release drug delivery, by both transdermal and subcutaneous routes
• Company 1016 - Intraoperative wavefront aberrometer for use in intraocular lens replacement surgeries
• Company 1017 - Technology to treat atrial fibrillation that allows doctors to perform radiofrequency ablation under direct visualization
• Company 1018 - Tests to "predict" chronic diseases/conditions, such as diabetes/osteoporotic bone fracture/a major cardiac event
• Company 1019 - Disposable/miniature/minimally invasive surgical devices including reusable endoscopes for visualization, initially for use in spinal surgeries
• Company 1020 - Dental implant that can be placed into a multi-rooted molar extraction site "immediately"
• Company 1021 - Biocompatible and biodegradable synthetic scaffold to aid soft tissue regeneration of the anterior cruciate ligament (ACL) of the knee
• Company 1022 - Ingestible/wireless capsule with sensor technology to measure pH, pressure and temperature from within the entire GI tract
• Company 1023 - Counter-stimulation technology to treat Restless Legs Syndrome (RLS)
• Company 1024 - Minimally invasive device to treat emphysema
• Company 1025 - Gene expression test for the diagnosis of ambiguous tumors
• Company 1026 - Non-invasive, rapid, quantitative measurement of metabolic health of the retina using a novel spectroscopic biomarker
• Company 1027 - Implantable neuromodulation device for the treatment of chronic pain and future applications
• Company 1028 - Home-use devices for hair removal/acne/skin rejuvenation
• Company 1029 - Technology that restores natural physiologic outflow as a foundation of significant/steady/sustained glaucoma management
• Company 1030 - Minimally invasive surgery system for simpler and safer soft-tissue suturing/fastening
• Company 1031 - Effective/consistent/non-invasive neuromodulation for the treatment of urinary incontinence and future applications
• Company 1032 - 1-Needleless mesotherapy to treat cellulite, 2-Non-invasive/non-thermal treatment for skin laxity/hypertrophic scars/striae
• Company 1033 - Laparoscopic instruments that articulate/rotate/lock for single port access/"scar-less" surgery
• Company 1034 - Miniature implantable sensors to accurately/continuously pinpoint the location of tumors in real-time, during radiation therapy delivery
• Company 1035 - Manual rongeur and access tools for use in spinal decompression procedures
• Company 1036 - Convenient/improved continuous glucose monitoring system
• Company 1037 - Coating that triggers the body to generate nitric oxide (NO) at the device surface, by using naturally circulating blood substances
• Company 1038 - Real-time/in vivo/cellular-level/3-D imaging for: image-guided surgery; early cancer diagnosis without a biopsy
• Company 1039 - In vivo transdifferentiation to regenerate ischemic/diseased organs
• Company 1040 - Technology that has demonstrated its usefulness in tracking all facets of in vivo oxygen metabolism using normally installed MRI scanners
• Company 1041 - True seizure "prediction" - up to an hour before the event
• Company 1042 - Wearable mobile device to accurately measure real-time energy (calorie) expenditure/combat obesity
• Company 1043 - 1-Non-embryonic cell technology that creates cells/tissues/organs for virtually anyone needing a transplant, 2-Non-toxic cancer vaccine that uses the body's natural immune response to fight cancer, 3-Cell separation system to diagnose/monitor cancer
• Company 1044 - Custom miniaturized mechanical components/devices for a broad range of medical device applications
• Company 1045 - Wireless/disposable sleep-monitoring device
• Company 1046 - 1-Next-generation, natural fibrin sealant, 2-Human thrombin
• Company 1047 - In vivo smart sensor to help women get pregnant, automatically detecting pregnancy and any early pregnancy loss, and screening for cervical cancer and other STDs, with additional uses central to women's health & lifestyle
• Company 1048 - Technologies that focus on wound diagnostics, infection control, and wound therapy
• Company 1049 - Wireless/MEMS-fabricated/nano-processed/dermal/percutaneous continuous glucose monitoring device
• Company 1050 - Diagnostic instrument to measure the material properties of bone
• Company 1051 - Electronic Brachytherapy (eBx) systems based upon miniaturized x-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments
• Company 1052 - Minimally invasive method for lumbar spine decompression to treat patients with lumbar spinal stenosis (LSS), which may be performed in conventional operating rooms or interventional radiology suites with fluoroscopic imaging
• Company 1053 - Next-generation respiratory device that delivers synchronization of flow/temperature/humidity/oxygen percentage, without discomfort, via nasal cannula
• Company 1054 - Minimally invasive system to treat emphysema and resolve prolonged air leaks following lung surgery
• Company 1055 - 3-D mesh pouches that are implanted empty, positioned, filled, then deployed to their full size for spinal/orthopedic applications
• Company 1056 - Painless photo-pulsation technology for diminishing fine lines/wrinkles/age spots on the face/neck/hands
• Company 1057 - Plastic surgery implantable devices for cosmetic and reconstructive surgery
• Company 1058 - The SENSIMED Triggerfish(R) "eye-Holter" is a paradigm-changing technology consisting of a disposable contact lens telemetric sensor, which for the first time provides ophthalmologists with the full ambulatory 24-hour IOP profile, conveniently and during uninterrupted daily activities and sleep
• Company 1059 - Technology for the non-fusion treatment of scoliosis
• Company 1060 - Atraumatic injectable plugs for 1-Temporary occlusion of blood vessels, 2-Kidney stone removal, and 3-future applications
• Company 1061 - Percutaneously deliverable endograft to treat Abdominal Aortic Aneurysms (AAA) and Thoracic Aortic Aneurysms (TAA)
• Company 1062 - Optical Coherence Tomography (OCT) for sub-surface biological tissue imaging at much greater resolution than ultrasound/MRI/CT scanners
• Company 1063 - Next-generation femtosecond laser that can operate inside the eye to make cataract surgery safer/more effective
• Company 1064 - Totally implantable pumps delivering targeted medications directly to the spinal cord
• Company 1065 - Point-of-care diagnostic tests for infectious diseases capable of detecting virulence markers produced only during ACTIVE infections
• Company 1066 - Therapeutic gene delivery
• Company 1067 - 1-Vertebral augmentation system and 2-On-demand ultra-high viscosity cement injection, for spinal applications
• Company 1068 - Miniature implantable neurostimulator for treating central nervous system disorders
• Company 1069 - Simple, point-of-care blood test for the detection/monitoring of traumatic brain injury (TBI)
• Company 1070 - Resurfacing system to treat lesions/defects in the body's weight bearing, non-weight bearing, and extremity joints
• Company 1071 - Molecular imaging of apoptosis (programmed cell death) for disease detection/monitoring
• Company 1072 - Technology to close incisions made during Natural Orifice Transluminal Endoscopic Surgery (NOTES) procedures
• Company 1073 - Transitional in vivo imaging
• Company 1074 - Collapsible titanium-alloy implant for spinal fusion
• Company 1075 - Non-invasive type 2 diabetes and pre-diabetes screening with no blood draw/no fasting/no waiting for a lab result
• Company 1076 - Devices for the destruction of pathogens responsible for: heart/blood/respiratory/gastrointestinal/periodontal/otological diseases, pancreatic cancer, and toe nail fungus
• Company 1077 - Device that delivers a low-level/precisely controlled heat for the treatment of acne
• Company 1078 - Nanomaterial-based MRI coil for higher image quality/faster scan times
• Company 1079 - Handheld/at-home hair removal via laser
• Company 1080 - Enhanced diabetes insulin pump
• Company 1081 - Transpedicular/minimally invasive approach to vertebral body reconstruction/anterior spinal column support
• Company 1082 - Next-generation Spinal Cord Stimulation (SCS) technology to treat chronic back/lower extremity pain
• Company 1083 - Dynamic and intelligent optics for use in spectacle lenses for the correction of presbyopia
• Company 1084 - Blood screening tests for breast and ovarian cancers
• Company 1085 - Implantable/battery-less diagnostic system to allow orthopedic surgeons to monitor spinal fusion progress
• Company 1086 - Next-generation coatings/advanced drug-delivery systems for cardiovascular stents and other implantable medical devices
• Company 1087 - Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) device for acute coronary syndrome (ACS) and heart failure patients
• Company 1088 - Ultra-thin/personalized/single-use/flexible/transdermal drug delivery patch
• Company 1089 - DNA-based diagnostic tests for early identification/management of cancer/acute diseases
• Company 1090 - Device with bio-active formulae to rapidly/painlessly treat/control the wound environment
• Company 1091 - Less invasive treatment for chronic sinusitis delivered via non-nasal access
• Company 1092 - Leadless/implantable pacing device for left ventricular stimulation/the treatment of heart failure
• Company 1093 - Technologies to acquire/process/visualize data from 3-D breast imaging
• Company 1094 - Mental stimulation system to help maintain mental acuity/quality of life
• Company 1095 - Implantable device to treat high blood pressure that cannot be controlled with medications/lifestyle modifications
• Company 1096 - Polymer technologies for cardiac/cranio-maxillofacial/orthopedic surgery applications
• Company 1097 - Leadless/subcutaneously implantable cardiac defibrillator (ICD)
• Company 1098 - 1-Handheld intelligent bone sculpting tool, 2-X-ray vision that appears "within" the patient
• Company 1099 - Synthetic peptides for tissue regeneration for the treatment of musculoskeletal/vascular/chronic wound diseases
• Company 1100 - Radiofrequency (RF) energy to reshape the cornea without incision
• Company 1101 - Endovascular treatment of peripheral arterial blood vessels that require re-vascularization
• Company 1102 - Cells derived from bone marrow which can be used in an allogeneic/off-the-shelf setting to treat kidney/other difficult to treat diseases
• Company 1103 - Thin-walled/removable/entirely covered stents designed to match the site to be treated and the surrounding anatomy
• Company 1104 - Technologies to: 1-Treat the progression of age-related macular degeneration (AMD) and retinitis pigmentosa (RP), 2-Stop/reverse some of the vision loss from Glaucoma, 3-Prevent diabetic retinopathy, 4-Greatly enhance pars plana vitrectomy surgery
• Company 1105 - Single device for high-frequency ultrasound imaging/therapeutic treatment
• Company 1106 - Low-level laser technology for aesthetics, bone healing, neck/shoulder pain, and wound healing
• Company 1107 - Light-based aesthetic systems that are pain-free/seven times faster than existing systems
• Company 1108 - 1-Image analysis technology for virus detection/analysis, 2-Antiviral drugs
• Company 1109 - Simultaneous testing of sobriety and identy that is simple/rapid/non-invasive, requiring no bodily fluids
• Company 1110 - Technology for diagnosing breast and ovarian cancers and determining responsiveness to new therapeutics
• Company 1111 - Synthetic graft/stent technology that reduces neo-intimal hyperplasia (NIH) and occurrence/rate of restenosis
• Company 1112 - Disposable endoscopic assist device that can be used with existing equipment to significantly improve flexible endoscopy procedures
• Company 1113 - Systems using radiofrequency (RF) energy for the treatment of GERD and fecal incontinence (FI)
• Company 1114 - Sutureless anastomosis systems to reduce/eliminate cross clamping time and suturing during minimally invasive surgery (MIS)
• Company 1115 - Anti-infective compounds designed to mimic host defense proteins, but with completely synthetic/non-peptide backbones, for serious, life-threatening, acute disorders
• Company 1116 - Minimally invasive interstitial laser therapy (ILT) as an alternative to lumpectomy
• Company 1117 - Less invasive approach for mitral valve repair, on a beating heart
• Company 1118 - High-resolution dermoscopy imaging technology to identify melanoma at an earlier stage/reduce the number of unnecessary excisions
• Company 1119 - Nanotechnology surface treatments for combination medical devices that address nosocomial (in-hospital) infections and thrombus
• Company 1120 - Non-invasive, fully automated system for the accurate assessment of: cardiovascular/diabetic autonomic neuropathy, effectiveness of beta-blocker therapy, and risk stratification of sudden cardiac death
• Company 1121 - Wireless/motorized orthopedic lengthening implants for applications in deformity correction/cosmetic limb lengthening/bone fractures
• Company 1122 - 3-D scaffold that enhances the biointegration of percutaneous/fully implanted current and next-generation devices
• Company 1123 - Injectable gels for localized and controlled release of biologicals
• Company 1124 - Portable/palm-held endoscopic imaging with a mobile platform for recording/sharing/archiving images
• Company 1125 - Hand-held ultrasound device to quantify strain and stiffness of tendons/ligaments
• Company 1126 - Lightweight brace support suit that restores mobility function for paraplegics/lower limb paralysis patients
• Company 1127 - Non-invasive gene expression-based tests for the monitoring of transplant rejection/autoimmune diseases
• Company 1128 - Cobalt-chromium, balloon-expandable stent, which marries with approved DES to treat the entire spectrum of coronary artery bifurcation lesions
• Company 1129 - Non-invasive intracranial pressure monitor to diagnose/treat head injury
• Company 1130 - Temperature-controlled/multi-functional next-generation cutting/sealing product
• Company 1131 - Interspinous/interlaminar functionally dynamic stabilization device and other non-fusion scoliosis technologies
• Company 1132 - CO2 lasers through flexible/rigid endoscopes for use in minimally invasive surgery and soft tissue procedures in otolaryngology/head and neck surgery/pulmonology
• Company 1133 - Real-time/PCR-based molecular diagnostic tests for life-threatening respiratory fungal infections
• Company 1134 - Ultra-lightweight/soft/non-palpable mesh technology to treat urinary stress incontinence/pelvic organ prolapse
• Company 1135 - Medipacs first-ever, solid-state polymer pump platform is the "end-game" for low cost, high precision drug delivery solutions and it will spawn electronic syringe products that reformulate markets
• Company 1136 - Surgical implants and biological products for spinal surgery
• Company 1137 - In situ formed hydrogels designed/indicated for ophthalmic surgery
• Company 1138 - Light-activated glue system to stabilize shattered bone
• Company 1139 - Non-contact imaging system that provides local anatomical and oxygenation information
• Company 1140 - Affordable/good quality standard-of-care surgical devices
• Company 1141 - Low-dose-rate brachytherapy that will replace individual seeds and provide more uniform/consistent radiation delivery to patients
• Company 1142 - Recombinant adeno-associated viral (AAV)-based gene therapy as a treatment for congestive heart failure (CHF)
• Company 1143 - Aortic valve bypass graft system for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy
• Company 1144 - Single-use catheter device w/controller that delivers radiofrequency energy during outpatient bronchial thermoplasty for the treatment of asthma
• Company 1145 - Ultrasonic energy for the selective dissection/fragmentation/debridement/cleansing of tissues
• Company 1146 - Percutaneous soft tissue lifts for the breast/neck/other soft tissue structures
• Company 1147 - Bioresorbable polymer surgical implants designed to prevent/reduce the formation of post-operative adhesions
• Company 1148 - Implanted electronic subretinal device to restore vision to those who are blind due to retinitis pigmentosa (RP) or age-related macular degeneration (AMD)
• Company 1149 - Noninvasive tests for the risk assessment of cardiovascular disease and the detection of early-stage lung/breast/colorectal cancer
• Company 1150 - Guidewire system intended to safely/quickly cross occluded peripheral and coronary vessels
• Company 1151 - Matrix therapy based technology that treats skin ulcers/reduces amputation
• Company 1152 - Artificial muscle technology for the treatment of sphincter dysfunction and urinary incontinence (UI)
• Company 1153 - Technology that selectively treats only cancer cells and avoids destruction of normal cells
• Company 1154 - Full line of precision-crafted/disposable/ultra-minimally invasive surgical instruments
• Company 1155 - Beam steering/target tracking/treatment planning solutions to the external beam radiation therapy market
• Company 1156 - Device that uses combined electric field and low-intensity, noninvasive ultrasound for the treatment of solid tumors without the need for chemotherapy
• Company 1157 - One-shot, instantaneous anastomotic stapling devices for open AAA, EVAR, and CLI applications
• Company 1158 - Stent to treat cerebral/aortic aneurysms by modulating hemodynamic flow
• Company 1159 - Biomotion sensors that enable easy/non-contact capture of high-quality physiological data - remotely/wirelessly
• Company 1160 - Flexible/single-use/sterile video-endoscopes which may be used at the patient bedside and which avoid all cross-contamination risks
• Company 1161 - Therapeutic gene delivery to treat diabetes/obesity/intestinal disorders/hemophilia/anemia
• Company 1162 - Non-invasive technique for sampling the surface layers of the skin to generate individual genetic profiles for diagnostic/prognostics
• Company 1163 - Non-invasive method designed to only kill fat cells and not harm the skin or other tissue
• Company 1164 - 3-D/single-piece/dual optic accommodating intraocular lens (IOL)
• Company 1165 - Cellular therapy to act directly at the level of the cause of autoimmune disorders, the dysregulated immune regulation
• Company 1166 - Next-generation transluminally placed endovascular grafts for the treatment of aneurysmal disease in the AAA/TAA
• Company 1167 - The first tomographic, real-time, high-resolution imaging system for pulmonary disease management. The Tomophase OCTIS(TM) is being deployed in major hospitals worldwide.
• Company 1168 - Very strong/customizable/biomimetic/easily revisable artificial disc implant, requiring no assembly in situ
• Company 1169 - Diagnostic and therapeutic catheter-based devices for prevention/treatment of heart attacks caused by soft plaque
• Company 1170 - Advanced method of photocoagulation to provide more rapid, precise, and safe treatment for a variety of retinal conditions
• Company 1171 - Next-generation personal diagnostics for hematological malignancies/autoimmune disorders
• Company 1172 - Soft tissue repair/replacement, using proprietary chemistry and organic collagen matrices
• Company 1173 - Sirolimus-based product as a next-generation therapeutic for the treatment/prevention of wet AMD and the treatment of diabetic macular edema
• Company 1174 - Phototherapy/ultraviolet light to inactivate the organisms that cause nail infections
• Company 1175 - Technology enabling detection and monitoring wirelessly, remotely, and with no contact to the subjects; also through clothing/barriers
• Company 1176 - Biochips to identify gene expression patterns
• Company 1177 - Automated blood analysis at point-of-care
• Company 1178 - Applicator for breast brachytherapy that delivers targeted dose of radiation
• Company 1179 - MRI contrast agents to monitor the position/quantity of transplanted cells non-invasively in vivo
• Company 1180 - A soft tissue aperture fixation system for anterior cruciate ligament (ACL) reconstruction using the hamstring/other soft tissue grafts
• Company 1181 - Non-invasive/convenient measurement and monitoring of human hydration status, using saliva as a sample
• Company 1182 - Cryotherapy to ablate diseased tissue
• Company 1183 - Reliable/accurate/solid-state laser system for customized treatment of many vision disorders
• Company 1184 - Non-invasive/iontophoretic drug delivery system with broad applicability for treating serious ocular diseases
• Company 1185 - Electrical stimulation technology, along with single-use disposables, to restore continence control to individuals with abdominal ostomies and eliminate the need for traditional ostomy pouching systems
• Company 1186 - MRI-guided laser ablation system for targeted, minimally invasive, focal tumor therapy
• Company 1187 - Medical devices that enable earlier detection/minimally invasive treatment of lung cancer
• Company 1188 - Non-invasive devices for the treatment of superficial venous disease
• Company 1189 - High-quality low-cost spine implants
• Company 1190 - 1-Catheter-based system for the treatment of ischemic brain injury; 2-Drug delivery systems; 3-Microcatheters; and 4-Aneurysm coil delivery systems
• Company 1191 - Cardiac assist device for patients in moderate/severe long-term heart failure
• Company 1192 - Digital image acquisition, coupled with proprietary CAD decision-making algorithms, to provide an immediate/automated colposcopic evaluation
• Company 1193 - Robotic system for fabrication of nano-material based wound dressings, delivered on-demand, at the POC
• Company 1194 - Unique spine functional testing that delivers improved surgical outcomes
• Company 1195 - Electromagnetic thermal therapy to relieve pain/improve function in patients suffering from osteoarthritis
• Company 1196 - System to inactivate pathogens in all three major blood components: platelets/plasma/red cells
• Company 1197 - Therapeutic approaches to prevent the abnormal tissue growth that inhibits recovery from surgical procedures/impairs normal wound healing
• Company 1198 - Biocompatible shape memory polymers which can be programmed to change shapes/rigidity when an initiating stimulus is applied
• Company 1199 - A fully integrated, affordable, sample-to-result platform for rapid, accurate PCR-based detection/differentiation of infectious disease
• Company 1200 - Technologies that will prevent infection for many large patient populations
• Company 1201 - Light-activated drug therapy to transform cancer into a treatable chronic disease
• Company 1202 - 1-Percutaneous venous valve, 2-Inferior vena cava filter, 3-Multi-purpose/disposable laparoscopic scissor grasper, 4-Multi-sized/multi-stiffness guidewire
• Company 1203 - Non-invasive infrared imaging system for the early detection of breast cancer
• Company 1204 - Device for the treatment of sudden cardiac arrest for both in- and out-of-hospital markets
• Company 1205 - Line of antimicrobial coatings to prevent microbial colonization/biofilm formation of endotracheal tubes/other indwelling medical devices
• Company 1206 - 3-D tracking devices for use in surgical navigation and MIS
• Company 1207 - Implantable patient alerting system for the detection and prevention of heart attacks
• Company 1208 - Minimally invasive/RF nerve ablation to reduce of migraine headache pain
• Company 1209 - Less invasive devices for the treatment of glaucoma, intended to replace current therapies
• Company 1210 - Natural cell-based technologies to restore normal neuron function in the central nervous system
• Company 1211 - Non-invasive/urine-based diagnostic assays for specific cancer types
• Company 1212 - Fluid-controlled accommodating intraocular lens (IOL) to restore vision of youth to middle-aged/elderly individuals
• Company 1213 - Single, multi-cannula laparoscopic port and specially designed curved instrumentation
• Company 1214 - Technology that provides the precision of a scalpel and the bleeding control of traditional electrosurgery, without extensive collateral tissue damage
• Company 1215 - More viable/cost-effective method for treating intracranial aneurysms
• Company 1216 - System that enables consistent tissue contact/complete lesions during cardiac surgery for the treatment of arrhythmias
• Company 1217 - Non-invasive neurorehabilitation system
• Company 1218 - Cerebral protection system to prevent embolic strokes
• Company 1219 - Catheter-based drug delivery using high-frequency/low-power ultrasound
• Company 1220 - Technology for real-time identification/localization of cancer cell clusters to enable complete/residual-free therapeutic excisions
• Company 1221 - Third-generation cancer-associated biomarkers using proteomics
• Company 1222 - Cardiac mapping system that is non-invasive, maps the entire heart in one beat, and provides catheter localization
• Company 1223 - Repair and regeneration technology platforms designed to mend and regrow hard tissue (such as bone) and soft tissue (such as cartilage)
• Company 1224 - Minimally invasive/flexible spinal implant technology to treat vertebral compression fractures and degenerative disc disease
• Company 1225 - Catheter-based drug delivery system designed to dissolve blood clots in a single/rapid/one-step procedure
• Company 1226 - Rapid DNA-based point-of-care diagnostics
• Company 1227 - Joint prostheses as an adjunct to laminectomy/laminotomy/neural decompression/facetectomy, in lieu of fusion
• Company 1228 - Advanced trilobal pericardial valve technologies
• Company 1229 - Protective coatings for medical instrumentation to combat bacterial biofilms
• Company 1230 - Wireless ECG monitoring
• Company 1231 - De-cellularized biological scaffolds meant to function like native tissue
• Company 1232 - Non-invasive, wearable, watch-sized metabolism measurement system that employs the use of a low-cost proprietary disposable sensor using direct-calorimetry, to accurately measure minute-by-minute caloric expenditures
• Company 1233 - Advanced, intuitive real-time imaging for abdominal minimally invasive surgery
• Company 1234 - Technology that improves vascular access accuracy and visualization of veins and arteries as well as related vascular events such as rolled veins, bifurcations, vasospasm, and extravasation
• Company 1235 - Regenerative medicine company developing novel treatments from hair growth to cancer therapies based on the products of cells grown under simulated embryonic conditions
• Company 1236 - Next-generation cell-based/tissue-engineered products
• Company 1237 - Mesh wrap for permanent implantation around the heart to prevent/reverse the progression of heart failure
• Company 1238 - Handheld/breath-based blood glucose monitor
• Company 1239 - More targeted/accurate radiation of cancer cells with significantly fewer side-effects
• Company 1240 - Bioactive glass-ceramic material that offers whiter and less-sensitive teeth while protecting from tooth decay
• Company 1241 - Membrane optimization, coatings technologies, and development of polymers for biomedical applications
• Company 1242 - System to process/concentrate cellular components from autologous bone marrow, including adult stem cells, at the point-of-care and in just 15 minutes
• Company 1243 - Devices to control bleeding post-hysterectomy/in other cases of pelvic area trauma
• Company 1244 - Safe, non-invasive body shaping technologies
• Company 1245 - Non-invasive/fast/accurate diagnostic kits for: fertility, hormones, infectious agents, auto-antibodies, and tumor markers
• Company 1246 - Gene therapy products for the treatment of inherited/acquired diseases.
• Company 1247 - Stent technology for the treatment of atherosclerotic disease at/near bifurcations
• Company 1248 - Neo-organs/tissues derived from the patient's own (autologous) cells
• Company 1249 - Computer-controlled pressure garments for the effective treatment of lymphedema/chronic wound healing
• Company 1250 - Small/portable/disposable infusion pump kit to treat post-operative pain more effectively than narcotics
• Company 1251 - Pulsatile perfusion generator technology to greatly enhance the preservation time window and organ transplant quality
• Company 1252 - The Argus II Retinal Prosthesis System is the world's first and only CE marked retinal prosthesis that utilizes electrical stimulation to partially restore sight in patients blinded by outer retinal degeneration
• Company 1253 - Device to improve drainage following heart, lung, and trauma surgery, as well as other procedures where drainage is critical
• Company 1254 - Next-generation/fully-automated/electronically-controlled/self-contained blood glucose system
• Company 1255 - Minimally invasive system for treating long-bone fractures using an intermedullary stent/cement
• Company 1256 - Non-invasive measurement of magnetic fields to diagnose functional brain disorders
• Company 1257 - Products to diagnose/treat dry and wet age-related macular degeneration (AMD) and other chronic diseases involving the alternative complement system
• Company 1258 - Wearable artificial kidney device
• Company 1259 - Multi-generational devices using hybrid technologies for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
• Company 1260 - Miniature patch that dispenses insulin
• Company 1261 - Microcatheter and imaging technologies for interventional ophthalmology
• Company 1262 - Easy, safe, and convenient injection of drugs and vaccines in a solid dosage form using the Glide SDI(R) (Solid Dose Injector)
• Company 1263 - Non-epigenetic cell reprogramming technology that enables the generation of patient-identical replacement tissue/organs on an as-needed basis
• Company 1264 - Device to percutaneously repair the mitral valve
• Company 1265 - Miniature intravascular flow augmentation device for every organ that needs temporary change of flow
• Company 1266 - Minimally invasive surgical procedure intended to reduce the incidence of stroke/thromboembolism associated with atrial fibrillation
• Company 1267 - Plaque vulnerability biomarkers to detect patients at risk for the development of stroke, myocardial infarction or claudication
• Company 1268 - A platform for minimally-invasive cardiac surgery (MICS) via single-port, subxiphoid access, and an endoscope that reaches any anatomical location, including complex paths, from one single access port
• Company 1269 - Percutaneous mitral valve replacement (PMVR) for Mitral Regurgitation (MR)
• Company 1270 - Medical devices for the osteoarthritis/rhinosinusitis markets
• Company 1271 - Miniaturized ultrasound probe that is easier-to-use/more flexible
• Company 1272 - Resonating sensor made out of piezoelectric ceramics that can be miniaturized and is suitable for use in diagnostic equipment
• Company 1273 - Bioresorbable peripheral/coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty
• Company 1274 - Disposable devices for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
• Company 1275 - True 3-D imaging to improve evaluation/planning of radiation treatments
• Company 1276 - Next-generation spinal implants
• Company 1277 - New unilateral posterior fusion technology
• Company 1278 - Products for nuclear replacement/augmentation, vertebral compression fracture repair, and spinal fusion
• Company 1279 - Second-generation, metal-on-metal cervical/lumbar artificial discs
• Company 1280 - Artificial cervical disc with controlled range of motion in all six degrees of freedom
• Company 1281 - Next-generation of biomaterials for spinal implants
• Company 1282 - Intradiscal arthroplasty device utilizing articulating PEEK-on-PEEK material
• Company 1283 - Hydrogel matrix with applications across multiple specialties
• Company 1284 - Intelligent microgels as injectable scaffolds for intervertebral disc repair
• Company 1285 - Minimally invasive disc augmentation system to repair/rehabilitate an intervertebral disc
• Company 1286 - Implant designed to retain motion following the removal of diseased disc and/or bone material in the upper spine
• Company 1287 - Tissue repair/surgical mesh systems for soft tissue repair
• Company 1288 - Silicon nitride implants with 3-D structured cancellous ceramic for strong capillary action
• Company 1289 - Tibial knee implant for stable fixation to the medial tibial plateau without bone cuts/cement/screws
• Company 1290 - Technologies to treat obstructive sleep apnea and snoring
• Company 1291 - The Superion Interspinous Spacer system is the most advanced and least invasive spacer system and is delivered through a percutaneous midline approach for the treatment of lumbar spinal stenosis
• Company 1292 - Tissue engineering technologies for orthopedic/sports medicine patients
• Company 1293 - Real-time imaging/image guidance for the operating room
• Company 1294 - Stent that provides protection from embolic showers during/post-procedure
• Company 1295 - Minimally invasive vapor technology to treat emphysema
• Company 1296 - Human-based tissue scaffolds
• Company 1297 - Simple, low-cost infusion pump that contains the IV bag within it
• Company 1298 - Non-intrusive patient-monitoring systems that facilitate timely intervention for cardiac/respiratory deterioration
• Company 1299 - Bifurcated stenting
• Company 1300 - Bioabsorbable implants for accurate soft tissue fixation either to apposing soft tissue/to bone
• Company 1301 - Drug delivery vehicles that can easily be targeted to specific cell types/disease state tissues
• Company 1302 - Minimally invasive therapies for interventional neuroradiology
• Company 1303 - Treatment for ischemia via stem cell-based therapies
• Company 1304 - Cellular therapy device to treat liver disease
• Company 1305 - Customizable vibration therapy devices to stimulate bone/muscle tissue
• Company 1306 - Deep brain stimulation (DBS) guidance system
• Company 1307 - Cellular imaging technology, using the Internet to transfer real-time/secure/accurate cellular resolution images
• Company 1308 - Minimally-invasive percutaneous aortic valve replacement systems
• Company 1309 - Off-the-shelf implantable allograft tissue to support peripheral nerve repair and regeneration
• Company 1310 - Advanced detection, staging, endoscopic treatment and follow-up care for acute and chronic lung disease
• Company 1311 - Minimally invasive therapy for the treatment of chronic disc pain
• Company 1312 - A minimally invasive device for stomach-reduction surgery consisting of a stapling tool that can be passed down the throat into the stomach
• Company 1313 - Kidney stone management device and urethral dilating introducer
• Company 1314 - Ventricular elastic support therapy for heart failure
• Company 1315 - Plastic medical devices for gynecological exams and surgeries
• Company 1316 - Inferior vena cava filters
• Company 1317 - Neuromodulation system for both traumatic brain injury (TBI) and stroke
• Company 1318 - Minimally traumatic, bone- and cartilage-preserving knee implants and instrumentation
• Company 1319 - Radio-frequency (RF)-based tissue sealing and cutting instruments with a long jaw sealing length and high quality seal to greatly reduce procedure time and surgeon fatigue
• Company 1320 - Fast, accurate, and easy-to-use in vitro molecular diagnostic products that rapidly identify infectious pathogens
• Company 1321 - Unique spinal implant designed to promote rapid fusion
• Company 1322 - Devices for Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures
• Company 1323 - Unique transcranial magnetic stimulation system that allows direct non-invasive activation of deep brain structures
• Company 1324 - Dynamic "shape memory" platform to optimize mitral/tricuspid valve repair
• Company 1325 - Single molecule DNA analysis system, with no requirement for prior sequence information/PCR/cloning/probes
• Company 1326 - Biomaterials-based medical devices focusing on cardiovascular, metabolic, inflammatory, and fibrotic diseases
• Company 1327 - Transdermal/wound dressing/mucosal drug delivery
• Company 1328 - A unique solution similar to ring annuloplasty/edge-to-edge repair, all in one modality, for mitral valve repair
• Company 1329 - Minimally invasive devices that improve oxygenation for patients with COPD
• Company 1330 - Hands-free internal retractor/internally-anchored laparoscope camera cleaner
• Company 1331 - Particle technologies for the treatment/prevention of chronic respiratory disorders
• Company 1332 - Minimally invasive, single-procedure approach for the repair of cartilage damage/osteoarthritis
• Company 1333 - Biodegradable synthetic hydrogels for general and specialty surgery use
• Company 1334 - Silk-based biomaterial platforms for tissue rejuvenation/connective tissue repair
• Company 1335 - Ankle replacement implant for patients with chronic pain/arthritis
• Company 1336 - Biomarker assays for the early detection of cancer
• Company 1337 - 1-Painless intradermal drug delivery, 2-GERD diagnostic device, 3-Non-invasive continuous glucose monitoring
• Company 1338 - Detection products for viral/bacterial infections, genetic diseases, mutations, cancers, etc.
• Company 1339 - Video integration and equipment management system to enhance the MIS market
• Company 1340 - Multi-pixel x-ray source for enhanced system performance/new capabilities
• Company 1341 - Combination ultrasound/electrical stimulation device for skin rejuvenation
• Company 1342 - Bioprosthetic two-piece tissue valve system for minimally invasive valve replacement utilizing a transapical approach
• Company 1343 - Advanced suturing technology for minimally invasive/NOTES/bariatric/cardiac/other surgical specialties
• Company 1344 - A minimally invasive electromagnetic navigation system for early detection of lung cancer
• Company 1345 - Patient-centric data system and analysis tools for translational medicine and research
• Company 1346 - Hand-held device to monitor post-operative/trauma patients for early warning signs of sepsis or infection in the bloodstream
• Company 1347 - Spinal cage with dynamic stabilization/MIS placement (3mm access) and easily revisable
• Company 1348 - Fully modular total hip replacement systems to reduce wear/add longevity
• Company 1349 - A "plug & play" system for treating non-invasive, curative, and palliative cancers and precursors
• Company 1350 - Products for the early detection of lung and oral cancers
• Company 1351 - System that performs a non-invasive, 30-second test to identify the risk of heart disease
• Company 1352 - Non-molecular bacterial screening, identification, and antibiotic susceptibility testing
• Company 1353 - Optical coherence tomography for evaluation of human tissue microstructure with real-time depth visualization
• Company 1354 - Wireless electronic skin patch sensors for the real-time measurement/monitoring/diagnosis/clinical management of cardiac arrhythmias
• Company 1355 - Non-fusion spinal solutions that control segmental motion/maintain the neutral zone simultaneously
• Company 1356 - Optical cell sorters used in stem cell/cell therapy treatments for cancer, autoimmune disease, and regenerative medicine applications
• Company 1357 - BQT®, a non-invasive point-of-care diagnostic test for osteoporosis and bone fracture risk
• Company 1358 - Low-mass PFO closure system capable of repairing the defect from within the tunnel
• Company 1359 - Third-generation biodegradable annuloplasty rings
• Company 1360 - Easy-to-use, instrument-free, disposable molecular diagnostic tests
• Company 1361 - 1-Bone cement to replace PMMA-based materials, 2-A liquid hydrogel wound dressing able to cure rapidly and in situ
• Company 1362 - Monitoring system to replace the manual assessment of labor progress with real-time/continuous information
• Company 1363 - Delivery of proteins and peptide drugs without burst, with near-zero order release, and with high bioavailability
• Company 1364 - Contrast agents/molecular imaging for detection using a modified porous Silicon (mpSi™) platform
• Company 1365 - Aerolase cosmetic lasers have user-validated superiority on key attributes: efficacy and safety, particularly on hard to treat darker complexions; unique multi-purpose function and portability; yet industry-low cost
• Company 1366 - SutureCross™: Knotless Anatomic Fixation System for double row arthroscopic rotator cuff repair
• Company 1367 - Biodegradable surgical adhesive for seroma reduction in plastic surgery
• Company 1368 - Miniature blood pump, designed to be placed superficially like a pacemaker, for the long-term treatment of chronic heart failure (CHF)
• Company 1369 - Devices that use bio-electric stimulation therapy (bio-current) to treat hard-to-heal wounds
• Company 1370 - Minimally invasive catheter-based ablation technologies to treat atrial fibrillation and other cardiac arrhythmias
• Company 1371 - Transvaginal, ultrasound image-guided HIFU device, capable of real-time guidance and monitoring of therapy
• Company 1372 - A portable breath collection apparatus (BCA) which can collect breath samples virtually anywhere, for highly sensitive laboratory analysis
• Company 1373 - Automatic tools to support image visualization, lesion detection and quantification, temporal evolution assessment, and automatic reporting in chest and abdominal CT scans
• Company 1374 - RNA-based therapeutics
• Company 1375 - Wireless seizure alarm systems for people with epilepsy
• Company 1376 - Arm training device to restore arm movement in stroke patients who have experienced arm paralysis
• Company 1377 - Ophthalmic formulation of mitomycin-C in a single-use kit, for use in the surgical treatment of glaucoma
• Company 1378 - Products to diagnose the risk for heart attacks by means of assessing endothelial function
• Company 1379 - Minimally invasive medical devices for patients who are at risk for or have suffered a stroke
• Company 1380 - AOKit™-bio: an adaptive optics kit for biologists which enhances microscopic imaging
• Company 1381 - Neowater®, a water-based nanotechnology which has physical properties that mimic intracellular water
• Company 1382 - Metabolomic profiling of biomarkers for the diagnosis of early forms of dementia and neurodegenerative diseases
• Company 1383 - A portable oxygen delivery and ventilation system
• Company 1384 - Interventional bronchoscopy devices for lung diseases
• Company 1385 - Advanced endotracheal tube for intubation, fitted with advanced fiberoptic visualization technology
• Company 1386 - Modular hip stem technology and total knee replacement systems
• Company 1387 - First viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF)
• Company 1388 - Fusion and non-fusion spinal implants
• Company 1389 - A device that seals blood vessels after hemodialysis as an alternative to central venous catheters for kidney-dialysis patients
• Company 1390 - Non-invasive ultrasound body contouring
• Company 1391 - Non-invasive, painless, Navigated Brain Stimulation (NBS) for brain diagnostics and therapy
• Company 1392 - Noninvasive breast cancer risk assessment device
• Company 1393 - Low cost, easy-to-use, credit-card-sized devices which will allow on-the-spot quantitative diagnosis
• Company 1394 - Telemedicine paired with state-of-the-art ophthalmologic imaging
• Company 1395 - Devices for treating cardiovascular disease
• Company 1396 - Precision surgical systems for computer-assisted 3D planning, surgical navigation, and surgeon-controlled robotic surgery
• Company 1397 - Female sterilization technology
• Company 1398 - Electromedical/electrotherapeutic equipment
• Company 1399 - Products for the minimally invasive repair of long bone fractures
• Company 1400 - Molecular diagnostic products for laboratories that are intended to enhance medical care by providing early diagnostic information rapidly
• Company 1401 - New pulmonary drug delivery system
• Company 1402 - Next-generation laser therapy
• Company 1403 - Devices for the in-office polypectomy/myomectomy market
• Company 1404 - Low-cost, fast, and accurate molecular diagnostic products
• Company 1405 - EXPANSE Vertebral Body Replacement Device for use in the thoracolumbar spine
• Company 1406 - An oncology visualization system that integrates advanced graphics processing capabilities with proprietary software algorithms to register multiple CT image sets in real-time
• Company 1407 - Minimally invasive, single-use, disposable devices that enable incisionless, transoral procedures for the treatment of a number of upper gastrointestinal problems, including gastrointestinal reflux disease (GERD) and failed bariatric surgery
• Company 1408 - Mobile phone-based data collection for chronic disease management
• Company 1409 - Advanced gene expression and DNA quantification products and services
• Company 1410 - Optical backscatter technology to improve the way cancer is detected and diagnosed
• Company 1411 - Laser, light-based, and radiofrequency devices for aesthetic and medical applications
• Company 1412 - Diagnostic methods using microarray gene expression profiling to determine specific properties of tumors
• Company 1413 - Catheter-based devices which rapidly provide quantitative data to the physician about vessel and stent size, suitable for peripheral and cardiac applications
• Company 1414 - Advanced wheelchair technologies
• Company 1415 - Human bionic devices that can instantaneously interact with the human body to replace or restore biomechanical or physiological functions
• Company 1416 - Cell-based epicardial patch designed to promote blood vessel growth in ischemic cardiac tissue
• Company 1417 - Methods for treating human tissue based on volumetric bipolar radio frequency ablation (RFA), and surface ablation of tissue
• Company 1418 - Infusing normothermic fluids from 10mL/hour-1200mL/minute with 30-second setup through a disposable cassette
• Company 1419 - Technology using opto-acoustics for functional imaging/cancer diagnosis
• Company 1420 - High-intensity focused ultrasound in a catheter to treat atrial fibrillation
• Company 1421 - 1-Alternative to instrument-based viscosity testing; 2-A disposable blood to plasma device for use in micro-fluidic assays; 3-A home-use test for clotting time
• Company 1422 - Portable, easy-to-use consumer device that allows for easy, safe and green disposal of used insulin syringes, lancets and pen needles by vaporizing the sharp
• Company 1423 - Site-specific catheter-guided system to deliver drugs and biologics directly to the adventitia
• Company 1424 - Device based therapy targeting ischemic brain stroke and chronic heart failure
• Company 1425 - Integrated wireless monitoring
• Company 1426 - Non-invasive robotic radiosurgery system for cardiac ablation
• Company 1427 - Ceramic components for spine, orthopaedic, and other implant needs
• Company 1428 - Target-specific recombinant human protein focused on spinal fusion surgery
• Company 1429 - Patient controlled analgesia device for pain management
• Company 1430 - Less invasive orthopaedic implant solutions employing advanced pliable structured materials and innovative designs
• Company 1431 - Dual function, automatic, handheld sinus irrigator and aspirator for OTC consumer use
• Company 1432 - Computer-integrated robotic instrumentation/navigation tools for orthopedic surgery
• Company 1433 - Next-generation disposable colonoscope incorporating diagnostic/therapeutic capabilities allowing for a potentially sedation-less treatment
• Company 1434 - Total hip replacement system that addresses resistance to wear and resistance to dislocation with ceramic and double mobility
• Company 1435 - Percutaneous mitral valve replacement system for treatment of mitral regurgitation
• Company 1436 - Non-invasive continuous glucose monitoring device, for patients with diabetes, based on a multi-sensor platform
• Company 1437 - Growth factor and biomaterial addressing the needs of spinal fusion, osteochondral defects, osteoarthritis, dental medicine, and other indications
• Company 1438 - Open-sky, cryogen-free, superconductive MRI scanner that uses a U-shaped magnet with no barriers in between the patient and the environment for orthopaedic, general purpose, and interventional applications
• Company 1439 - Minimally invasive retractors for pelvic surgery to optimize pneumoperitoneum pressure and patient position (OP5)
• Company 1440 - Handheld device which measures the amount of calories a person requires to maintain body weight
• Company 1441 - Intelligent nasal drug delivery devices for topical, systemic and nose-to-brain applications
• Company 1442 - Developing a fully implantable extra-aortic counterpulsation device designed to provide long-term, cost-effective treatment and significantly improve quality of life for heart failure patients
• Company 1443 - An absolutely non-invasive, radiation- and side-effect free electro physiological high speed cardiac diagnostic system to identify upcoming heart attacks and sudden cardiac deaths
• Company 1444 - DART is utilizing an interstitial radiation source that by nuclear decay recoil mechanism emits high-energy alpha particles widely dispersed by diffusion and by convection in the tumor mass
• Company 1445 - Producer of surgical devices including a self-attaching hernia patch, anti-clog surgical drain, and cavity implosion device
• Company 1446 - Non-surgical serum based cure, proven effective for PAD, Diabetic and Cardiovascular disorders
• Company 1447 - Portable and networked medical devices such as handheld ultrasounds
• Company 1448 - Single-use rigid endoscopes, with superior image quality, at a reduced per-use cost
• Company 1449 - Providing private and hospital-based OB/GYNs, Perinatologists, and Radiologists with integrated reporting and image management systems
• Company 1450 - Minimally invasive ophthalmic device therapy for Dry Macular Degeneration and other blindness causing diseases
• Company 1451 - Minimally invasive surgical technology that uses ionizing radiation to treat wet age-related macular degeneration (AMD)
• Company 1452 - An automated blood glucose monitor for the intensive care unit using near infra-red spectroscopy
• Company 1453 - Human Globin, a biopolymer to replace animal collagens in dermal fillers and create biomaterials for tissue repair
• Company 1454 - Indigo Orb, Inc is a technology leader in "Automatic Detection of Epidural Cavity"
• Company 1455 - Developing and marketing EEG systems, tools and services for Neurologists, Neurosurgeons, and Neuroscience Researchers
• Company 1456 - Orthopedic products, specifically for upper and lower extremity small bone applications
• Company 1457 - Lumbar system for dynamic stabilization without fusion, artificial discs, and minimally invasive surgery systems
• Company 1458 - Reintroducing CHYMOPAPAIN, the only proven minimally-invasive therapy for herniated discs; it allows nuclear regeneration.
• Company 1459 - 1-Lumbar cage with integrated fixation screws, 2-Pedicle screw product line, 3-Access systems and implants for use in minimally invasive surgery (MIS)
• Company 1460 - Surgical adhesives that serve to augment or replace sutures and staples/tacks
• Company 1461 - Revisable cervical and lumbar total disc replacement that can be converted to fusion
• Company 1462 - Proprietary, non-fusion spinal motion preservative total disc replacement technology (ErgoFlex) that provides permanent solutions for lower back (lumbar) area disc problems. The technology is easily adaptable to the entire spine and the company's next target area is the neck (cervical).
• Company 1463 - Two clinically proven lumbar, motion-preservation spinal implants that offer surgeons: 1-a lumbar joint replacement that has provided superior treatment over fusion and disc replacement, for patients with degenerative lumbar joint disease and 2-a posterior dynamic stabilization system used to restabilize the spine after surgery for spinal stenosis, as an alternative to lumbar fusion
• Company 1464 - Building on an exclusive intellectual property platform for both fusion and non-fusion products
• Company 1465 - Tumor necrosis factor alpha (TNF-a) inhibitor therapy for treatment of chronic persistent radiculopathy (including sciatica) related to disc herniation.
• Company 1466 - Spinal implants, cervical, thoracolumbar, interbody, bone substitutes, motion preservation
• Company 1467 - Biocellulose technology that eliminates the risks/complications/limitations inherent in animal, human, and synthetic biomaterials
• Company 1468 - Wireless patient vital signs monitoring
• Company 1469 - Disease management system for early detection of heart failure using a noninvasive cardiovascular-sleep prognostic marker
• Company 1470 - 1-Soft tissue attachment nanotechnology, 2-Bioactive/biocompatible/osteoconductive synthetic bone filler, 3-Biodegradable fiberglass fiber & composites
• Company 1471 - Noninvasive blood glucose monitor that will measure glucose in sweat in a disposable dermal patch
• Company 1472 - Affordable thermal systems that are portable, easy-to-use, and comfortable to wear
• Company 1473 - High Intensity Focused Ultrasound for incisionless male surgical sterilization
• Company 1474 - Ambulatory infusion pumps and disposables that require no programming and use pre-filled solution containers
• Company 1475 - ViaDerm - home use transdermal drug delivery system creating microscopic passageways in the top skin layer
• Company 1476 - Tools for enabling adult stem cell based regenerative medicine
• Company 1477 - Lectin-based cell adhesion technology which enables stents that traffic cells in the bloodstream
• Company 1478 - Programmable lab-on-a-chip platform for applications ranging from drug discovery to consumer diagnostics
• Company 1479 - Technology that enables real-time tracking of the position and orientation of any interventional tool - biopsy device, catheter, endoscope, ablation probe, marker dispenser, etc.
• Company 1480 - Blood tests for the early detection of breast cancer, ovarian cancer, lung cancer, Alzheimer's, and other serious diseases where significant unmet clinical needs exist
• Company 1481 - Spinal implants utilizing elastomeric polymers for non-fusion treatment of disc degeneration
• Company 1482 - ECG software for assessing acute ischemia and cardiac safety surrogates in clinical trials
• Company 1483 - Resorbable pegylated hydrogel for surgical wound sealing/adhesion prevention/sustained and targeted drug delivery
• Company 1484 - The Sensation
• Company 1485 - Robot-assisted stroke therapy devices
• Company 1486 - Endothelial management - less trauma combined with new agents for improved healing in vascular interventions
• Company 1487 - Digital Pulse Analyzer - provides early detection of arterial wall stiffness and biological age of arteries
• Company 1488 - Diagnostic platform with a test for measuring unbound Bilirubin for the management of newborn jaundice
• Company 1489 - Percutaneous light activation reduces intra-abdominal fat, returning Type 2 diabetic patients towards normoglycemia
• Company 1490 - 1-Cartilage implant for the knee, 2-Injectable cell therapy for the spinal disc/nucleus, 3-Bone graft extender to treat spinal deformities
• Company 1491 - Protein free induction of endochondral ossification, no human origin, not contagious, no soft tissue ossification
• Company 1492 - 1-Instant-on/instant-off proximal occlusion funnel catheter, 2-Scoring balloon with drug delivery capability
• Company 1493 - An internal adhesive biotechnology designed for strength, biocompatibility, and ease-of-use with applications in cardiovascular surgery
• Company 1494 - Technology that prepares the spinal disc for a nucleus replacement/minimally invasive fusion device
• Company 1495 - Tissue repair devices exploiting shear force transfer and large-interface substrates for adherent new tissue formation
• Company 1496 - Advanced skin biopsy and wound healing solutions to dermatology, cosmetic, primary care, and oncology clinicians
• Company 1497 - Advanced optical systems/services that are changing the way doctors evaluate and treat the eye
• Company 1498 - Non-invasive cardiac output monitoring to assess stroke volume, contractility, cardiac output, cardiac index, and thoracic fluid content
• Company 1499 - 1-Cardiovascular-directed growth factor therapeutics; 2-Endovascular catheter-based system to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events
• Company 1500 - A drug delivery platform that approaches the endovascular bifurcation challenge from a completely different angle
• Company 1501 - A bioactive ceramic that delivers better/faster spine fusion and bone repair
• Company 1502 - Percutaneously delivered implantable system to treat mitral valve regurgitation and improve congestive heart failure
• Company 1503 - Electro-grafting coating technology for implantable biomedical applications; used for the fast healing post drug-eluting-stent (DES) implantation (avoiding late stage thrombosis)
• Company 1504 - Noninvasive medical device for the treatment and prevention of obesity using controlled hypoxia
• Company 1505 - An implantable ophthalmic device to treat vision correction associated with Age-Related Macular Degeneration (AMD)
• Company 1506 - Accommodating and multifocal phakic IOLs, CE-approved for $ billion refractive IOL market
• Company 1507 - Biocompatible polymer implant to prevent or reverse the progression of chronic heart failure and mitral valve regurgitation
• Company 1508 - Noninvasive device used in the differential diagnosis of disc or facet mediated low back pain
• Company 1509 - Surgical stapling devices for open and laparoscopic procedures developed for the growing China market
• Company 1510 - The first-and-only, fully self-contained, low-cost, and market-proven disposable iontophoretic patch - topical drug delivery platform for enhanced penetration and efficacy
• Company 1511 - IBraces - 100% customized, invisible orthodontic braces designed for efficient, effective treatment of teens and adults
• Company 1512 - Flash Ultrasound
• Company 1513 - Free-floating optical probe with multiple LD scanning and magnetic stabilization for noninvasive blood glucose monitoring
• Company 1514 - Repositionable/removable percutaneous heart valve, precision controlled delivery device, and calcified valve encapsulation system
• Company 1515 - Next-generation estrogen-based drug-eluting coronary stent and an orthopedics/sports injury pain management device
• Company 1516 - Heart pump that achieves superior flow and pressure performance, mimicking the physiological performance of the human heart, and reducing post-surgery kidney failure, mortality, and complications cost by 50%
• Company 1517 - Porcine-derived tissue devices for ligament, cartilage, bone, and soft tissue replacement and augmentation
• Company 1518 - MIS platform technologies for creating cavities in tissue and partially molding an orthopedic implant in situ
• Company 1519 - Orbital atherectomy for the treatment of peripheral vascular disease
• Company 1520 - Functional brain imaging centers that identify Alzheimer's, brain injury, stroke, ADHD, bipolar, depression, anxiety, OCD
• Company 1521 - A protein therapeutic biotreatment that regresses solid tumors and protects against relapses
• Company 1522 - Analyze, search, store, mine, share and unlock the power of digital tissue images
• Company 1523 - Smart devices to harness human physiology for health care, industrial safety, and law enforcement applications
• Company 1524 - Naturally-derived/non-crosslinked/collagen-based extracellular matrix to repair/remodel damaged tissues
• Company 1525 - Facet fixation system that is a less-invasive/faster alternative to pedicle screw fixation
• Company 1526 - The Extremity Compartment Syndrome (ECS) System is being launched as the only FDA-cleared continuous monitoring device that assists physicians with diagnosing a limb-threatening complication
• Company 1527 - Shielded reciprocating tissue sculpturing instrument, able to navigate into neural foramen to relieve nerve compression
• Company 1528 - 1-LIFEBACK® Spine Programs for non-operative and post-operative spine patients and 2-the LTX 3000® Rehabilitation System
• Company 1529 - Stable and extractable self locking intramedullary nails and proximal femoral fixation
• Company 1530 - Emperor Mobile Spinal Disc, P.E.E.K Cages, Pedicle Screw System, and Saturn Hip Resurfacing
• Company 1531 - Rapid table-mounted retraction/surgical site access for MIS placement of hip/knee/shoulder/spine implants
• Company 1532 - Lumbar dynamic stabilization with MIS compatibility and pedicle screws
• Company 1533 - Real-time image-guidance technology with an FDA-accepted accuracy claim of +/-1mm at 1 meter
• Company 1534 - Noninvasive, ambulatory, portable, 3-D traction technology providing an effective and unique therapy for spinal disorders
• Company 1535 - Fusion technology platforms and second-generation artificial discs for the lumbar and cervical spine
• Company 1536 - A biological and mechanical solution to annular repair and spine fusion
• Company 1537 - Low-profile implants/less invasive surgical instruments to treat spinal disorders utilizing fusion and non-fusion technologies
• Company 1538 - A CE-marked resorbable plating system for cervical fusions allowing for load sharing
• Company 1539 - Biomaterials-based product that augments or replaces the diseased nucleus pulposus of the spinal disc
• Company 1540 - Nitric oxide-based therapies to accelerate healing of tendon, bone, and other musculoskeletal tissue
• Company 1541 - Drug product for the treatment of acute spinal cord injury, cancer, macular degeneration, and glaucoma
• Company 1542 - Synthetic bone that duplicates the microstructure, composition, and performance of human bone
• Company 1543 - Implanted oscillating field stimulation device which regenerates acute and sub-acute damaged spinal cord nerve tissue
• Company 1544 - PuraMatrix injectable synthetic nanofibrous hydrogels for bone, cartilage and soft tissue regeneration, and drug delivery
• Company 1545 - Noninvasive device providing substitute vestibular sensory information through the tongue for treatment of balance disorders
• Company 1546 - Naturally occurring neuropeptide to treat ischemia associated with myocardial infarction, heart failure, and angina
• Company 1547 - Miniature/patient-controllable/valved catheter to improve quality of life/decrease urinary tract infections in patients suffering urinary retention
• Company 1548 - Phase-shifting technology for Contrast Ultrasound imaging
• Company 1549 - Innovative, implantable, combination drug+device products that utilize novel biomaterials. TYRX's first commercially available products include the AIGISRx(R) Antibacterial Envelope & Flat Sheet technologies, designed to reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs).
• Company 1550 - Laparoscopic surgical access technology based on a No-Seal platform
• Company 1551 - Theramers
• Company 1552 - Respiratory diagnostics for noninvasive assessment of airway acidification in Asthma, COPD, and GERD
• Company 1553 - A "preventative" vaccine for HIV-AIDs
• Company 1554 - Post-proteomics multiplexed MS-based diagnostics/theranostics linked to drug development and personalized medicine
• Company 1555 - Image-guided therapy for metastatic liver disease
• Company 1556 - Biomaterial that regulates resorbability and enhances bone regeneration
• Company 1557 - Drug/device products for post-operative pain and orthopedic drug delivery indications using syntinate synthetic absorbables
• Company 1558 - Ultrasonic medical devices for minimally invasive therapeutic procedures for treatment of cancer/other healthcare purposes
• Company 1559 - Multi-channel implantable microelectrodes for deep brain stimulation and recording, enabling enhanced neuromodulation therapies
• Company 1560 - Aesthetic treatment device using collimated high-energy light and laser, delivered simultaneously by fiber delivery system
• Company 1561 - A remotely controlled, wireless-powered implantable 230-channel nerve stimulator built on a 15
• Company 1562 - Real-time, noninvasive monitoring of blood loss, anemia, and other vital blood measurements
• Company 1563 - Small/portable/handheld device for diagnosing brain hematomas
• Company 1564 - Fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify lipid rich plaques in the coronary arteries
• Company 1565 - Laparoscopic surgeons maintain direct control of the laparoscope movement/placement with GMP's Laparocision
• Company 1566 - Rapid testing systems led by the Growth Direct
• Company 1567 - World's smallest leg compression device for the prevention of deep vein thrombosis (DVT) in surgical patients, as a safe and effective alternative to Lovenox, for a significantly reduced price
• Company 1568 - Ultraviolet light technologies for the inactivation of RNA viruses in/out of the body
• Company 1569 - Minimally invasive percutaneous neuromodulation pain therapy
• Company 1570 - The Axya Shoulder Fixation System generates ultrasonic energy for knotless suture welding in shoulder surgery
• Company 1571 - Gene-based products for the diagnosis and treatment of spinal disorders
• Company 1572 - A platform aerosol drug delivery nebulizer device for multiple- and single-use applications with disposables
• Company 1573 - Non-invasive continuous measurement of tissue oxygenation for various intraoperative and post-operative applications
• Company 1574 - Vascular stents and grafts with increased patency by improved flow dynamics, reducing stenosis and restenosis
• Company 1575 - 1-Next-generation liquid embolic for treating cerebral aneurysms and arteriovenous malformations (AVMs); 2-Two wound management products that will be out-licensed
• Company 1576 - SurfLink
• Company 1577 - Bifurcated coronary stent
• Company 1578 - Monitoring products based on microsensor technology allowing minimally invasive, real-time measurement of clinical chemistry parameters and therapeutic drug concentrations
• Company 1579 - Noninvasive, outpatient bariatric device for overweight/obesity
• Company 1580 - A suite of tools for automated CT Angiography (CTA) diagnostics for Coronary Artery Disease
• Company 1581 - Magnetically actuated telescopic intramedullary (IM) nail activated by an induced low power directional magnetic field
• Company 1582 - Transdermal delivery system of levodopa (L-DOPA) for the treatment of Parkinson's Disease
• Company 1583 - Immediate, active, device-less, and painless topical drug delivery, of small/macromolecules, for local/systemic indications
• Company 1584 - Endotracheal tube with video, self-locking orthopedic implants, structured TPN lipids, cell therapy for cancer, etc.
• Company 1585 - Products that digitize manual breast examination tissue elastic properties into objective computerized visual maps/reports
• Company 1586 - Technology for the manipulation of adult stem cells to repopulate chronically diseased liver tissue
• Company 1587 - Non-invasive airway clearance in ICU patients to prevent ventilator associated pneumonia
• Company 1588 - Unique add on and removable needle safety product that fits to standard glass/plastic syringes
• Company 1589 - Medical devices utilizing radiofrequency and microwave energy which are cost-effective and clinically relevant
• Company 1590 - Non-invasive screening of Peripheral Arterial Disease (PAD), combining postural/infrared blood volume testing
• Company 1591 - Tissue fixation implants, injectable bone grafting biomaterials, and tissue scaffolds with drug releasing properties
• Company 1592 - Miniature implantable, continuous blood glucose sensor for diabetics, incorporating noninvasive wireless monitoring
• Company 1593 - Coronary guidewire, to provide real-time ultrasonic measurement of coronary arteries to determine stent size and apposition without exchange of catheters
• Company 1594 - Bioabsorbable, bioactive, and drug-releasing medical device products for various fields of surgery
• Company 1595 - 1- Interventional single-use cardiac support device and drug delivery platform, 2- Implants for use in/with magnetic resonance imaging (MRI) systems
• Company 1596 - A tubular valve implanted through the mouth during an ambulatory procedure for the treatment of gastroesophageal reflux disease (GERD), although future applications for the technology include obesity and irritable bowel syndrome
• Company 1597 - Cellular implants for orthopedic, trauma, and spinal applications based on a biological form stable matrix
• Company 1598 - SmartStep
• Company 1599 - Dynamic optimization of pacing intervals according to hemodynamic sensors for CRT devices
• Company 1600 - Neuro-monitoring systems for brain protection and stroke acute care in stroke units, cardiovascular ORs, during stenting, and in the ICU
• Company 1601 - Medical devices that enable diabetes disease management and the prevention of lower extremity amputations
• Company 1602 - Customized miniature disposable stereoscopic cameras that provide 3D vision, measurements, and image fusion in real-time
• Company 1603 - Infusion catheter for treatment of tumors which are unresponsive to systemic chemotherapy by the local delivery of drugs and other agents
• Company 1604 - Non-invasive imaging tool designed to provide automated, 3-D ultrasound images of the breast
• Company 1605 - RFID hardware and software platform for test tubes/ apheresis device for blood component separation
• Company 1606 - Saliva-based consumer diagnostic systems, which enable the development of personalized therapeutics
• Company 1607 - Disposable, noninvasive, pump-less, and valve-less automatic blood pressure monitor "on-a-chip"
• Company 1608 - Noninvasive neural vision enhancement
• Company 1609 - Nanotechnologies for use in orthopedic implants, dental implants, and stents
• Company 1610 - Specialty and standard electrophysiology catheters that have superior performance, advantageous features, and are affordable
• Company 1611 - Dedicated angioplasty and stent systems for the treatment of arterial bifurcations
• Company 1612 - System to ablate cardiac tissue as a means to potentially treat atrial fibrillation
• Company 1613 - Point-of-care IVD platform that provides rapid, accurate, automated laboratory testing using low cost, disposable biochips
• Company 1614 - Interventional MRI technology for cardiovascular imaging including detection/treatment of vulnerable plaque
• Company 1615 - System analyzes a patient's susceptibility to cardiac arrest and consequent need for implantable defibrillator
• Company 1616 - Patient recovery system for cosmetic and reconstructive surgery
• Company 1617 - Microscope slide scanners and information management software that enable the digitization of pathology
• Company 1618 - SutureLock - a versatile suture-securing knot-replacement device for endoscopic wound approximation
• Company 1619 - Multi-Sensing Wireless Catheter platform attached along the GI-Uro tract detecting GERD, incontinence, and other abnormalities
• Company 1620 - Noninvasive medical device providing low-risk hypoxic treatment that induces appetite suppression and weight loss
• Company 1621 - Minimally invasive telemetric and continuous measurement of left atrial blood pressure at heart failure
• Company 1622 - Catheter-based photoreactive treatment system for endovascular intervention in coronary and peripheral atherosclerotic disease
• Company 1623 - Transcatheter mitral valve repair technology offering minimally invasive treatment option for mitral regurgitation/congestive heart failure
• Company 1624 - A platelet reactivity test to measure the effect of anti-platelet drugs, particularly aspirin and Plavix
• Company 1625 - OmniWave(R) catheter-based technology that delivers transverse ultrasonic energy to targeted thrombus in a diseased blood vessel, without damaging the surrounding vessel walls
• Company 1626 - A portable laseroptical system for noninvasive differentiation between ischemic stroke and spontaneous intracerebral hemorrhages
• Company 1627 - Alginate-based embolic material designed to fill blood vessel defects thereby displacing blood pressure effects and preventing vessel rupture
• Company 1628 - A wearable continuous ultrafiltration device that removes fluid overload in patients with Congestive Heart Failure
• Company 1629 - Minimally-invasive cardiac implantable devices for treating mitral valve regurgitation without atriotomy or cardiopulmonary bypass
• Company 1630 - Surgical and percutaneous cardiac valve repair
• Company 1631 - Percutaneous mitral valve repair simulating precision of surgical annuloplasty
• Company 1632 - Pressure and flow sensing systems for vascular and other applications
• Company 1633 - Advanced ECG-heart sound analysis to enable superior diagnosis/monitoring of CHF/ACS patients
• Company 1634 - Minimally invasive interventional radiology/vascular surgery devices
• Company 1635 - PeriVasc
• Company 1636 - Perfusion monitoring for preventing septic shock, the greatest hospital mortality
• Company 1637 - A noninvasive test for endothelial dysfunction using digital (fingertip) thermal monitoring
• Company 1638 - Stentless aortic valve prosthesis to be delivered via catheter
• Company 1639 - Catheter-based therapy which increases cerebral perfusion for the treatment of ischemic stroke and vasospasm
• Company 1640 - Catheter-based devices to reconstruct the ventricle and downsize the heart volume
• Company 1641 - Non-invasive device using muscular counter pulsation (MCP) technology for the treatment of acute and chronic heart failure (CHF) in a clinical, ambulatory, or at-home setting
• Company 1642 - 1-Bio-therapeutic designed from autologous stem cells and committed to a cardiac lineage before implantation, 2-Corresponding catheter for accurate transmyocardial injection
• Company 1643 - Minimally invasive device-based technologies targeting the treatment of hemodynamic instability and perfusion
• Company 1644 - Peptide-based therapeutic to enhance stent/graft patency
• Company 1645 - Biomimetic coronary stent coating that prevents restenosis/reduces the need for extended courses of dual antiplatelet therapy
• Company 1646 - Disposables for drawing blood -- percutaneous or from a catheter -- neonates to geriatrics
• Company 1647 - Electrode sensor array, with integrated lead wires, simple, accurate and repeatable ECGs
• Company 1648 - In vivo plasmapheresis and ultrafiltration to remove excess fluid from CHF patients in clinical trials
• Company 1649 - Noninvasive therapeutic ultrasound to enhance perfusion for treatment of acute myocardial infarction
• Company 1650 - Affordable handheld metabolic monitor (indirect calorimeter) with both medical and consumer weight management applications
• Company 1651 - Unique microsphere-based technology for chronic/acute wounds
• Company 1652 - Technologies that utilize flexible cross linking and sterilization processes which stabilize and sterilize biological tissue for use in orthopedic, wound, oral/dental, spine and neurological, breast, abdominal and thoracic applications
• Company 1653 - Devices for mechanically induced bone growth, together with a "smart device" system for risk management
• Company 1654 - Nitric oxide releasing surface treatments for enhanced biocompatibility in medical devices
• Company 1655 - Automated implantable pump systems for moving fluids around inside the body
• Company 1656 - Minimally invasive surgical access system used in laparoscopic surgery
• Company 1657 - Long-term, miniature drug delivery implant with physician- controllable, zero-order release characteristics
• Company 1658 - 1-Single-use, patented, disposable, hemorrhoid banding system; 2-Two-tier colon cancer diagnostic screen, Fecal Occult Blood Testing (FOBT)
• Company 1659 - Interventional catheter-based system precisely measures stent and arterial size and cardiovascular repair tissue patch products
• Company 1660 - Device for the treatment of mitral regurgitation and heart failure without requiring open heart surgery
• Company 1661 - Light-based therapy for eradication of ulcer-causing Helicobacter pylori
• Company 1662 - Non-invasive medical radar imaging for cardiopulmonary ambulatory monitoring and diagnosis
• Company 1663 - Enteric Dialysis with Kibow Biotics - a food-grade microbial Gel cap formulation towards kidney failure applications
• Company 1664 - IYIA has developed a proprietary, clinically effective device, O2Misly, for treating slow healing foot wounds, primarily diabetic foot ulcers
• Company 1665 - Genetic and personal history based testing to predict age-specific risk of breast cancer diagnosis
• Company 1666 - Controlled fluid delivery system for every medical application without batteries or power cords
• Company 1667 - Non-contact intelligent medical vigilance for the hospital
• Company 1668 - Capture and analysis of heart sounds leading to rapid and accurate diagnosis of cardiac pathologies
• Company 1669 - Blood test that screens/diagnoses cervical cancer without need of a cervical exam/pap smear
• Company 1670 - Implantable Left Ventricular Assist Device (LVAD) for heart failure
• Company 1671 - Bioabsorbable drug eluting stents and stent coatings for treatment of vulnerable plaque and coronary stenosis
• Company 1672 - Electronic pill for oral delivery of low bioavailability drugs
• Company 1673 - Microsyringe delivery of cells, genes, and drugs to the vasculature/deep tissues of the body
• Company 1674 - Percutaneous noninvasive heart valve replacement
• Company 1675 - Molecular FingerPrinting process for early-stage diagnosis of cancer, enabling point-of-care therapeutics based on gene regulation
• Company 1676 - Percutaneous access management system to provide early ambulation/eliminate major complications, leaving nothing behind in patient
• Company 1677 - Totally implantable LVAD that does not interface with circulating blood
• Company 1678 - Blood test for breast cancer measuring 5 protein biomarkers using super-sensitive ELISA with 95% accuracy
• Company 1679 - Ablation technology that delivers radiofrequency energy endoscopically, to eliminate Barrett's esophagus and prevent esophageal cancer
• Company 1680 - A device for the left atrial appendage for stroke prevention in patients with atrial fibrillation
• Company 1681 - Noninvasive monitor to measure exhaled nitric oxide for the management of asthma
• Company 1682 - Microplate-based electronic biosensor system for label-free, real-time cell based assays
• Company 1683 - Interactive intraoperative CT scanning technology for image-guided interventions
• Company 1684 - High Intensity Focused Ultrasound for minimally invasive thermal treatment of disc herniation without disc penetration
• Company 1685 - Percutaneous systems to treat lower back pain
• Company 1686 - Least invasive approach for the delivery of lumbar fusion and motion preservation therapies
• Company 1687 - Telemeterized natural motion elastomer disc
• Company 1688 - Interspinous process implant to treat Lumbar Spinal Stenosis (LSS)
• Company 1689 - Clinical expertise, facility development, new technology, and business services including marketing and contracting
• Company 1690 - Advance and commercialize less invasive spinal deformity surgical treatment without fusion
• Company 1691 - Lumbar, thoracic, and cervical fusion devices including less invasive instrumentation; lumbar and cervical artificial discs
• Company 1692 - Lumbar spine motion preservation via dynamic stabilization utilizing a semi-rigid rod and screw system
• Company 1693 - 1-Stand-alone anterior lumbar IBF device and 2-Stand-alone cervical IBF device
• Company 1694 - Compliant artificial lumbar disc with graduated modulus for restoration of normal spine biomechanics/enhanced durability
• Company 1695 - 1-Synthetic alternatives to autograft/cadaver-based bone material, 2-Surgical hemostat as an adherent matrix/impermeable barrier to blood flow, 3-Bone augmentation material for injections in osteoporotic spines to treat vertebral compression fractures
• Company 1696 - Orthopeutics, LP introduces Intrabrace a new non-surgical, injectable treatment for resisting spinal curvature in scoliosis.
• Company 1697 - Bioactive synthetic bone graft substitute that is osteostimulative, osteoconductive, antimicrobial, and hemostatic
• Company 1698 - Next-generation fusion, motion sparing, and minimally invasive spinal implant products
• Company 1699 - Minimally invasive fusion system
• Company 1700 - Fluidjet devices for open and MIS fusion, discectomy, artificial nucleus, and artificial disc procedures
• Company 1701 - Osteogenica - bone marrow concentration system
• Company 1702 - Dascor Arthroplasty System, spinal implants technology
• Company 1703 - BioDisc, a nucleus replacement product based on an injectable, flexible, and durable protein hydrogel technology
• Company 1704 - Second-generation, viscoelastic artificial disc restoring native function to the spine
• Company 1705 - Three-dimensional surgical visualization technologies and expanding portfolio for digital surgical environment and digital healthcare network
• Company 1706 - Real-time disposable stereotactic navigation devices for biopsy/targeted therapy compatible with CT, fluoroscopy, and MRI
• Company 1707 - Minimally invasive cancer therapy using Magnetically Energized (ME) Thermotherapy
• Company 1708 - Magneto-Optical Enantiomeric Detection (MOPED) for real-time, non-contact analysis of chiral pharmaceuticals
• Company 1709 - First noninvasive, transcutaneous sensor array that continuously monitors peripheral circulation and/or core body temperature
• Company 1710 - Disposable balloon cervical dilator for improved uterine access that decreases pain, avoids tearing and perforations
• Company 1711 - Biological therapeutics for the treatment of neurological disorders including: Alzheimer's disease, epilepsy, Huntington's disease, Parkinson's disease, and neuropathic pain
• Company 1712 - Complete pre-configured system for implementing minimized cardiopulmonary bypass
• Company 1713 - Catheter-based sealing of heart defects associated with stroke, migraine headaches, and other brain attacks
• Company 1714 - Technology for imaging peripheral nerves in regional anesthesiology, pain management, and other markets
• Company 1715 - Nanomagnetic particles enabling controlled drug delivery and elution for drug targeting and medical device applications
• Company 1716 - MRI-compatible, precision- guided laser therapy for the treatment of brain tumors
• Company 1717 - Implantable blood pump with magnetic levitation technology for patients suffering from heart failure
• Company 1718 - Virtual Bone Biopsy MRI scanner add-on, allowing noninvasive imaging of bone microstructure for osteoporosis monitoring
• Company 1719 - The Renaissance(TM) Surgical Guidance System is transforming spine surgery from freehand procedures to highly-accurate, state-of-the-art operations that raise the standard of care with better clinical outcomes
• Company 1720 - Nanotechnology-based cancer therapy with contactless activation of tumor-specific nano-particles, adaptable to all solid tumors
• Company 1721 - Point-of-care platform technology for assessing risk of cardiovascular disease and renal dysfunction
• Company 1722 - Continuous blood gas monitoring and cardiac output measurement for the intensive care unit
• Company 1723 - Non-blood contacting, active implantable direct cardiac compression device for the treatment of CHF
• Company 1724 - Augmented reality simulators that train surgeons in the skills required for minimally invasive surgery
• Company 1725 - Continuous, non-invasive glucose monitor for tight glycemic control at the hospital and at home
• Company 1726 - ERBLAN MIS Surgical Devices allow safe entry into virtually any actual or potential anatomical space
• Company 1727 - Technology that non-invasively measures/monitors mechanical heart function and disease utilizing a disposable brachial cuff
• Company 1728 - Endovenous ablation system for varicose veins with 1320 nm CoolTouch laser
• Company 1729 - Micro-porous ceramic wound treatment device that creates optimal conditions for normal wound healing
• Company 1730 - Direct, real-time vision through flowing blood to guide therapy inside the heart and vessels
• Company 1731 - Cath lab solution providing rapid onset of circulatory support in patients with acute heart failure
• Company 1732 - Novel bone void filler made from magnesium which provides a resorbable and biocompatible binding platform for synthetic bone grafting following trauma
• Company 1733 - AepEX auditory evoked potential depth of anesthesia monitor and aepEX-Fusion servo-controlled anesthesia delivery system
• Company 1734 - Posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion
• Company 1735 - Site-specific biological and drug delivery
• Company 1736 - HistoScanning(TM) is an innovative imaging-based modality available in the Tissue Characterization market; the only one offering accurate 3D detection and localization of cancer lesions
• Company 1737 - Non-irritating dry electrodes now enabling long-term cardiac monitoring
• Company 1738 - Non-incisional female sterilization
• Company 1739 - Biopharmaceuticals targeting osteo-renal indications, including the complications of chronic kidney disease and dialysis, bone and cartilage repair and regeneration, and general dental and oral care
• Company 1740 - Portable, compact, easy-to-use automated external defibrillators with full energy delivery and complete resuscitation solutions
• Company 1741 - Rapid, point-of-care in vitro diagnostics
• Company 1742 - Endoscopy systems allowing physicians to see very small, early-stage cancer and subtle pre-cancerous lesions
• Company 1743 - Surgical instruments employing thermal welding technology to seal and cut tissue
• Company 1744 - Minimally invasive disc replacement for chronic back pain
• Company 1745 - A smart, communicating cigarette case, online support, and daily e-mails delivering an effective stop-smoking method
• Company 1746 - A wireless personal emergency alert system that integrates with, and enhances, existing implanted medical devices
• Company 1747 - Artificial total intervertebral disc capable of normal physiological movement and weight loading
• Company 1748 - Catheters designed to diagnose, terminate, and treat cardiac arrhythmia during EP and ablation procedures
• Company 1749 - Conservative Motion Preservation technology including minimally invasive facet joint replacement
• Company 1750 - BioSilicon, nano-structured porous silicon for applications in drug delivery, diagnostics, tissue engineering, and orthopedics
• Company 1751 - System that prevents embolic events by removing plaque and thrombus found in diseased arteries
• Company 1752 - Bioresorbable polymer implants for use in a variety of orthopedics and spine surgical applications
• Company 1753 - Liposomal formulation of recombinant IL-2 for use as chemotherapy or cancer vaccine adjuvant
• Company 1754 - Helical stent providing enhanced abilities and flexibilities in drug delivery, scaffolding, and embolic protection
• Company 1755 - Trabectome, an FDA-cleared, minimally invasive medical device technology for the treatment of open angel glaucoma
• Company 1756 - ClearSolution represents the next wave in integrated, intra and interoperative physiologic monitoring. ClearSolution enables a non-invasive, wireless solution for continuous, multi-modal patient monitoring for image-facilitated minimally invasive surgery, improved CAD detection, and remote patient monitoring.
• Company 1757 - Prevention of scarring caused by disease, medical intervention, or trauma via a beta emitting biopolymer
• Company 1758 - Noninvasive, site-specific drug delivery technology to deliver compounds to the posterior segments of the eye
• Company 1759 - Real-time, CT-guided, robotically controlled needle drivers for minimally invasive cancer therapy
• Company 1760 - Automated, continual blood glucose monitoring for critically ill patients
• Company 1761 - Molecular diagnostics based on patented, standardized, next-generation, multi-gene expression (StaRT-PCR) products and high margin services
• Company 1762 - THERMOCEPS - a handheld, wireless device that stops bleeding during surgical procedures using focused, thermal coagulation
• Company 1763 - Interventional catheter system for the mechanical recanalization of arterial chronic total occlusions quickly and reliably
• Company 1764 - Portable automated critical care neuro instruments using advanced digital signal processing technology
• Company 1765 - Monitor for autonomic nervous system displaying sympathovagal balance in real-time for diabetes/ anesthesia/cardiology applications
• Company 1766 - Branched endografts for aortic disease
• Company 1767 - Next-generation biomaterials using bioactive-ceramics technology platform
• Company 1768 - Immunodiagnostics of placental recombinant markers to screen the risk of preeclampsia, preterm delivery, and IUGR
• Company 1769 - Methods for eyebrow lifting, non-thermal loading of degradable matrices, and degradable implants
• Company 1770 - Non-invasive modality for the treatment of insulin resistance/diabetic neuropathy
• Company 1771 - Minimally invasive needle biosensor for in vivo glucose or lactate monitoring of intensive care patients
• Company 1772 - P-15: a small peptide attachment factor for bone formation in orthopedics
• Company 1773 - MIST Therapy using non-contact ultrasound to stimulate healthy cells allowing chronic wounds to heal
• Company 1774 - Arthroscopic surgical devices
• Company 1775 - Electronic device that closes the gap between drugs and surgery in osteoarthritis of the knee
• Company 1776 - Cell-based therapy products for the treatment of heart failure secondary to myocardial infarction
• Company 1777 - A five-carbon carbohydrate that increases cellular energy, improving cardiovascular health and tissue function
• Company 1778 - The most advanced Infrared Light Therapy technology available that is clinically proven to reduce sports injury healing time by >60%, with additional applications for oral tissue and migraines
• Company 1779 - Next-generation non-vascular interventional pulmonary and gastrointestinal stenting technology
• Company 1780 - A revolutionary device that will facilitate broad implementation of extracorporeal CO2 removal and oxygen supplementation resulting in the avoidance of airway intubation, sedation, and invasive mechanical ventilation
• Company 1781 - Intravascular temperature management systems and catheters for cardiac and neuro intensive care patients
• Company 1782 - Implantable devices for the endovascular treatment of hemorrhagic stroke
• Company 1783 - Ultrasound catheters for targeted thermal ablation of tumors

* Corporate License allows for multi-user and/or enterprise wide access.